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Fibroblast" growth" factor" receptor"3" (FGFR3)" signalling" is"altered" in"~80%"of"non!
muscle!invasive" and" ~40%" of" muscle!invasive" bladder" cancers" via" activating"
mutations" (point" mutations" or" gene" fusions)," overexpression" or" both." FGFR"




FGFR" inhibition." Isogenic" resistant"cell" lines," termed"RT112"R1,"R2,"R3"and"RT4"
R1" were" derived" by" long!term" culture" of" parental" cells" in" the" FGFR" inhibitor"
PD173074.""
RT112" R1," R2" and" RT4" R1" had" an" altered" morphology" and" reduced"
proliferation" rate" compared" to" the" parental" lines." These" changes" were" reversed"
when" the" resistant" cells" were" cultured" without" PD173074" for" four" passages."
Following" this" ‘drug" holiday’" RT112" R1" and" R2" retained" PD173074" resistance,"
whereas"RT4"R1"did"not."The"resistance"mechanism"in"RT112"R1,"R2"and"RT4"R1"
appears" to" be" epigenetic." RT112" R3" retained" an" epithelial" morphology" and" a"
proliferation"rate"similar"to"parental"RT112."Exome"sequencing"uncovered"a"HRAS"
G12S"mutation" in"RT112"R3."The"retroviral" transduction"of"a"HRAS"G12"mutation"
in" RT112" parental" induced" PD173074" resistance." Microarray" analysis" was"
conducted" to" examine" expression" changes" between" parental" and" resistant" lines."
Metacore™" analysis" identified" the" differential" expression" of" pathways" relating" to"
cell" cycle," epithelial!mesenchymal" transition" and" Oncostatin" M" signalling."


























































































































































































































































































































































































































































































































































































































bladder" cancers" are" urothelial" carcinoma" (Eble" et! al.," 2004q" Malats" and" Real,"
2015)." Bladder" cancer" occurs" more" frequently" in" males" than" females" with" a"
worldwide"sex"ratio"of"3.5:1"(Ferlay"et!al.,"2015)."Smoking"cigarettes,"exposure" to"
chemicals"such"as"aromatic"amines"and"consumption"of"phenacetin"are"major"risk"
factors" for" developing" bladder" cancer" (Miyazaki" and" Nishiyama," 2017)." Bladder"
cancer" patients" commonly" present" with" painless" haematuria." Cystoscopy,"
transurethral"resection"of"the"bladder"tumour"(TURBT),"computed"tomography"and"
magnetic" resonance" imaging" are" used" in" the" diagnosis," staging" and" grading" of"
bladder"cancer"(Witjes"et!al.,"2014).""
Bladder"cancers"are"classified"with"the"TNM"staging"system"as"follows:"Tis:"
known" as" carcinoma" in! situ," the" tumour" is" non!invasiveq" Ta:" the" tumour" is" non!
invasive"with"a"papillary"structure"protruding"into"the"bladder"lumenq"T1:"the"tumour"
has" invaded" the" subepithelial" connective" tissueq" T2:" the" tumour" has" invaded" the"
bladder’s" muscle" wallq" T3:" the" tumour" has" invaded" the" perivesical" fatty" tissue"
surrounding"the"bladder,"and"T4:"the"tumour"has"invaded"adjacent"organs"such"as"
the" uterus," vagina," prostate," pelvic" wall" or" abdominal" wall" (Cheng" et! al.," 2009)."
Non!invasive" urothelial" carcinomas" are" graded" with" the" 2004" World" Health"
Organisation" (WHO)" classification" system" according" to" cellular" appearance" as"
papillary"urothelial"malignancy"of" low"malignant"potential,"non!invasive," low"grade"
papillary" urothelial" carcinoma" or" non!invasive," high" grade" papillary" urothelial"
carcinoma" (Eble" et! al.," 2004)." Previously" bladder" cancers" were" graded" with" the"




Worldwide," 70!80%" of" bladder" cancers" present" as" non!muscle!invasive."
These"non!muscle!invasive"bladder"cancers"(NMIBCs)"recur"in"50!70%"of"patients"
following" treatment" and" progress" to"muscle!invasive" disease" in" 10!15%" of" cases"
(Prout"et!al.,"1992)."The"high"rate"of"recurrence"means"that"patients"require"lifetime"
surveillance"and"often"multiple" treatments"during" their" lifetime."Therefore,"bladder"
cancer" is" expensive" to" treat" (Svatek" et! al.," 2014)." Sylvester" et! al." analysed" the"
records" of" 2596" patients"with" superficial" bladder" cancer" treated"with" TURBT" and"
identified" that" the"presence"of"multiple" tumours," larger" tumours"and"a"higher"prior"
recurrence" rate" were" all" prognostic" of" a" greater" risk" of" disease" recurrence."
Classification" of" the" tumour" as" T1" rather" than" Ta," concomitant" carcinoma" in! situ"
and"a"higher"tumour"grading"were"all"prognostic"of"a"greater"risk"of"progression"to"
muscle!invasive" bladder" cancer" (MIBC)" (Sylvester" et! al.," 2006)." Following" the"
diagnosis"of"NMIBC,"which"is"dependent"upon"the"histological"analysis"of"a"tissue"
sample"obtained"with"TURBT,"patients"with"low"risk"of"recurrence"and"progression"
receive" treatment" with" a" single" immediate" postoperative" instillation" of"
chemotherapy" such" as" the" DNA" crosslinking" agent"mitomycin" C." Patients" with" a"
high" risk" of" recurrence" and" progression" receive" intravesical" Bacillus" Calmette!
Guérin" (BCG)"vaccine" instillations" (Babjuk"et!al.," 2016)."BCG" reduces" recurrence"
and"progression"of"NMIBC" (Kamat"et!al.," 2017)."NMIBC"patients"with" the"highest"
risk"of"progression"may" receive" radical" cystectomy" (Babjuk"et!al.," 2016)."MIBC" is"
treated" with" the" neoadjuvant" chemotherapy" combination" of" methotrexate,"
vinblastine," doxorubicin" plus" cisplatin" (MVAC)" or" gemcitabine" plus" cisplatin"
(GemCis)" and" radical" cystectomy." Neoadjuvant" chemotherapy" has" been"
demonstrated" to" increase" overall" patient" survival" in" randomized" controlled" trials"




MIBC" patients" (Leow" et! al.," 2014)." There" is" a" need" to" improve" survival" in"MIBC"
patients:"patients"with" locally"advanced"or"metastatic"MIBC"have"a"5!year"survival"
rate" of" approximately" 15%" (von" der"Maase"et! al.," 2005)." Although"more" tumours"
are"diagnosed"in"males,"females"have"a"higher"mortality"rate"from"their"disease"and"
are"more" likely" to"present"with"MIBC."This"may"be"due" to" females"experiencing"a"
greater" time" from" the" onset" of" symptoms" to" GP" referral" and" to" treatment" with"
TURBT"(Bryan"et!al.,"2015).""
"3"
The" immunotherapeutic" monoclonal" antibodies" atezolizumab,"
pembrolizumab," nivolumab" are" approved" by" the" United" States" Food" and" Drug"
Administration" (FDA)" and" the" European" Medicines" Agency" (EMA)" for" use" as"
postplatinum" single" agents" for" the" treatment" of" advanced" urothelial" carcinoma."
Avelumab" and" durvalumab" are" also" approved" by" the" FDA" but" not" the" EMA" for"
treatment"of"this"condition."Atezolizumab"and"pembrolizumab"are"also"approved"by"
the" FDA" and" EMA" as" single" agent," first!line" treatments" of" advanced" urothelial"
carcinoma" patients" ineligible" for" treatment" with" cisplatin" (Godwin" et! al.," 2018)."
Pembrolizumab" and" nivolumab" bind" programmed" cell" death" 1" (PD!1)" and"
atezomomab,"avelumab"and"durvalumab"bind"programmed"death"ligand"1"(PD!L1)."
Monoclonal" antibodies" targeting" PD!1" and" PD!L1" prevent" the" PD!1" and" PD!L1"
interaction" and" therefore" prevent" the" inhibition" of" T!cell" activation" and" enable" T!
cells" to" induce" cancer" cell" death" (Topalian" et! al.," 2015)." Atezolizumab" was"
approved" for" use" in" urothelial" carcinoma" following" a" phase" II" clinical" trial" which"
assessed"its"efficacy"in"advanced"urothelial"carcinoma"patients"whose"disease"had"
progressed" since," or" who" were" ineligible" for" treatment" with," platinum!based"
chemotherapy." The" objective" response" rate" of" 15%" was" statistically" significant"
compared"to"the"historical"objective"response"rate"of"10%"(Rosenberg"et!al.,"2016)."
Since" then" a" phase" III" clinical" trial" has" been" published" assessing" the" efficacy" of"
atezolizumab" in" advanced" urothelial" carcinoma" patients" whose" disease" had"
progressed" following" platinum!based" chemotherapy." Overall" survival" was" not"
significantly" different" between" the" atezolizumab" and" chemotherapy" treatment"
groups" (Powles" et! al.," 2018)." The" efficacy" of" pembrolizumab" was" assessed" in" a"
phase" III" clinical" trial" with" patients" whose" urothelial" carcinoma" had" recurred" or"
progressed" following" chemotherapy."Median" overall" survival"was" 10.3"months" for"
the" pembrolizumab" group" and" 7.4" months" for" the" chemotherapy" group." This"
increase" in"overall" survival"was"significant" (Bellmunt"et!al.," 2017)."The"efficacy"of"






NMIBC" and" MIBC" have" distinct" molecular" profiles." FGFR3" overexpression" and"
mutations" in"FGFR3,"KDM6A,!STAG2" and"RAS"occur"more" frequently" in"NMIBC"
whilst"alterations" in"genes"which"regulate"TP53"and"the"cell"cycle"pathways"occur"
"4"
more" frequently" in" MIBC." TERT" mutations" occur" frequently" in" both" NMIBC" and"
MIBC." Mutation" rates" are" higher" in" MIBC" (Hurst" et! al.," 2017q" Robertson" et! al.,"
2017).""
Genetic" alterations" in" the" TP53/cell" cycle" pathway" occur" frequently" in"
bladder" cancer" (Lianes"et! al.," 1994)."The" frequency"of"TP53"mutations" increases"
with" stage" and" grade" and" alterations" in" TP53" are" weakly" predictive" of" mortality,"
tumour"progression"and" recurrence" (Esrig"et!al.,"1993q"Malats"et!al.,"2005)."TP53"
encodes" the" transcription" factor" TP53," which" is" a" tumour" suppressor." TP53"
regulates"expression"of"genes"which"control"cell"cycle,"metabolism,"DNA"repair"and"
apoptosis"(Fischer,"2017)."Robertson"et!al."conducted"analysis"including"RNA!seq,"
whole" exome" sequencing" and" copy" number" analysis" on" a" cohort" of" 412" MIBC"
tumours" (Robertson"et!al.,"2017)."They" reported" that" the"TP53/cell" cycle"pathway"
was" inactivated" in" 89%"of"MIBC" tumours." 48%"of" the"MIBC" tumours" had"mutant"




by" the" proteasome" (Merkel"et! al.," 2017)."CDKN2A" encodes" p16INK4A"which" binds"
and"inhibits"CDK4"and"CDK6"preventing"the"phosphorylation"of"RB1"and"so"inhibits"
cell" cycle" progression." CDKN2A" also" encodes" p14ARF" which" inhibits" MDM2"
(Pomerantz" et! al.," 1998q" Zhao" et! al.," 2016)." Amplification" and" overexpression" of"
MDM2" occurs" in" bladder" cancer" (López!Knowles"et! al.," 2006q"Maluf"et! al.," 2006q"
Tuna"et!al.,"2003)."TP53"mutations"occur"mutually"exclusively"with"amplification"of"
MDM2" and"deletion"of"CDKN2A" (López!Knowles"et!al.," 2006q"Veerakumarasivam"
et!al.,"2008q"Robertson"et!al.,"2017)."MDM2"amplification"and"overexpression"were"
found"in"6%"and"19%"of"tumours,"respectively"in"a"cohort"of"412"MIBC"(Robertson"
et! al.," 2017)." Additionally," it" was" observed" that" focal" deletion" of" 9p21.3," which"
contains"the"tumour"suppressor"CDKN2A,"occurred"in"22%"of"MIBCs"and"CDKN2A"
mutations"occurred" in"7%"of"MIBCs."Alterations"between"CDKN2A"were"mutually"
exclusive" with" mutations" observed" in" TP53" and" RB1" (Robertson" et! al.," 2017)."
Pietzak"et!al."observed"genomic"alteration,"predominantly"amplification,"of"MDM2"in"
8%"of"NMIBCs"and"genomic"alteration,"predominantly"deletion,"of"CDKN2A"in"19%"
of" NMIBCs" (Pietzak" et! al.," 2017)." They" observed" that" alterations" in" TP53" and"
MDM2"were"associated"with"a"higher"stage"and"grade"of"bladder"cancer"(Pietzak"et!
al.," 2017)." Homozygous" deletion" of" CDKN2A" occurs" more" frequently" in" bladder"
cancers" with" mutant" FGFR3" than" those" with" wildtype" FGFR3" and" homozygous"
deletion"of"CDKN2A"associated"with"a"higher"stage"in"tumours"with"mutant"FGFR3"
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but" not" those" with" wildtype" FGFR3" (Rebouissou" et! al.," 2012)."RB1" encodes" the"
tumour" suppressor"RB1"which" regulates" cell" cycle"progression"by"modulating" the"
activity" of" E2F" transcription" factors." Inactivating"mutations" in" RB1" are" a" frequent"
event"in"bladder"cancer"and"are"associated"with"a"higher"stage"and"grade"(Hong!Ji"
et! al.," 1993q" Horowitz" et! al.," 1990q" Ishikawa" et! al.," 1991)."RB1" mutations," which"
were"predominantly" inactivating,"were"observed" in"17%"of"MIBCs"and"deletion"of"
RB1"was"observed"in"4%"of"MIBCs"(Robertson"et!al.,"2017)."Pietzak"et!al."observed"
deletion" and" mutation" of"RB1" in" 6%" of" NMIBCs." Alterations" in" cell" cycle" control"
genes"were"significantly"associated"with"a"higher"stage"and"grade" (Pietzak"et!al.,"
2017).""
Fibroblast" growth" factor" receptor" 3" (FGFR3)" is" frequently" overexpressed"
and"FGFR3" is" frequently"mutated" in" bladder" cancer." Alterations" in"FGFR3" occur"
more" frequently" in" bladder" cancers" of" a" lower" stage" and" grade" (Kimura" et! al.,"
2001)."Tomlinson"et!al."screened"158"urothelial"carcinoma"samples"for"mutations"in"
FGFR3"exons"7,"10"and"15"with"direct"sequencing"and"examined"FGFR3"protein"
expression" in" 149" samples" with" immunohistochemistry." Bladder" cancer" tumours"
were"of"a" range"of" stages"and"grades." It"was"observed" that"81%"of"non!invasive"
and" 54%" of" invasive" urothelial" carcinomas" had" an" activating"FGFR3"mutation" or"
overexpressed"FGFR3"(Tomlinson"et!al.,"2007)."Robertson"et!al."observed"FGFR3"
mutations" in"14%"of"MIBCs,"FGFR3" fusion"events" in"2%"of"MIBC"and" focal"copy"
number"gain"of"the"FGFR3"locus"(4p16.3)"in"2%"of"MIBCs"(Robertson"et!al.,"2017)."
Genomic" alterations" were" observed" in" FGFR3" in" 49%" of" 105" NMIBC" patients,"
FGFR3"amplification"was"observed"in"2"tumours"(2%"of"the"cohort),"FGFR3"fusion"
events"were"observed"in"4"tumours"(4%)"and"missense"mutations"were"observed"in"
47" tumours" (45%)" (Pietzak"et! al.," 2017)."FGFR3"mutations" occurred" in" 79%"of" a"
cohort" of" 82" Ta" urothelial" tumours" examined" with" either" exome" sequencing" or"
selective" target" capture" followed" by" next!generation" sequencing" (NGS)" (Hurst" et!
al.,"2017)."FGFR"expression"in"urothelial"carcinoma"is"further"discussed"in"section"
1.3.2.""
Expression," mutation" and" copy" number" gain" of" members" of" the" EGFR"
family" of" receptor" tyrosine" kinases" (RTKs)" are" common" in" bladder" cancer."
Approximately" 6%" of" MIBC" exhibit" gain" of" copy" number" of" region" 7p11.2" which"
contains" EGFR" (Robertson" et! al.," 2017)." Examination" of" membranous" EGFR"
expression"with"immunohistochemistry"showed"that"61%"of"74"bladder"tumours"of"a"




7q12," which" contains" ERBB2," occurs" in" 5%" of" MIBC" (Robertson" et! al.," 2017)."
Examination" of" ERBB2" expression" with" immunohistochemistry" in" 1005" MIBC"
tumours"showed"that"ERBB2"overexpression"occurred"in"9%"of"tumours"(Laé"et!al.,"
2010)." Fluorescence" in! situ" hybridization" (FISH)" in" the" tumours" in" which"
immunohistochemistry" had" identified"ERBB2"overexpression," revealed" that" 5%"of"
the" cohort" of" 1005" tumours" exhibited" ERBB2" amplification" (Laé" et! al.," 2010)." A"
single"ERBB2" missense"mutation" and" no"ERBB2" amplifications" were" found" in" a"




Alterations" in" the" PI3" kinase" pathway" are" frequently" found" in" bladder"
cancers"(Askham"et!al.,"2010q"Aveyard"et!al.,"1999q"Cairns"et!al.,"1998q"Knowles"et!
al.,"2003q"Platt"et!al.,"2009q"Ross"et!al.,"2013q"Wang"et!al.,"2000)."PIK3CA"encodes"
the" phosphatidylinositol!3" (PI3)" kinase" p110#" subunit." PI3" kinase" phosphorylates"
phosphatidylinositol!4,5!bisphosphate" (PIP2)" to"produce"phosphatidylinositol!3,4,5!
triphosphate" (PIP3)."This" leads" to"AKT"activation"which"promotes" cell" growth"and"
survival"(Fruman"et!al.,"2017)."TSC1"forms"part"of"the"TSC"complex"which"inhibits"
the" activity" of" the" mTORC1" complex" which" in" turn" regulates" cell" growth" via" the"
promotion" of" translation." TSC1" is" inhibited" by"AKT" (Mieulet" and" Lamb," 2010)."Of"
the"412"MIBCs"examined"with"whole"exome"sequencing,"22%"harboured"PIK3CA"
mutations," which" were" predominantly" activating," and" 8%" had" TSC1" mutations,"
which"were"often"truncating"(Robertson"et!al.,"2017)."PIK3CA"and"TSC1"mutations"
were"observed" in" 28%"and"11%"of" a" cohort" of" 105"NMIBC" respectively."PIK3CA"
and" TSC1" mutations" were" found" not" to" be" significantly" associated" with" bladder"
cancer"stage"and"grade"(Pietzak"et!al.,"2017).""








and" ARID1A" are" frequently" mutated" in" bladder" cancer" (Gui" et! al.," 2011q" van"
Haaften" et! al.," 2009)." KDM6A" encodes" a" histone" H3" lysine!27" (H3K27)"
"7"
demethylase."One"consequence"of" the"histone"demethylation"activity" of"KDM6A"
in" fibroblasts" is" an" increase" in" expression" of" retinoblastoma" binding" proteins"
required" for" the" function"of"RB1"as"a" tumour"suppressor" (Wang"et!al.,"2010)." Its"
role"in"epithelial"cells,"including"the"urothelium,"is"unknown."CREBBP"and"EP300!
encode! CREB!binding" protein" and" p300" respectively" which" can" act" as" both"
tumour"suppressors"or"oncogenes."These"proteins"have"a"similar"structure,"with"
63%"amino"acid"sequence"identity,"and"are"largely"functionally"redundant."CREB!
binding" protein" and" p300" function" as" histone" acetyltransferases," interact" with"
transcription" factors" and" recruit" transcription" machinery" and" transcriptional"
coactivators"to" the"promoter."The"tumour"suppressive"role"of" these"proteins"may"
be"due"to"their"interaction"with"TP53,"BRCA1,"and"FOXO3a"(Wang"et!al.,"2013a)."
ARID1A" is" a" subunit" of" the"BAF"chromatin" remodelling" complex."BAF"has"been"
found" to" bind"RB1," aiding"RB1" repression" of" E2F1" activity:" this" could" be" a" key"
tumour"suppressive"function"of"the"BAF"complexes"(Hodges"et!al.,"2016q"Trouche"
et!al.,"1997).""
Gui" et! al." identified"mutations" in" 9"MIBC"with" whole" exome" sequencing."
Genes"identified"as"mutated"in"this"initial"cohort"were"then"examined"with"targeted"
exon" sequencing" in" a" further" 51"MIBC" and" 37" NMIBC" (Gui" et! al.," 2011)." They"





greater" exhibiting" mutated" KDM6A." ARID1A," CREBBP" and" EP300" mutations"
were"not"significantly"associated"with" tumour"stage"and"grade"(Gui"et!al.,"2011)."
In" the" Robertson" et! al." cohort" of" 412" MIBCs," mutations," predominantly"
inactivating,"were"observed"in"greater"than"5%"of"tumours"in"each"of"the"following"
chromatin" remodelling" genes:" KDM6A! (26%)," KMT2A" (11%)," KMT2C! (18%),"
KMT2D" (28%)," CREBBP! (12%)," EP300! (15%)," KANSL1! (6%)," ARID1A! (25%),"
ASXL1"(6%)"and"ASXL2!(9%)"(Robertson"et!al.,"2017)."In"a"panel"of"105"NMIBC,"
KDM6A,! ARID1A,! CREBBP! and! EP300" were" mutated" in" 38%," 21%," 21%" and"
15%" of" NMIBCs" respectively" (Pietzak" et! al.," 2017)." Hurst" et! al." observed"
predominantly" inactivating" mutations" in"KDM6A" (52%),"KDMT2D" (30%),"EP300"
(18%),"ARID1A"(18%),"KDMT2C"(15%)"and"CREBBP"(15%)"in"a"cohort"of"82"Ta"
urothelial"tumours"(Hurst"et!al.,"2017).""
" Reduced" expression" of" stromal" antigen" 2" (STAG2)" occurs" in" bladder"
cancer"due"to" truncating"and"missense"mutations"(Gui"et!al.,"2011q"Taylor"et!al.,"
"8"
2014)." STAG2" functions" as" a" subunit" of" the" cohesin" complex" to" adhere" to" the"
centromeric" regions" of" sister" chromatids" following" DNA" replication" in" the" cell"
cycle."This"maintains" the"cohesion"of"sister"chromatids"until" they"are"required" to"








may" promote" aneuploidy" and" tumour" evolution" due" to" its" role" in" regulating"
chromosomal" segregation." However," examination" of" STAG2" expression," with"
immunohistochemistry,"and"chromosomal"alterations,"with"high"resolution"SNP"or"
BAC" arrays," in" a" panel" of" 23" TaG1/TaG2" urothelial" carcinomas" showed" that" 9"
tumours"lacked"STAG2"expression"and"loss"of"STAG2"expression"often"occurred"
in" chromosomally" stable" tumours" (Balbás!Martínez" et! al.," 2013)." Additionally"
knockdown" of" STAG2" in" the" bladder" cancer" cell" lines" RT112," UM!UC!11" and"
639V" did" not" increase" the" development" of" aneuploidy" (Balbás!Martínez" et! al.,"
2013)." Furthermore," Taylor" et! al." observed" that" STAG2" mutation" was" not"
associated"with"an"increase"in"copy"number"alterations"in"bladder"cancer"(Taylor"
et! al.," 2014)." Therefore," loss" of" STAG2" may" exert" its" function" as" a" tumour"









express" TERT" are" able" to" undergo" only" 50!90" rounds" of" replication" prior" to" the"
induction" of" cell" senescence" (Heidenreich" and" Kumar," 2017)." TERT" promoter"
mutations"create"binding"sites"for"the"E!twenty!six"(ETS)"transcription"factors"(Bell"
et!al.,"2015q"Horn"et!al.,"2013)."Borah"et!al."showed"that"TERT"promoter"mutations"








Gene" expression" profiling" of" bladder" tumours" has" been" used" to" identify"
molecular"subtypes"with"differing"clinical"outcomes."Sjdahl"et!al."performed"mRNA"
microarray"expression"analysis"and"unsupervised"hierarchical"cluster"analysis"on"a"
cohort" of" 308" NMIBCs" and" MIBCs." Additionally," tumours" were" examined" for" the"
presence"of"FGFR3,"PIK3CA"and"TP53"mutations"and"the"expression"of"key"genes"
was"determined"with" immunohistochemistry."This" identified"5" subtypes"of" bladder"
cancer:"urobasal"A,"urobasal"B,"genomically"unstable,"infiltrated"and"squamous"cell"
carcinoma"(SCC)!like."The"tumour"subtype"with"the"best"prognosis"was"urobasal"A"
whilst" urobasal" B" and" SCC!like" had" the" worst" prognosis." Urobasal" A" and" B"
subtypes" both" exhibited" high" expression" of" FGFR3,! CCND1! and" TP63" and"
frequently"harboured"FGFR3"mutations."However,"whilst"urobasal"A"had"a"similar"
pattern" of" cytokeratin" expression" to" normal" urothelium," urobasal" B" exhibited" high"
expression"of"KRT6A,"KRT6C"and"KRT14."Urobasal"B"also"had"a"high"frequency"of"
TP53" mutations." The" SCC!like" subtype" also" exhibited" high" expression" of" basal"
markers" but" did" not" exhibit" the" FGFR3" gene" expression" signature" observed" in"
urobasal"A"and"B."The"genomically"unstable"subtype"had"a"high"frequency"of"TP53"
mutations"and"grossly" rearranged"genomes."The" infiltrated"subtype"exhibited"high"
expression" of" immunologic" and" extracellular"matrix" genes." Immunohistochemistry"
revealed"a"high"expression"of"CD3"and"ACTA2"in"the" infiltrating"subtype"tumours,"
confirming"the"presence"of"T"cells"and"myofibroblasts"(Sjodahl"et!al.,"2012).""
Damrauer" et! al." performed" consensus" clustering" on" gene" expression" data,"
curated" from" publically" available" datasets," from" 262" high" grade" NMIBCs." This"
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analysis" identified" two" subtypes." In" one" subtype" tumours" exhibited" higher"
expression"of"urothelial"basal"markers"(KRT14,"KRT5,"KRT6B"and"CD44)"and"had"
a"higher"frequency"of"alterations"in"the"RB1"pathway."In"the"other"subtype"tumours"
exhibited" higher" expression" of" markers" associated" with" urothelial" umbrella" cells"
(UPK1B,"UPK2,"UPK3A" and"KRT20)" and" this" subtype"had"a"higher" frequency"of"
FGFR3" and" TSC1" mutations." It" was" observed" that" the" basal!like" subtype" of"
tumours"had"a"significantly"shorter"disease"specific"and"overall"survival"(Damrauer"
et!al.,"2014)."





VIM)" and" p63" pathway" genes." This" subtype" had" a" significantly" shorter" disease"
specific" survival." Luminal" tumours" expressed" luminal" markers" (FGFR3,! FOXA1,!
GPX2,!ERBB2,!ERBB3,!CYP2J2,!GATA3,!PPARG,!KRT19,!KRT7,!KRT6,!FABP4,!
KRT20,! CD24,! KRT18! and! XBP1)," exhibited" PPAR"" pathway" activation" and" this"
subtype"was"enriched"with"activating"FGFR3"mutations."The"p53!like"subtype"also"
expressed" luminal"markers"but"possessed" the"determining" feature"of"an"activated"
wild!type"p53"gene"expression" signature." p53!like" subtype" tumours"were" typically"
resistant"to"chemotherapy."Expression"profiling"was"conducted"with"a"cohort"of"43"
MIBC"prior"to"and"following"neoadjuvant"chemotherapy."It"was"observed"that"post!
treatment," resistant" tumours"were"enriched"with" the"p53!like" subtype" (Choi"et!al.,"
2014)."""
" Robertson" et! al." conducted" consensus" clustering" with" the" RNA!seq" data"
generated" from"408"MIBCs."This"split" the"MIBCs" into"5"subtypes:" luminal," luminal"
papilliary," luminal" infiltrated," basal!squamous" and" neuronal" (Robertson" et! al.,"
2017)." The" luminal," luminal" papilliary" and" luminal" infiltrated" subtypes" had" high"
expression"of"UPK2,"UPK1A,"PPARG,"FOXA1"and"GATA3."The" luminal"papilliary"
subtype" was" enriched" with" tumours" with" a" papillary" structure" whilst" the" luminal"
infiltrated" subtype" exhibited" a" myofibroblast" and" smooth" muscle" expression"
signature"and"had"increased"expression"of"immune"markers."The"basal!squamous"
subtype"exhibited"high"expression"of"the"basal"and"stem!like"markers"CD44,"KRT5,"
KRT6A" and" KRT14" and" high" expression" of" TGM1," DCS3" and" PI3! which! are!
markers" of" squamous" differentiation." This" subtype" was" enriched" with" TP53"
mutations."The"neuronal"subtype"exhibited"high"expression"of"markers"of"neuronal"




after" 5" years" was" highest" for" the" luminal" papilliary" subtype," intermediate" for" the"
luminal" and" basal" squamous" subtypes" and" lowest" for" the" luminal" infiltrated" and"
neuronal"subtype"(Robertson"et!al.,"2017).""
" Sjodahl" et! al." conducted" hierarchical" cluster" analysis" with" microarray"
expression" data" and" examined" the" expression" of" 28" proteins" with"
immunohistochemistry" in" 307"MIBCs." This" categorised" tumours" into" the" following"
subtypes:" urothelial!like," genomically" unstable," basal/SCC!like,"mesenchymal!like,"
and" small!cell/neuroendocrine!like." The" urothelial!like" and" genomically" unstable"
subtypes"both"exhibited"expression"of"luminal"markers."However,"the"urothelial!like"
subtype"was"distinct" from" the"genomically"unstable"subtype"as" it" exhibited"higher"
expression" of" FGFR3," CCND1" and" RB1" and" lower" expression" of" E2F3." The"
basal/SCC!like," mesenchymal!like," and" small!cell/neuroendocrine!like" subtypes"
exhibited" lower" expression" of" luminal" markers." The" basal/SCC!like" subtype"
exhibited"high"expression"of"KRT5"and"KRT14"and"low"expression"of"GATA3"and"
FOXA1" whereas" the" mesenchymal!like" subtype" exhibited" high" expression" of" the"
mesenchymal"markers" vimentin" and" ZEB2" and" the" small!cell/neuroendocrine!like"
subtype"exhibited"high"expression"of"the"neuroendocrine"marker"TUBB2B"and"the"
epithelial"marker"EpCAM"(Sjödahl"et!al.,"2017)."
Seiler" et! al." conducted" expression" profiling" with" 343" MIBC" prior" to" these"
tumours" being" treated" with" neoadjuvant" chemotherapy" and" developed" a" single!
sample" genomic" subtyping" classifier" to" categorize" tumours" as" claudin!low," basal,"
luminal!infiltrated" or" luminal." 476"MIBC,"which"were" not" treated"with" neoadjuvant"
chemotherapy," from" previously" published" datasets" were" assigned" subtypes." This"
study"found"that"patients"with"basal"tumours"had"a"poor"prognosis"when"not"given"
neoadjuvant"chemotherapy"but" that" the"overall" survival"of"patients" in" this"subtype"
was"improved"when"treated"with"neoadjuvant"chemotherapy."Patients"with" luminal"
subtype"tumours"had"a"good"prognosis"whilst"the"luminal!infiltrated"and"claudin!low"
subtypes" had" a" poor" overall" survival." Treatment" with" neoadjuvant" chemotherapy"
had" little" effect" on" the" prognosis" of" the" luminal," luminal!infiltrated" or" claudin!low"
subtypes"(Seiler"et!al.,"2017)."
Hedegaard"et!al."conducted"RNA!seq"analysis"on"a"cohort"of"460"NMIBCs"and"
conducted" consensus" clustering" with" this" expression" data." This" identified" three"
subtypes"which"were"named"class"1!3"and"a"117"gene"classifier"was"developed"to"
assign" independent" samples" to" a" subtype/class."Hedegaard"et! al." suggested" that"
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the" luminal!like" class" 2" may" represent" a" Tis" pathway" of" progression" whilst" the"
basal!like"class"3"tumours"may"represent"a"Ta"pathway"of"progression."Class"1"and"
2" tumours" both" exhibited" high" expression" of" uroplakins" compared" to" class" 3"
tumours."However,"class"1"tumours"had"high"expression"of"genes"associated"with"
early" cell" cycle" in" contrast" to" class" 2" tumours"which" exhibited" high" expression" of"
genes"associated"with"late"cell"cycle."Additionally,"class"2"tumours"exhibited"higher"
expression"of"KRT20"which" is"a" luminal"marker"and"associated"with"carcinoma" in!
situ."The"class"3"subtype"did"not"exhibit"high"expression"of"early"or" late"cell"cycle"
genes." Low" expression" of" uroplakins" and" high" expression" of" the" basal" markers"
KRT5" and"KRT15" was" observed" in" class" 3" tumours" and" some" class" 3" tumours"
exhibited" high" expression" of"CD44." High" expression" of"KRT14," was" observed" in"
both"class"2"and"3"tumours."Class"1"and"2"tumours"exhibited"a"higher"frequency"of"
FGFR3" mutations" whilst" class" 3" tumours" exhibited" a" higher" frequency" of" TP53"




The" different" attempts" to" use" gene" expression" profiling" to" classify" bladder"
cancer"have"differed"in"the"subtypes"identified."However,"there"is"a"consensus"that"
there" are" basal" and" luminal" subtypes" of" bladder" cancer" and" that" tumours"






Targeted" therapies" act" against"molecules" specific" to," or" aberrantly" expressed" in,"
cancerous"cells"to"induce"cell"death"and"reduce"cell"division."In"contrast,"traditional"
chemotherapy"acts"less"specifically"by"targeting"rapidly"dividing"cells"whether"or"not"
they" are" cancerous." Targeted" therapies" can" take" the" form" of" either" monoclonal"
antibodies," small" molecule" inhibitors" or" gene" therapy." Gene" therapy," including"
oncolytic"viral"therapy,"involves"the"delivery"of"DNA"or"RNA"to"target"cells."The"aim"
is" to" induce" gene" expression" of" an" absent" or" defective" gene" in" target" cells," to"
increase" expression" of" a" gene" which" will" induce" cell" death," by" for" example"
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stimulating" an" immune" response," or" to" cause" cell" death" due" to" viral" infection."
Delivery"of" the"DNA"is"usually"achieved"with"a"viral"vector"(Fukuhara"et!al.,"2016q"
Naldini," 2015)." This" Introduction" will" focus" on" monoclonal" antibody" and" small"
molecule"inhibitor"treatments"as"these"therapies"are"most"relevant"to"this"project.""
Many" targeted" therapies" have" been" developed" against" RTKs," a" class" of"
proteins" which" are" frequently" activated" in" cancer." Upon" ligand" binding" RTKs"
undergo"a" conformational" change"which" results" in"oligomerisation."The"oligomers"
then" use"ATP" to" autophosphorylate" tyrosine" residues" in" the"RTK" tyrosine" kinase"
domain" and" to" phosphorylate" intracellular" signalling" molecules" (Ullrich" and"
Schlessinger," 1990)." RTKs" activate" intracellular" signalling" pathways" such" as" the"
MAP" kinase" and" the" PI3" kinase" pathways." Small" molecule" inhibitors" commonly"
have"specificity"for"the"ATP"binding"site"of"tyrosine"kinases"which"enables"them"to"
competitively" or" non!competitively" inhibit" RTK" activity" and" downstream" signalling"
(Klein"et!al.,"2005)."Monoclonal"antibodies"have"been"developed"with"specificity"for"
RTKs." These" monoclonal" antibodies" can" induce" cell" death" by" a" number" of"
mechanisms"including"cell"surface"receptor"agonist"or"antagonist"activity,"induction"
of" phagocytosis" and" antibody!dependent" cell!mediated" cytotoxicity." Monoclonal"
antibodies" and" small" molecule" inhibitors" specific" for" tyrosine" kinases" are" now"
established" treatments" for"cancer" (Fabbro,"2015q"Scott"et!al.,"2012)."Examples"of"
targeted" agents" which" have" been" found" to" increase" patient" survival" are" detailed"
below."
The"monoclonal"antibody" trastuzumab" is" specific" for" the"human"epidermal"
receptor"2"(ERBB2/HER2)."Binding"of"trastuzumab"to"ERBB2"reduces"downstream"
signalling" through" the" PI3" and" MAP" kinase" pathways" and" induces" antibody!
dependent" cellular" cytotoxicity" (Vu"and"Claret," 2012)." Trastuzumab" increased" the"
ten!year" overall" survival" rate" from" 75.2" to" 84%" in" women"with" primary," operable"
node" positive" or" high!risk" node" negative," ERBB2!positive" breast" cancer" without"
metastasis" when" used" in" conjunction" with" adjuvant" chemotherapy" (Perez" et! al.,"
2014).""
Hussain" et! al." examined" the" efficacy" of" treatment" with" trastuzumab,"
paclitaxel,"carboplatin,"and"gemcitabine" in"patients"with"ERBB2!positive"advanced"
urothelial" carcinoma." Out" of" the" cohort" of" 44" patients," there" were" 5" complete"
responses"and"26"partial"responses"to"treatment"(Hussain"et!al.,"2007)."Powles"et!
al." conducted" a" phase" III" clinical" trial" in" patients" with" EGFR!" or" ERBB2!positive"
metastatic" urothelial" carcinoma." The" efficacy" of" maintenance" treatment" with"
lapatinib," an" EGFR" and" ERBB2" small" molecule" inhibitor," following" first!line"
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chemotherapy," was" compared" to" treatment" with" a" placebo." Lapatinib" did" not"
significantly" increase" progression!free" survival" or" overall" survival" (Powles" et! al.,"
2017).""
The" small" molecule" inhibitor" erlotinib" is" a" first!generation" EGFR" tyrosine"
kinase" inhibitor" (TKI)." Erlotinib" reversibly" binds" the" adenosine" triphosphate" (ATP)"
binding" site" on" the"epidermal" growth" factor" receptor" (EGFR)" intracellular" domain."
Erlotinib"was"the"first"EGFR"TKI"to"be"approved"by"the"FDA,"following"a"phase"III"
clinical"trial"in"patients"with"non!small"cell"lung"cancer"(NSCLC)"which"accounts"for"
80!85%" of" lung" cancers." This" trial" found" that" erlotinib" could" prolong" survival" in"
these"patients"following"the"failure"of"one"or"two"chemotherapy"regimens"(Gridelli"et!
al.,"2010q"Zhang,"2016)."
Seront" et! al." assessed" the" efficacy" of" the" mTOR" inhibitor" everolimus" in"
patients" whose" urothelial" carcinoma" had" progressed" following" treatment" with"
platinum!based" chemotherapy." A" disease" control" rate" of" 27%"was" observed" at" 8"
weeks"(Seront"et!al.,"2012)."Milowsky"et!al."assessed"the"efficacy"of"everolimus"in"
patients" with" progressive" metastatic" urothelial" carcinoma" previously" treated" with"




mutation" in"TSC1! (Iyer"et!al.,"2012)."TSC1"acts" in"complex"with"TSC2"to"regulate"
the" GTPase" activity" of" Rheb" and" therefore" inhibit" activation" of" the" mTORC1"
complex"which"contains"mTOR"(Huang"and"Manning,"2008)." Iyer"et!al."examined"
the"tumours"of"a"further"13"patients"who"were"enrolled"in"the"same"clinical"trial"with"
a" targeted" deep" sequencing" assay" and" identified" that" three" other" tumours" had"
TSC1"nonsense"mutations."Two"of" the"three"patients"whose"tumours"had"a"TSC1"
mutation"had"a"minor"response"to"everolimus,"as"did"a"patient"who"had"a"somatic"
TSC1" missense" mutation" of" unknown" consequence." Of" the" 9" patients" whose"
tumours"were" identified"to"have"wildtype"TSC1,"only"one"patient’s"disease"did"not"
progress"(Iyer"et!al.,"2012)."








intracellular" signalling" molecules" which" induce" cell" proliferation" and" survival" by"
activating"intracellular"signalling"pathways"such"as"the"PI3"kinase"and"MAP"kinase"
pathways." Resistance" to" targeted" agents" frequently" occurs" via" maintaining"
activation" or" re!activation" of" the" intracellular" signalling" pathways" vital" for" cell"
proliferation"and"survival."This"can"occur"via"the"activation"of"an"RTK"not"inhibited"
by" the" targeted" agent" or" maintenance" of" signalling" via" the" targeted" RTK" due" to"
upregulation"or"mutation"of"the"receptor."Alternatively,"resistance"to"targeted"agents"
can" occur" due" to" alterations" in" intracellular" signalling" molecules" which" induce"
intracellular" pathway" activation" independent" of" upstream" signalling." Examples" of"
how" resistance" has" arisen" against" a"wide" variety" of" targeted" agents" are" detailed"
below."
The" first" generation" EGFR" small" molecule" TKIs" erlotinib," gefitinib" and"






was"absent" in" the"patient’s" original" biopsy" specimen"but" present" after" the"patient"
relapsed"after" treatment"with"gefitinib."This"mutation" introduces"a"methionine"side"
chain," which" impedes" EGFR" TKI" binding" to" the" ATP" binding" site" of" EGFR"
(Kobayashi" et! al.," 2005)." Activation" of" the" T790M" mutation" accounts" for"
approximately"60%"of"cases"of"acquired"resistance" to" first"generation"EGFR"TKIs"
(Zhang," 2016)." Second" generation" EGFR" TKIs" were" developed" to" overcome"
resistance"arising" from" the"T790M"mutation."These"TKIs" irreversibly" inhibit"EGFR"
by"covalent"bonding" to" the"ATP"binding"site" in" the"EGFR"tyrosine"kinase"domain."
However," patients" treated" with" second" generation" EGFR" TKIs" suffer" epithelium!
based"toxicities"due"to" inhibition"of"wildtype"EGFR,"limiting"the"tolerated"dose"and"









(Santarpia" et! al.," 2017)." Other" EGFR"mutations" that" induce" resistance" to" EGFR"
TKIs" include"D761Y," L747S"and"T854A,"which"are" located" in" the" tyrosine" kinase"
domain."The"mechanisms"by"which"these"mutations"induce"resistance"are"unknown"
(Balak"et!al.,"2006q"Bean"et!al.,"2008q"Costa"et!al.,"2007)."
Overexpression" or"mutation" of" an" alternative"RTK," or" overexpression" of" a"
receptor"ligand,"are"mechanisms"by"which"resistance"to"EGFR!targeted"agents"can"
arise." These"mechanisms" enable" the" activation" of" growth" and" survival" pathways"
such"as"MAP"kinase"and"PI3"kinase."Signalling"via"other"EGFR" family"members,"
MET," insulin!like" growth" factor" 1" receptor" (IGF1R)," vascular" endothelial" growth"
factor" receptors" (VEGFRs)," FGFRs" and" platelet" derived" growth" factor" receptor"
(PDGFR)"have"all"been"implicated"in"resistance"to"inhibition"of"EGFR"(Akhavan"et!
al.,"2013q"Azuma"et!al.,"2014q"Bianco"et!al.,"2008q"Engelman"et!al.,"2007q"Nakata"et!
al.," 2014q" Peled" et! al.," 2013)." For" example," amplification" of" ERBB2" and"
downstream" re!activation" of" the" MAP" kinase" pathway" has" been" identified" as" a"
mechanism" of" resistance" to" cetuximab" in" derivatives" of" colorectal" cancer" and"
NSCLC"cell" lines"which"had"undergone" long!term"culture" in"cetuximab"(Yonesaka"
et! al.," 2011)." ERBB2" amplification" has" been" identified" as" a" mechanism" of" both"
intrinsic" and" acquired" resistance" to" treatment" with" anti!EGFR" monoclonal"
antibodies"in"colorectal"cancer"patients"(Martin"et!al.,"2013q"Yonesaka"et!al.,"2011)."
Sartore!Bianchi"et!al." conducted"a"phase" II"clinical" trial" testing" the"combination"of"
trastuzumab" and" lapatinib" in" ERBB2!positive" metastatic" colorectal" cancer"
previously" treated" with" cetuximab" or" panitumumab." An" objective" response" was"
observed"in"8"out"of"27"patients"(Sartore!Bianchi"et!al.,"2016)."
Mutant!KRAS" is"found"in" lung"adenocarcinomas"with"wildtype"EGFR,"most"
commonly" mutated" at" G12," G13" or" Q61," which" reduce" GTPase" activity" and"
permanently" activate" RAS." Constitutively" active" KRAS" induces" MAP" kinase"
pathway"signalling"irrespective"of"RTK"activation."Patients"with"mutant"KRAS"have"
a"worse"response"rate"to"EGFR"TKIs"(Pan"et!al.,"2016q"Pao"et!al.,"2005)."Colorectal"













common" activating" BRAF" mutation" is" V600E" which" accounts" for" 90%" of" BRAF!




cetuximab" and" chemotherapy" that" have"mutant"BRAF" have" a" significantly" worse"




in" patients" with" BRAF!mutant" advanced" colorectal" cancer" has" been" examined" in"
phase"I/II"clinical"trials"and"found"to"have"acceptable"tolerability"and"clinical"activity"
(Atreya"et!al.,"2015q"Schellens"et!al.,"2015q"Yaeger"et!al.,"2015)."BRAF"activating"




et! al.)." Melanomas" have" been" found" to" activate" the" MAP" kinase" pathway" to"
overcome"treatment"with"BRAF"TKIs."Mutations"in"NRAS,"KRAS"and"MEK1"as"well"
as"amplification"and"alternative" splicing"of"BRAF" are" found" in"melanoma"patients"
who"developed"resistance"to"BRAF"TKI"monotherapy"(Shi"et!al.,"2014)."The"RTKs"
EGFR,"IGF1R"and"PDGFR$"have"been"reported"to"be"activated"as"mechanisms"of"
acquired" resistance" to"BRAF" inhibition" (Girotti"et!al.," 2013q"Nazarian"et!al.," 2010q"
Villanueva" et! al.," 2010)." Treatment" of" melanomas" with" the" MEK" inhibitors"
cobimetinib"and"trametinib"used"in"combination"with"BRAF"TKIs"has"been"found"to"
be" more" effective" than" BRAF" TKI" monotherapy." The" combinatorial" treatment"
hinders" the"emergence"of" resistance"via" re!activation"of" the"MAP"kinase"pathway"
and" is" less" toxic" (Grimaldi" et! al.," 2017)." The" combination" of" BRAF" and" MEK"
inhibition" is" also" effective" in" some" BRAF!mutant" metastatic" colorectal" cancer"
patients"(Corcoran"et!al.,"2015)."
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Activation"of" the"PI3" kinase"pathway" can"also" lead" to" resistance" to"BRAF"
inhibition." Mutations" in" the" PI3" kinase" pathway" genes" AKT1," AKT3," PIK3CA,"




Monoclonal" antibodies"and"TKIs" have"been"developed" that" are" specific" to"
ERBB2."Aberrant"activation"of"ERBB2"signalling,"via"overexpression,"amplification"
or," less" frequently," mutation" is" found" in" cancers" including" breast," gastric," lung,"
bladder,"colon,"ovary,"endometrium"and"head"and"neck."The"monoclonal"antibody"
trastuzumab"is"used"in"the"treatment"of"ERBB2!overexpressing"breast,"gastric"and"
gastroesophageal" cancer" (Iqbal" and" Iqbal," 2014)." In" order" to" determine" the"
suitability" of" patients" for" treatment" with" trastuzumab," ERBB2" overexpression" or"
amplification" is" determined" by" immunohistochemistry" or" in! situ" hybridisation"
(Bartley"et!al.,"2016q"Wolff"et!al.,"2013).""
One"mechanism"of" resistance" to" trastuzumab" is" the"synthesis"of" truncated"
ERBB2," termed"p95HER2,"which" lacks" the"extracellular"portion"of" the"protein"due"
to" cleavage" of" the" extracellular" domain" of" full" length" ERBB2" by" matrix"
metalloproteases"(Codony!Servat"et!al.,"1999).""Alternatively,"initiation"of"translation"
can" occur" from"methionine" residues" located" close" to" the"ERBB2" transmembrane"
domain" at" codons" 611" and" 678" of" full!length" ERBB2," generating" a" C!terminal"
ERBB2"fragment"(Anido"et!al.,"2006)."p95HER2"proteins"can"be"classified"by"their"
size:" either" 100" to" 115kDa" or" 95" to" 100kDa." 100!115kDa" fragments" are"
constitutively" active" homodimers" due" to" intermolecular" disulphide" bonds" formed"
between" cysteine" residues" in" the" short" extracellular" portion" of" this" protein." 95!
100kDa" sized" proteins" lack" these" cysteine" residues" and"most" likely" form" dimers"
due" to" homotypic" affinity" between" the" ERBB2" transmembrane" and" intracellular"
domains"(Arribas"et!al.,"2011)."The" trastuzumab"binding"site" is" in" the"extracellular"
domain"of"ERBB2"and"therefore"this"antibody"does"not"bind"p95HER2."It"has"been"
demonstrated"that"inducing"expression"of"p95HER2"in"breast"cancer"cell"lines"and"






Heterodimerisation" of" IGF1R" with" ERBB2" has" been" described" as" a"
mechanism" of" resistance" in" the" breast" cancer" cell" line" SK!BR!3" which" became"
trastuzumab" resistant" following" long!term" culture" in" trastuzumab." Inhibition" of"
IGF1R" increased" sensitivity" to" trastuzumab" by" reducing" IGF1R" and" ERBB2"
heterodimerization" (Nahta" et! al.," 2005)." " Patients" whose" breast" tumours" express"
IGF1R" at" the" cell" membrane," as" opposed" to" those" with" tumours" with" mainly"








which" was" observed" to" induce" resistance" to" lapatinib," an" EGFR!" and" ERBB2!
targeted" TKI," when" expressed" in" breast" cancer" cell" lines." The" T798M" ERBB2"
mutation" is"analogous" to" the"EGFR"T790M"mutation" in" the"EGFR"kinase"domain"
ATP"binding"site"(Bose"et!al.,"2013q"Rexer"et!al.,"2013)."Lapatinib"resistance"could"
be"overcome"by"treatment"with"the"irreversible"EGFR"and"ERBB2"TKI"neratinib."In"
July"2017,"neratinib"was"approved"by" the"FDA" for"early" stage"breast" cancer"with"






culture" in" lapatinib." This" mutation" enabled" the" resistant" derivative" to" maintain"
activation" of" the" PI3" kinase" pathway" in" the" presence" of" lapatinib," as" PIK3CA" is"
downstream" of" ERBB2." In" contrast," lapatinib" inhibited" the" PI3" kinase" pathway" in"
parental"BT474"(Rexer"et!al.,"2014)."Rexer"et!al."also"observed"that"treatment"with"
the"PI3K"inhibitor"BKM120"in"addition"to"trastuzumab"and"lapatinib"induced"tumour"
regression" in" an" ERBB2" amplified," mutant" PIK3CA" mouse" xenograft" model" of"
breast"cancer"whereas," treatment"with" trastuzumab"and" lapatinib"without"BKM120"
did"not" (Rexer"et!al.,"2014)."The" link"between"PI3"kinase"pathway"alterations"and"
trastuzumab" resistance" has" been" examined" in" breast" cancer" patients." Further"




and" trastuzumab" could" overcome" resistance" to" trastuzumab" in" breast" cancer" cell"
line" and" xenograft" models" (Lu" et! al.," 2007)." The" efficacy" and" safety" of" adding"
everolimus," an" mTOR" inhibitor," to" the" combination" of" trastuzumab" and" the"
chemotherapeutic"agent"vinorelbine"was"tested"in"a"phase"III"clinical"trial"in"patients"
with" ERBB2!positive," trastuzumab!resistant" breast" cancer." It" was" found" that"
everolimus" increased" the" progression!free" survival" of" patients" although" this"
additional"treatment"also"increased"adverse"effects"(André"et!al.,"2014)."
The" Philadelphia" chromosome" is" found" in" greater" than" 90%" of" cases" of"
chronic" myeloid" leukaemia" (CML)" and" 10!15%" of" cases" of" adult" acute"
lymphoblastic" leukaemia" (ALL)." This" genetic" alteration" is" formed" by" the"
Philadelphia" chromosomal" translocation:" t(9q22)(q34qq11)," and" results" in" the"
production" of" BCR!ABL" fusion" protein" which" has" constitutive" activity," unlike" ABL"
kinase" (Salesse" and" Verfaillie," 2002q" Wong" and" Witte," 2004)." Treatment" of"
Philadelphia" chromosome!positive" CML" with" imatinib," an" inhibitor" of" BCR!ABL,"
improves" patient" survival" (Hochhaus"et! al.," 2017q"O'Brien"et! al.," 2003)."However,"
resistance" to" imatinib" is" common," with" 60!95%" of" chronic" stage" CML" patients"
becoming"unresponsive"to"the"TKI"within"12"to"24"months."Mutations"in"BCRUABL"
are" a" mechanism" of" intrinsic" and" acquired" resistanceq" the" kinase" domain" of" the"
protein" is" a" mutation" hotspot." The" most" common" BCR!ABL" mutations" to" arise"
following"treatment"with" imatinib"are"T315I,"G250E,"M244V,"M351T,"and"E255K/V"
(Soverini" et! al.," 2014)." The" second" generation" ABL" TKIs" nilotinib," dasatinib" and"











TKI" ponatinib," which" inhibits" a" number" of" kinases" including" ABL," VEGFRs" and"
FGFRs,"was"developed" to"avoid" the"steric"clash"with" the"bulky" isoleucine" residue"
and" therefore" inhibits" T315I" BCR!ABL" in" addition" to"wildtype"ABL." Ponatinib" has"
been"approved"by" the"EMA"and"FDA" for"Philadelphia" chromosome"positive"CML"
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harbouring" the"T315I"mutation"and" for" the" treatment"of"Philadelphia"positive"CML"
resistant"to"or"intolerant"to"other"TKIs"(Jabbour"et!al.,"2015)."However,"resistance"to"
ponatinib"has"been"found"to"arise"via"further"mutation"of"residue"315:"I351M,"or"via"
compound"BCRUABL"mutations" including" E255V/T315I" (Zabriskie"et! al.," 2014)." A"
less"common"mechanism"of"resistance"to"imatinib"is"an"increase"in"BCRUABL"copy"
number" via" amplification" of" BCRUABL" or" gain" of" an" additional" Philadelphia"
chromosome." The" additional" copies" of" BCRUABL" induce" increased" protein"
expression" and" activation" of" BCR!ABL" (Hochhaus" et! al.," 2002q" le" Coutre" et! al.,"
2000).""
Studies" using" cancer" cell" lines" have" shown" that" cells" can" enter" a" drug!
tolerant" or" resistant" state" mediated" by" gene" expression" changes" and" epigenetic"
resistance"mechanisms"with"an"apparent" lack"of"genetic"alteration."Sharma"et!al."
generated"derivatives"of" the"NSCLC" line"PC9" tolerant" to"EGFR"TKIs"by"culturing"
parental" PC9" in" gefitinib" for" 9" days." These" cells" mediated" their" resistance" by"
activation"of"IGF1R"and"this"drug"tolerant"state"was"dependent"upon"the"activation"
of"the"histone"demethylase"KDM5A"(Sharma"et!al.,"2010)."Hou"et!al."reported"that"
KDM5A" protein" and" RNA" expression" was" increased" in" the" breast" cancer" lines"
SUM149"and"SUM102"following"6"and"9"days"culture" in"erlotinib."They"conducted"
stable"knockdown"of"KDM5A"in"the"breast"cancer"cell"lines"SUM149"and"HCC1937."
It" was" observed" that" stable" KDM5A" knockdown" reduced" the" number" of" drug"
tolerant"SUM149"and"HCC1937" cells" following" 30!day" culture" in" erlotinib" (Hou"et!
al.,"2012)."Gale"et!al."developed"the"KDM5A"inhibitor"YUKA1."It"was"observed"that"
treatment"with"YUKA1" reduced" the" formation" of" gefitinib!resistant" colonies" during"




PC9" cells" in" gefitinib" for" 2" weeks." Some" pools" of" PC9" cells" produced" resistant"
derivatives"with" the" EGFR" T790M"mutation" and" some"PC9" pools" produced" drug"
tolerant"derivatives"which"did"not"have"this"gatekeeper"mutation,"similar"to"the"PC9"
derivatives" described" by" Sharma" et! al." (Hata" et! al.," 2016q" Sharma" et! al.," 2010)."
Repetition" of" this" procedure" with" the" third" generation" EGFR" TKI"WZ4002," which"
effectively" inhibits" EGFR"T790M," yielded" only" the" drug" tolerant" derivatives"which"
lacked" the" T790M" mutation." Further" culture" of" the" drug" tolerant" derivatives" in"
gefitinib" led" to" acquisition" of" the" EGFR" T790M" mutation." However," these" cells"
retained"resistance"to"WZ4002"induced"apoptosis."This"study"indicates"that"further"
"22"
resistance" mechanisms" can" arise" from" cancer" cells" persisting" in" a" drug" tolerant"
state,"highlighting"the"importance"of"targeting"drug"tolerant"cells"(Hata"et!al.,"2016)."
" Ramires" et! al." expanded" a" single" clone" of" PC9" for" approximately" 20"
doublings."This"population"of"cells"was"then"treated"with"erlotinib"for"approximately"
2"months"at"which"point"the"emergent"colonies"of"drug"tolerant"cells"were"isolated"
and"cultured" in"erlotinib" for"a" further"6!8"months." In" total," this"process"yielded"17"
different" resistant" colonies." These" colonies" all" retained" greater" resistance" to"
erlotinib" than" PC9" following" culture" without" erlotinib" for" 40" weeks." They" then"
conducted" a" drug" screen," testing" the" sensitivity" of" the" resistant" cells" to" 560"
compounds"in"combination"with"erlotinib."Exome"sequencing"data"was"then"used"to"
attempt" to" identify" a" genetic" basis" for" the" drug" sensitivities" identified" in" the" drug"
screen."Despite" the" fact" that" the" resistant" cells"were"derived" from"a" single" clone,"
the" cells" exhibited" differential" sensitivity" to" drugs" in" the" screen." Some" colonies"
exhibited" broad" resistance" to" the" drugs" tested." One" resistant" clone" exhibited"
sensitivity" to"MET" inhibitors"and"was" found" to"contain"a"MET"amplification."Some"
exhibited" sensitivity" to" EGFR" inhibitors" capable" of" inhibiting" EGFR" T790M," and"
were" observed" to" have" acquired" this" mutation." Other" colonies" were" sensitive" to"
MEK" inhibitors" and" were" observed" to" have" acquired" NRAS" or" RAF1" mutations"
(Ramirez" et! al.," 2016)." This" study" demonstrates" that" several" mechanisms" of"
resistance"can"emerge"from"a"single"clone"in"a"drug"tolerant"state."
" Gastrointestinal"stromal"tumours"(GISTs)"often"have"activating"mutations"in"
the" RTK" encoding" genes"KIT" and"PDGFRA! (Heinrich" et! al.," 2003q" Hirota" et! al.,"
1998)."Mühlenberg"et!al."observed"that"the"combination"of"the"non!selective"histone"
deacetylase" inhibitor"vorinostat"and" imatinib"was"additive" in"KIT!positive"GIST"cell"
lines." Vorinostat" was" shown" to" reduce" KIT" mRNA" expression" and" increase"
acetylation"of"HSP90,"a"KIT"chaperone," inducing"KIT"degradation" (Muhlenberg"et!
al.,"2009)."Bauer"et!al." conducted"a"phase" I"clinical" trial"assessing" the"efficacy"of"
the" combination" of" imatinib" and" the" non!selective" histone" deacetylase" inhibitor"
panobinostat" in" overcoming" resistance" in" patients" with" GISTs" refractory" to" the"
combination" of" imatinib" and" the" multitargeted" TKI" sunitinib." One" out" of" the" 11"
patients" showed" a" partial" response," 7" had" stable" disease" and" 3" patients" had"
progressive"disease"(Bauer"et!al.,"2014).""
15!20%" of" colorectal" cancer" patients" have" global" high" CpG" island"
methylation" phenotype"which" induces" inactivation" of" tumour" suppressors" such"as"
the" mismatch" repair" gene" MLH1" (Mojarad" et! al.," 2013)." Garrido!Laguna" et! al."
conducted"a"phase"I/II"clinical" in" treated"metastatic"colorectal"cancer"patients"with"
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affect" tumour" drug" resistance." Paulsson" et! al." used" immunohistochemistry" to"
examine" the" stromal" expression" of" PDGFRβ," a" regulator" of" fibroblasts," in" 360"
tumours" from" premenopausal," and" 528" tumours" from" postmenopausal," breast"
cancer"patients"treated"with"and"without" tamoxifen,"a"selective"oestrogen"receptor"
modulator." Kaplan!Meier" analysis" showed" that" pre!" and" postmenopausal" patients"
with" low" expression" of" PDGFRβ" had" a" significant" increase" in" recurrence!free"
survival"when"treated"with"tamoxifen."In"contrast,"a"significant"treatment"benefit"was"
not"observed"in"patients"with"high"stromal"PDGFRβ"expression."This"study"did"not"
identify" a" causal" link" between" high" stromal" PDGFRβ" expression" and" tamoxifen"
resistance" (Paulsson" et! al.," 2017)." Park" et! al." reported" that" depletion" of" CD8+"
cytotoxic"lymphocytes"with"an"anti!CD8α!"antibody"induced"rapid"tumour"relapse"in"







The" FGFR" family" of" transmembrane" glycoproteins" (FGFRs1!4)" bind" to" and" are"
activated"by"18"FGFs"and"4"FGF"homologous" factors" that"have"differing"affinities"
for"each"of"the"FGFRs"and"their"splice"variants."The"different"FGFs"signal"through"
FGFR" in" a" paracrine" or" endocrine" manner" by" forming" a" complex" of" 2" FGFs," 2"
FGFRs"and"2"heparan"sulphate"molecules"(Ornitz"et!al.,"1996q"Zhang"et!al.,"2006)."
Fibroblast" growth" factor" receptor" like!1" (FGFRL1)," also" known" as" FGFR5," is" the"
most"recently" identified"member"of" the"FGFR"family"(Sleeman"et!al.,"2001)." It"has"
been"suggested"that"FGFRL1"is"a"decoy"receptor"(Steinberg"et!al.,"2010q"Trueb"et!
al.," 2003)" although"more" recent" evidence" indicates" that" it" may" activate" the"MAP"
kinase" pathway" independently" of" ligand" (Silva"et! al.," 2013)."Upon" ligand" binding,"
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FGFRs1!4" form" homodimers," and" intracellular" autophosphorylation" can" lead" to"
signalling" through" the" MAP" kinase," PI3" kinase," PLC"" and" JAK/STAT" pathways"
(Böttcher" and" Niehrs," 2005q" Klint" and" Claesson!Welsh," 1999)." From" the"
extracellular"N!terminus"through"to" the"C!terminus"FGFR1!4"contain" the"following:"
a" signal" peptide," immunoglobulin" (Ig)!like" domain" I," an" acid" box" consisting" of" a"
sequence"of"glutamic"and"aspartic"acids,"the"heparan"sulphate"binding"domain,"Ig!
like"domain"II,"Ig!like"domain"III,"a"transmembrane"domain,"a"juxtamembrane"linker,"
a" split" tyrosine" kinase" domain" and" an" inhibitory" carboxy!terminal" tail" (Fig."
1.1)(Belov"and"Mohammadi,"2013)."The" Ig!like"domains" I!III"are"named"D1!3"with"
D1"at"the"N!terminus"and"D3"proximal"to"the"membrane."D1"and"the"acid"box"are"
autoinhibitory" whilst" D2" and" D3" bind" FGFs" and" therefore" are" responsible" for"
specificity" of" each" receptor." FGFR1" can" be" alternatively" spliced" to" produce"
FGFR1#,"which"contains"Ig!like"domains"I!III"or"FGFR1$"which"contains"only"Ig!like"
domains"II"and"III"(Johnson"et!al.,"1991)."FGFR1#"exhibits"greater"affinity"for"FGF1"
and" heparan" than" FGFR1$" (Shi" et! al.," 1993q" Wang" et! al.," 1995)." FGFR1!3" can"
undergo" alternative" splicing" expressing" either" exon" 8" or" 9," producing" IIIb" or" IIIc"
isoforms" respectively."Exons"8"and"9"encode" the"C!terminus"of"D3"and" therefore"
this"alternative"splicing"event"affects"ligand"specificity."For"example,"FGF1"activates"
all" FGFRs" whereas" FGF2" preferentially" activates" the" FGFR" IIIc" isoforms."
Expression" of" FGFR" IIIb" isoforms" is" found" in" epithelial" tissue," in" contrast" to" IIIc"
isoforms"which"are"expressed"in"mesenchymal"tissue"(di"Martino"et!al.,"2012q"Olsen"
et! al.," 2004q" Ornitz" et! al.," 1996q" Zhang" et! al.," 2006)." FGFR3" IIIb" contains" the"
following" tyrosine" phosphorylation" sites:" Y579," Y649/650," Y726," Y762" and" Y772"
(Fig." 1.1)." " Phosphorylation" of" residue" Y726" is" important" in" the" activation" of" the"
MAP" kinase," PI3" kinase," STAT1" and" STAT3" pathways." Phosphorylation" of"
Y649/650,"which"are"situated"in"the"protein’s"activation"loop,"is"required"for"kinase"
activity." Phosphorylation" of" Y762" allows" binding" of" PLC"" and" the"PI3" kinase" p85"























FGFR" signalling" is" activated" in" many" different" cancers:" some" examples" are"
summarised"below."
" Moelans" et! al." observed" amplification" of" FGFR1" in" 17%" of" 104" invasive"
breast" cancers" examined" with" multiplex" ligation!dependent" probe" amplification"
(Moelans"et! al.," 2010)."Turner"et! al." interrogated"whole"genome"gene"expression"
data"from"295"invasive"breast"cancers,"examining"overexpression"of"genes"located"
in"the"8p11!12"amplicon,"which"contains"FGFR1."It"was"observed"that"amplification"
of"FGFR1"was" associated"with" the" luminal"B" breast" cancer" subtype"which" has" a"





Amplification" and" mutation" of" FGFR1" are" uncommon" events" in" bladder"
cancer." Fischbach" et! al." identified" FGFR1" amplification" in" 2" out" of" 122" bladder"
cancers"of"a"range"of"stages"and"grades"with"FISH"(Fischbach"et!al.,"2015)."Ross"
et! al." conducted" NGS" targeting" the" exons" of" 182" cancer" related" genes" and" the"
introns" of" 14" genes" often" rearranged" in" cancer" on" a" panel" of" 35" stage" IV,"
predominantly"high"grade"urothelial"carcinomas."Three" tumours"had"FGFR1"gene"
amplification," one" patient" had" a" T141R" FGFR1" mutation" and" one" tumour" had" a"
FGFR1!NTM" fusion" (Ross"et! al.," 2014)."Tomlinson"et! al." examined"expression"of"
FGFR1" in"27"bladder"cell" lines"and"73"bladder" tumours"with"quantitative"real" time"
PCR"(qRT!PCR)"and"observed"that"FGFR1"mRNA"expression"was"increased"in"the"
majority" of" bladder" cancer" cell" lines" and" tumours" compared" to" normal" human"
urothelial"cells."Knockdown"of"FGFR1"and"treatment"with"the"FGFR"TKI"PD173074"
(PD)" identified" the" bladder" cancer" cell" line" JMSU1" as" dependent" upon" FGFR1"




A" higher" ratio" of" FGFR1β! to! FGFR1α" expression" was" associated" with" a" higher"
stage"and"grade"in"tumours."Low"concentrations"of"FGF1"were"found"to"activate"the"
MAP" kinase" pathway" and" cell" proliferation" to" a" greater" extent" in" immortalized"
normal" human" urothelial" cells" transduced" to" express" FGFR1α" compared" to" cells"
transduced" to" express" FGFR1β" (Tomlinson" and" Knowles," 2010).! FGFR1"
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expression"has"been"associated"with"a"mesenchymal"phenotype"in"bladder"cancer"






examined" with" immunohistochemistry." Diez" de" Medina" et! al." examined" FGFR2"
mRNA"expression"in"54"urothelial"carcinomas"of"a"variety"of"stages"and"grades"and"






due"to" the" juxtaposition"of"FGFR3"with" IGH!gene"regulatory"sequences"(Kalff"and"




The" prevalence" of" FGFR3" mutation" and" overexpression" in" NMIBC" and"
MIBC"is"discussed"in"section"1.1.2."The"most"common"FGFR3"mutations"in"bladder"
cancer" are" S249C," Y375C," R248C" and" G372C" (Fig." 1.1)." All" these" mutations"
introduce" a" cysteine" in" or" close" to" D2" or" the" transmembrane" domain" of" the"
receptor,"inducing"the"formation"of"intermolecular"disulphide"bonds"and"constitutive"
phosphorylation" and" activation" of" FGFR3" (Bernard!Pierrot" et! al.," 2006)."
K650E/M/Q/T" FGFR3" kinase" domain" mutations" are" found" in" less" than" 1%" of"
urothelial" carcinomas" and" stabilise" the" kinase" in" its" active" state" (Huang" et! al.,"
2013)." FGFR3" mutations" are" normally" mutually" exclusive" with"RAS" mutations" in"
bladder"cancer,"suggesting" that"mutations" in" these"genes"perform"an"overlapping"
function"(Jebar"et!al.,"2005).""






The" first"FGFR" fusion"protein" to"be" identified"was"FGFR3!TACC3" in"glioblastoma"
multiforme" (Singh" et! al.," 2012)." FGFR1!TACC1" or" FGFR3!TACC3" fusions" are"









FGFR3!TACC3" fusion"containing" residues"1!760" (IIIb" isoform)"of"FGFR3,"but" this"
fusion"contains"TACC3"residues"433!638"(Fig"1.1)" (Williams"et!al.,"2013)."TACC3"
forms" a" complex" with" ch!TOG" and" clathrin" which" aids" the" formation" of" inter!
microtubule"bridges,"stabilising"kinetochore"fibres"during"mitosis"(Booth"et!al.,"2011q"
Peset" and" Vernos," 2008)." These" FGFR3!TACC3" fusions" are" due" to" a"
rearrangement" of" the" 4p16.3" region" containing" both"FGFR3"and"TACC3."SW780"






19" contains" a" PLC"" binding" site," Y762," and" a" site" involved" in" the" negative"
regulation"of"the"PI3"kinase"pathway,"Y772"(Hart"et!al.,"2001)."As"anticipated,"when"
expressed" in" immortalized" normal" human" urothelial" cells," the" FGFR3" fusion"
proteins" did" not" induce" phosphorylation" of" PLC"" but" did" induce" ERK"
phosphorylation" (Williams" et! al.," 2013)." Williams" et! al." considered" the" possibility"
that"the"FGFR3!TACC3"fusion"proteins"may"possess"aberrant"activation"compared"
to"wildtype"FGFR3"due"to"the"loss"of"FGFR3"exon"19."The"fusion"proteins"induced"
anchorage!independent" growth" and" a" more" spindle!like" morphology" when"
ectopically"expressed"in"the"mouse"embryonic"fibroblast"cell"line"NIH3T3."This"is"in"
contrast"to"the"result"of"ectopic"expression"of"a"truncated"FGFR3"with"a"stop"codon"
at" the" end" of" exon" 18" to" prevent" expression" of" C!terminal" exon" 19." This" did" not"
induce" a"morphological" change" and" induced" anchorage!independent" growth" to" a"
lesser"extent."This" suggests" that" the" fusion"partner" rather" than"simply" loss"of" the"
"29"
FGFR3"terminal"exon"is"important"for"the"oncogenic"potential"of"the"fusion"proteins"
(Williams"et! al.," 2013)." TACC3" is" thought" to" regulate"microtubule" stability" via" the"
formation"of"a"complex"with"ch!TOG"and"clathrin"(Ding"et!al.,"2017)."The"FGFR3!
TACC3" fusion" contains" the" TACC3" TACC" domain" which" mediates" dimerization"
(Guo" et! al.," 2015q" Simpson" et! al.," 2004)." The" inclusion" of" the" TACC" domain" in"
FGFR3!TACC3" may" mediate" homodimerization" of" the" fusion" protein," inducing"
activation" of" the" tyrosine" kinase" domain." Compared" to" wildtype" FGFR3," FGFR3!
TACC3" is" reported" to" have" increased" total" kinase" activity," additional"
phosphorylation"sites"and"an"increase"in"FGF"independent"activation"of"the"MAPK"
pathway"(Nelson"et!al.,"2016)."
* Sequencing"of"126"urothelial" tumours" identified" the" following"gene" fusions:"
one" FGFR1UNTM," four" FGFR3UTACC3," one" FGFR3UJAKMIP1" and" one" FGFR3U
TNIP2." Information" on" the" stage" and" grade" of" tumours" was" not" provided" in" this"
study"(Helsten"et!al.,"2016)."Guo"et!al."identified"two"FGFR3UTACC3"fusion"events"
in"a"panel"of"42"urothelial"carcinomas"of"a"variety"of"stages"and"grades"with"RNA!
Seq" (Guo" et! al.," 2013)." One" FGFR3!TACC3" fusion" event" was" present" in" a"
superficial" tumour"and"one"was"present" in"an" invasive" tumour" (Guo"et!al.," 2013)."
Robertson"et! al." examined" 412"MIBCs"with"RNA!Seq" and" identified" that" FGFR3!









TKI." Trudel"et! al." observed" that" dovitinib" inhibited" FGFR1," FGFR3,"KIT," vascular"
endothelial"growth"factor"receptor"1"(VEGFR1),"VEGFR2,"VEGFR3,"FLK3,"platelet!
derived" growth" factor" receptor" #" (PDGFR#)" and" PDGFR$" with" IC50s" less" than"
28nM"in"an"in!vitro"kinase"assay"(Trudel"et!al.,"2005)."It"has"been"trialled"in"patients"




patients." Although" it" was" well" tolerated" it" had" limited" single" agent" activity" in"
urothelial" cancer" patients" with" either"mutant" or" wildtype" FGFR3" (Milowsky" et! al.,"
2014).""
The" FGFR1!2," VEGFR1!3," PDGFR" α" and" PDGFRβ" TKI" lucitanib" was"
evaluated"in"a"phase"I/IIa"clinical"trial"in"76"patients"with"advanced"metastatic"solid"
tumours" including" breast," colon," rectal," lung" and" thyroid" cancer." Lucitanib" was"
assessed"in"patients"with"FGFR1"or"FGF3/4/19"amplification"or"whose"disease"was"
of" a" histological" type" potentially" sensitive" to" anti!angiogenic" therapy" patients" and"
whose"disease"was"progressing"following"previously"stable"disease"in"response"to"
anti!angiogenic!based" treatment." The" objective" response" rate" was" 30.4%" in" the"




gastroesophageal" cancer." In" these" trials" AZD4547" was" well" tolerated" but" the"
efficacy" of" AZD4547"was" often" disappointingq" however," Smyth"et! al." did" report" a"
confirmed"response"in"3"out"of"9"patients"with"FGFR2!amplified"gastroesophageal"
cancer"(Arkenau"et!al.,"2014q"Paik"et!al.,"2017q"Smyth"et!al.,"2015)."Other"trials"with"
AZD4547" are" in" progress" or" yet" to" commence," including" a" phase" I" trial," ID"
NCT02546661," in" metastatic" MIBC" patients" who" have" progressed" on" prior"
treatment"(Powles"et!al.,"2016)."
The"FGFR1!3"TKI"BGJ398"has"been"assessed" in"a"phase" I"clinical" trial" in"
patients"with"advanced"solid"tumours"with"FGFR"alterations."BGJ398"was"found"to"
have" a" tolerable" safety" profile" and" a" partial" response" was" observed" in" some"
patients" with" FGFR1!amplified" squamous" NSCLC" and" FGFR3!mutant" urothelial"
cancer" (Nogova" et! al.," 2017)." Pal" et! al." evaluated" the" efficacy" of" single" agent"
treatment"with"BGJ398"in"67"patients"with"metastatic"urothelial"carcinoma"who"had"
progressed" on" or" were" intolerant" to" platinum!based" chemotherapy" and" whose"
tumours"had"alterations"in"FGFR3."There"was"an"overall"response"rate"of"25%"and"
disease" stabilisation" was" observed" in" an" additional" 39%" of" patients." FGFR3"
gatekeeper"mutations" (V443L,"V443M," and" L496V)"were" detected" in" the" cell!free"
DNA"(cfDNA)"of"4"patients"during"treatment"(Pal"et!al.,"2018)."
The" FGFR1!4" TKI" erdafitinib" has" been" assessed" in" a" phase" I" trial" in" a"
number" of" advanced" solid" tumours."Of" the" 8" urothelial" carcinoma" patients" in" this"
trial," a" partial" response" was" reported" in" 2" patients" with" FGFR3UTACC3"
translocations" and" a" patient" with" a" FGFR2UBICC1/FGFR2UCASP7" translocation"
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(Tabernero"et!al.,"2015a)."Erdafitinib"was"assessed"in"another"phase"I"clinical" trial"
in" patients"with" advanced" solid" tumours" and" found" to" have" a"manageable" safety"
profile." No" patients" had" a" partial" or" complete" response." This" trial" had" only" one"
bladder" cancer" patient" (Tabernero"et! al.," 2015b)."Completed," ongoing"or" planned"
























































mutation" introduces" a" large" methionine" side" chain" mutation" that" causes" steric"
hindrance" with" the" FGFR" inhibitors" PD" and" E3810" but" not" others" such" as"
AZD4547." AZD4547" retains" binding" affinity" due" to" flexibility" caused" by" an" ethyl"
linker" in" its"structure."This"mutation"also" increases" the"stability"of" the"hydrophobic"
"32"
spine"of" residues" indicative"of" the"active" form"of" the"catalytic"domain" (Sohl"et!al.,"
2015q"Yoza"et!al.,"2016)."
Long!term"culture"of"the"myeloma"cell" line"KMS!11"with"the"FGFR"inhibitor"
AZ12908010," which" was" discovered" during" the" development" of," and" is" closely"
related" to," AZD4547," produced" a" resistant" derivative" with" an" FGFR3" V555M"
mutation," analogous" to" the" FGFR1" V561M" gatekeeper" mutation." The" KMS!11"
AZ12908010!resistant"derivative"had"also"acquired"resistance"to"AZD4547"and"PD."






were" expanded." This" screening" procedure" was" repeated" with" Ba/F3" cells" stably"
expressing" the"FGFR2!activating"mutations,"S252W"or"N550K." In" total"14"FGFR2"
mutations" which" induced" resistance" to" dovitinib" were" identified," 13" of" which"
occurred" in" the" FGFR2" tyrosine" kinase" domain" (M536I," M538I," I548V,"
N550H/K/S/T," V565I," E566A/G," L618M," K642N" and" E719G)." One" mutation,"
Y770fsX14,"was"in"the"FGFR2"c!terminal"tail."One"of"these"mutations"was"N550K,"
which" accounts" for" 25%" of" FGFR2!mutant" endometrial" cancers." This" mutation"
induced" the" greatest" cross!resistance" to" PD." N550" is" part" of" an" autoinhibitory"
network"of"residues,"and"mutations"affecting"this"site"allow"the"kinase"to"adopt"an"
active"state."The"only"mutation"identified"that"caused"resistance"to"ponatinib,"a"TKI"
that" inhibits" BCR!ABL" and" FGFR1!4," was" V565I." The" gatekeeper" residue" V565I"
stabilizes" the" hydrophobic" spine," in" a" similar" way" to" some" of" the" other" reported"
mutations,"but"also"sterically"hinders"FGFR"TKI"binding."This"steric"hindrance"is"a"
possible"cause"of"the"ponatinib"resistance"(Byron"et!al.,"2013)."




model" showed" that" treatment" with" PD" and" gefitinib" reduced" tumour" volume" to" a"
greater" extent" than" either" of" the" drugs" given" separately" (Herrera!Abreu" et! al.,"
2013)."
"33"
Long" term" treatment" of" RT112" with" the" pan!FGFR" TKI" BGJ398" yielded"
resistant" derivatives"with" phosphorylated"ERBB2" and"ERBB3" and" sensitivity" to" a"
combination"of"inhibitors"of"the"EGFR"family"(Wang"et!al.,"2014).""
A"screen"of"a"shRNA"library"that"targeted"kinases"and"kinase!related"genes"
in"RT112" identified" that" inhibition"of" the"PI3"kinase"pathway"and"EGFR"enhanced"
the" effect" of" AZD4547." Phosphorylation" of" EGFR" and" ERBB3" was" observed" in"
RT112" following" AZD4547" treatment." The" pan!PI3" kinase" inhibitor" BKM120" plus"
AZD4547" synergistically" reduced" proliferation" in"RT112" and" JMSU!1," a" urothelial"
carcinoma"cell"line"with"FGFR1"amplification"(Wang"et!al.,"2017b)."
A" secreted" protein" cDNA" library" was" screened" in" RT112" cultured" in"
BGJ398." The" EGF" family" ligands" neuregulin" 1" (NRG1)," NRG2" and" transforming"




In" order" to" examine" how" urothelial" carcinomas"may" acquire" resistance" to" FGFR"
TKIs"this"study"has"made"use"of"the"cell"lines"RT112"and"RT4."RT112"was"derived"





line" has" a" BRCA2! Q2731R" missense" mutation," a" CDH6" S2380X" nonsense"
mutation," a" TERT" promoter" mutation" and" homozygous" deletion" of" CDKN2A"
(Aveyard"and"Knowles,"2004q"Earl"et!al.,"2015q"Nickerson"et!al.,"2017)."BRCA2" is"
crucial" in" the" repair" of" DNA" double" strand" breaks" by" homologous" recombination"
maintaining" genomic" stability" (Fradet!Turcotte" et! al.," 2016)." CDH6" encodes"
cadherin"6"which"is"a"type"II"classical"cadherin"(Shimoyama"et!al.,"1999).""
RT4" is" mainly" tetraploid," has" a" DNMT3A" S129L" missense" mutation," an"
ELF3" 217_219del" frameshift" deletion," ESPL1" P1937A" missense" mutation," FAT4"
R3716H" missense" mutation," a" PALB2" L337S" missense" mutation" and" a" TSC1"





al.," 2014)." ELF3" frameshift" deletions" and" insertions," splice" site" and" missense"
mutations" are" found" in" bladder" cancer" (Dadhania" et! al.," 2016)." Guo" et! al." found"
ESPL1! mutations" in" 6%" of" urothelial" carcinomas" (Guo" et! al.," 2013)." ESPL1!




which"binds"BRCA2"and"recruits" it" to" the"site"of"DNA"damage"(Park"et!al.,"2014)."
RT112"and"RT4"express"wildtype"FGFR3"and"FGFR3!TACC3"fusion"proteins"(Fig."
1.1)"(Williams"et!al.,"2013)."
RT112" and" RT4" were" chosen" for" this" study" as" they" are" reported" to" be"
sensitive"to"PD"(Lamont"et!al.,"2011)."PD"acts"by"binding"the"ATP!binding"pocket"in"
the" tyrosine" kinase" domain" of" FGFR1" and" FGFR3" (Mohammadi" et! al.," 1998)."
Lamont" et! al." reported" RT112" and" RT4" as" having" IC50s" of" 15nM" and" 5nM"
respectively"for"PD"(Lamont"et!al.,"2011)."Herrera!Abreu"et!al."found"that"treatment"
of" RT112" with" 1mM" PD" for" 3" days" reduced" cell" viability" by" over" 50%" (Herrera!
Abreu"et! al.," 2013)." In" order" to"produce"a"model" of" acquired" resistance" to"FGFR"
inhibition," RT112" and" RT4" were" cultured" in" PD" for" 20" passages." Resistant"





now"entering"clinical" trials" to"assess" their" suitability" for" the" treatment"of"urothelial"





























The" TKIs" used" in" this" study"were" the" FGFR" inhibitor" PD173074" (Sigma!Aldrich),"
the"EGFR" inhibitor" Erlotinib" (Cayman"Chemical)," the"EGFR," ERBB2" and"ERBB3"
inhibitor" Sapitinib" (ApexBio" Technology)," the" IGF1R" inhibitor" Linsitinib" (Biovision)"
and" the"MET" inhibitor"Capmatinib" (Adooq"Bioscience)."All"TKIs"were"dissolved" in"






et! al.," 1986)." The" cell" line" identity" of" parental" RT112" and" parental" RT4" was"
confirmed"with"short"tandem"repeat"profiling"in"2012."The"RT112"and"RT4"profiles"
were" compared"with" reference" profiles" from" the"ATCC"and"DSMZ"databases."All"
resistant" derivatives" were" previously" generated" in" the" Knowles" lab" (described" in"
Chapter" 3)."RT112"R1,"RT112"R3" and"RT4"R1"were" cultured" in" 1μM"PD173074"









g" for" 4" min" then" resuspended" in" an" appropriate" volume" of" growth" medium" and"
transferred" to" sterile" 25cm2" or" 75cm2" vented" canted!neck" cell" culture" flasks"
(Corning)."Cells"were"maintained"at" 37°C" in"a"humidified" incubator" (Sanyo)" in"an"
atmosphere" of" 5%" CO2" in" air." RT112" cells" were" cultured" in" RPMI!1640" growth"
medium"(Sigma!Aldrich)"supplemented"with"10%"foetal"calf"serum"(FCSq"Biosera)"
and"2mM"GlutaMAX"(Life"Technologies)."RT4"was"cultured" in"McCoy’s"5A"growth"
medium" (Sigma!Aldrich)" supplemented" with" 10%" FCS" and" 2mM" GlutaMAX."
Resistant" derivatives" were" cultured" in" the" same"media" as" their" parental" cell" line"
supplemented"with"PD173074."The"resistant"derivatives"RT112"R1,"RT112"R3"and"
RT4"R1"were"routinely"cultured"in"1μM"PD173074"whilst"RT112"R2"was"cultured"in"




Cells" were" routinely" passaged" at," or" just" prior" to," confluence." Medium" was"









Cells" were" counted" to" seed" plates" with" the" correct" number" of" cells" per" well" for"
growth"curves"and"cell"viability"assays,"and"to"calculate"cell"numbers"during"growth"
curves." A" single" cell" suspension" was" produced" as" described" above." Cells" were"











For"each"cell" line"a"70!80%"confluent" 75cm2" flask"was"selected"and"a" single" cell"
suspension"produced"as"described"above."A" flat!bottomed"96"well"plate" (Corning)"
was" seeded" with" 100μl" of" cells" per" well" in" medium" without" any" TKI" or" vehicle"
present."Cells"were"seeded"at"a"density"that"would"give"80%"confluence"at"the"end"






37°C" in" 5%" CO2." Fluorescence" was" measured" on" a" Berthold" Mithras" LB" 940"
Multimode"microplate"reader."Excitation"was"at"540nM"and"emission"was"at"590nM"
respectively."Results"were"blanked"with"a"medium"no"cell"control"and"normalized"to"






Amphotropic" retrovirus" was" produced" as" follows:" 50%" confluent" Phoenix" Ampho"
cells" were" transfected" overnight" with" virus" backbone" plasmids:" pBABEpuro,"


















with" phosphate" buffered" saline" (PBS)." Cells" were" lysed" on" ice" in" 250μl" of" RIPA"
buffer"(Appendix"A)"containing"6.25μl"protease"inhibitor"cocktail"(P8340)"and"2.5μl"
phosphatase" inhibitor" cocktail" 2" (P5726)" (Sigma!Aldrich)." The" flasks" were"
incubated"on"ice"for"5"min"then"cells"were"detached"using"a"cell"scraper"(Sarstedt)."





Proteins" used" for" immunoblotting" and" immunoprecipitation" were" quantified" by"
Bradford"assay."Protein"concentrations"were"measured"using" the"Bio!Rad"protein"
assay," which" is" based" on" the" Bradford" dye!binding" method," according" to" the"
manufacturer’s" protocol." The" absorbance" of" a" series" of" bovine" serum" albumin"
standards" was" measured" on" a" Bio!Rad" SmartSpec" Plus" spectrophotometer" and"




Protein" samples"were"diluted"with"RIPA"buffer" to" contain"30μg"of"protein" in"20μl."
5μl"of"5x"SDS"loading"buffer"(Appendix"A)"was"added"and"samples"were"denatured"
for" 3" min" at" 100°C" then" placed" on" ice" for" 3" min." 10μl" of" Precision" Plus" Protein"
"40"
Prestained" Standard" (Bio!Rad)" and" 20μl" of" samples" were" loaded" onto" 7.5%"
polyacrylamide" Bio!Rad" Mini!PROTEAN" TGX" precast" gels." Gels" were"
electrophoresed" in"1x"TGS"buffer" (Bio!Rad)" (Appendix"A)"at"3W"per"gel,"until" the"
blue" dye" front" reached" the" bottom" of" the" gel." Proteins" were" transferred" to"
nitrocellulose"membranes"using"the"high"molecular"weight"program"on"a"Trans!Blot"
Turbo"Transfer"System"(Bio!Rad)"with"a"Trans!Blot"Turbo" transfer"pack"(Bio!Rad)"
of" either" mini" or" midi" format." Membranes" were" blocked" in" 4%" (w/v)" non!fat" milk"




incubated" with" HRP!conjugated" secondary" antibody" in" 2%" (w/v)" non!fat" milk" in"
PBS!T" for"1"h"at"RT"or"overnight"at"4°C"on"a"shaking"platform."Membranes"were"
then" washed" for" 4" x" 10" min" in" PBS!T." HRP!labelled" antibody" was" detected" by"
chemiluminescence"using"Luminata"Forte"Western"HRP"Substrate"(Merk"Millipore)"
and" imaged" with" a" ChemiDoc" MP" System" and" Image" Lab" software" (Bio!Rad)."












1°*antibodies* " " "
β!actin"(ACTBD11B7)* Santa"Cruz"sc!81178* Mouse"monoclonal* 1/3000*




CK5/6"(D5/16B4)" Dako"M7237" Mouse"monoclonal" 1/1000"
E!cadherin"[HECD!1]* Abcam"ab1416" Mouse"monoclonal" 1/500"
EGFR"(1005)* Santa"Cruz"sc!03" Rabbit"polyclonal" 1/1000"
Erbb2* Abcam"ab2428" Rabbit"polyclonal" 1/1000"
Erbb3"(C!17)* Santa"Cruz"sc!285" Rabbit"polyclonal" 1/1000"
Erk"(K23)* Santa"Cruz"sc!94" Rabbit"polyclonal" 1/1000"
FGFR3"(B!9)* Santa"Cruz"sc!13121" Mouse"monoclonal" 1/1000"
FLG"(C!15)"(FGFR1)" Santa"Cruz"sc!121" Rabbit"polyclonal" 1/500"
N!cadherin"(13a9)" Santa"Cruz"sc!59987" Mouse"monoclonal" 1/500"
Met" Cell"Signalling"#4560" Rabbit"polyclonal" 1/1000"
"41"
phospho!Akt"(Ser473)"
(D9E)" Cell"Signalling"#4060" Rabbit"monoclonal" 1/1000"
phospho!EGFR"
(Tyr1068)"(D7A5)" Cell"Signalling"#3777" Rabbit"monoclonal" 1/1000"
phospho!Erbb2"
(Tyr1221/1222)"(6B12)" Cell"Signalling"#2243" Rabbit"monoclonal" 1/1000"
phospho!Erbb3"
(Tyr1289)"(21D3)" Cell"Signalling"#4791" Rabbit"monoclonal" 1/1000"
phospho!Erk"(Tyr204)"
(E!4)" Santa"Cruz"sc!7383" Mouse"monoclonal" 1/1000"
phospho!Met"
(Tyr1234/1235)"(D26)" Cell"Signalling"#3077" Rabbit"monoclonal" 1/1000"
phospho!Stat1"
(Tyr701)"(58D6)" Cell"Signalling"#9167" Rabbit"monoclonal" 1/1000"
phospho!Stat3"
(Tyr705)" Cell"Signalling"#9131" Rabbit"polyclonal" 1/1000"
SCD1"(M38)" Cell"Signalling"#2438" Rabbit"polyclonal" 1/1000"
SREBP1"(A4)" Santa"Cruz"sc!13551" Mouse"monoclonal" 1/1000"
Stat1" Cell"Signalling"#9172" Rabbit"polyclonal" 1/1000"
Stat3"(79D7)" Cell"Signalling"#4904" Rabbit"monoclonal" 1/1000"
Vimentin"(H!84)" Santa"Cruz"sc!5565" Rabbit"polyclonal" 1/500"
2o*Antibodies" " " "








RNA" was" extracted" using" an" RNeasy" Mini" Kit" (Qiagen)" according" to" the"
manufacturer’s" protocol" and" the" concentration" determined" by" measuring" the"









34μl" for" 15" minutes" at" RT." The" reaction" was" inhibited" by" the" addition" of" 4μl" of"
25mM" EDTA" (all" reagents" from" Life" Technologies)." The" sample" volume" was"




and" the" 260/280nm" absorbance" ratio" respectively." The" integrity" of" the" RNA" was"







optical" density" (OD)" (NanoDrop)." The" cDNA"was" normalised" and" hybridised" onto"
Affymetrix"Human"Transcriptome"2.0"microarrays"for"16"hours"at"45°C."Microarrays"
were" washed" and" stained" using" the" Affymetrix" GeneChip®" Hybridization," Wash,"
and" Stain" Kit" according" to" manufacturer’s" instructions" using" the" Affymetrix"





Quality" control" of" individual" sample" hybridisations" and" normalisation" of" data" was"
conducted"with"Affymetrix"Expression"Console."To"adjust"for"the"variability"in"probe"





gene" expression" between" experimental" conditions." The" criteria" for" a" significant"
change"in"intensity"were"a)"a"linear"fold"change"greater"than"or"equal"to"2"and"b)"an"
unpaired" one!way" Analysis" of" Variance" (ANOVA)" p!value" less" than" 0.05."
MetaCore™" was" used" to" examine" which" pathways" were" significantly" altered"
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RNA"was" reverse" transcribed" into" first" strand"cDNA"using"SuperScript" II"Reverse"
Transcriptase"(Life"Technologies)"according"to"the"manufacturer’s"protocol."1μg"of"
RNA," 250ng" random" primers" and" 1μl" dNTP" mix" (10mM" each)" were" added" to" a"




to" each" tube." Samples" were" incubated" at" room" temperature" for" 2" min" then" 200"
units" of" SuperScript" II" reverse" transcriptase" were" added" to" each" tube." Samples"






PCR"was" performed" using" first" strand" cDNAs" to" examine" the" expression" of" total"
FGFR2,"FGFR2"IIIb,"FGFR2"IIIc"and"HPRT1."Each"reaction"contained"1x"AmpliTaq"
Gold®"360"buffer,"1.5mM"MgCl2,"0.2μM"of"forward"and"reverse"primers"(see"Table"
2.2" for" primer" sequences)," 200μM" dNTPs," 1U" AmpliTaq" Gold®" 360" DNA"








DNA" ladder" (New" England" Biolabs," N3231S)" and" 10μl" of" PCR" products" were"
loaded"onto"2%"agarose"(w/v)"gels"cast"using"1x"TBE"(Severn"Biotech)(Appendix"
A)" and" containing" 0.6μg/ml" ethidium" bromide" (Severn" Biotech)." Gels" were"




























SYBR" Green" assays." For" TaqMan" assays," pre!made" and" optimised" gene"
expression" assays" (Applied" Biosystems)" were" used" (Table" 2.3)." Each" reaction"
contained"10μl"2x"TaqMan"Gene"Expression"Master"Mix"(Applied"Biosystems),"1μl"
TaqMan" gene" expression" assay," 7μl" dH20" and" 2μl" cDNA." Previously" optimised"
SYBR"Green"assays"were"used"for"analysis"of"KDM6A"mRNA"levels."Each"reaction"
contained" 12.5μl" 2x" SYBR"Green"mix," 1.5μl" of" each" forward" and" reverse" primer"
(10μM" stock)" (see" Table" 2.4" for" primer" sequences)," 9μl" dH20" and" 2μl" cDNA."
Reactions" were" performed" in" triplicate" in" 96!well" optical" plates" (Applied"
Biosystems)" in" a" 7500" Real!Time" PCR" System" (Applied" Biosystems)." Cycling"
conditions" consisted" of" an" initial" hold" at" 50°C" for" 2"min," followed" by" 95°C" for" 10"
min,"then"40"cycles"of"95°C"for"15"s"and"60°C"for"1"min.""Melt"curve"analysis"was"
performed" for" SYBR"Green" assays" after" the" PCR" amplification" step." Expression"
levels" were" normalised" to" the" expression" of" the" housekeeping" gene" succinate"















































the" PicoGreen" dsDNA" quantitation" assay" (Thermo"Scientific)" as" follows:" Lambda"
DNA" standards" were" prepared" to" final" concentrations" of" 1000," 100," 10," 1" and" 0"
ng/ml"and"samples"were"diluted"1"in"500"in"1"x"TE"buffer."100μl"of"these"standards"
and"diluted"samples"were"pipetted"into"a"black"96"well"optical"plate"(BMG"Labtech"
Ltd)." Then" 100μl" of" PicoGreen" reagent" (diluted" 200" fold" in" 1x" TE)"was" added" to"
each"well."Standards"and"samples"were"mixed"by"pipetting"and"incubated"at"RT"for"















Libraries"were"generated"and"enriched" for"exomic" regions"using" the"SureSelectXT"
Human" All" Exon" V6" capture" library" (Agilent)" according" to" the" manufacturer’s"
protocols."An"overview"of" the"production"of" libraries" for"NGS" is"shown" in"Fig."2.2."
The" concentration" and" size" of" DNA" fragments" was" assessed" using" a" 2200"
TapeStation"(Agilent)"with"High"Sensitivity"D1000"ScreenTapes"(Agilent)"according"
to" the" manufacturer’s" instructions." The" points" at" which" the" 2200" TapeStation"
(Agilent)"was"used"to"determine"the"concentration"and"size"of"DNA"fragments"are"
detailed" in" Fig" 2.2." RT112" parental," RT112" R1," RT112" R3" and" 2" samples" not"
relevant"to"this"project"were"indexed,"pooled"and"run"in"a"single"lane"on"an"Illumina"




Procedure" conducted" by" Dr" Olivia" Alder:" Base" calling" and" quality" control" was"
performed" using" Illumina’s" Real" Time" Analysis" software" with" standard" settings."
Sequence" files" were" QC" checked" using" FastQC" (v0.10.0)" before" preprocessing."
Adapter" contamination" and" low!quality" read" ends" (<" 20)" were" trimmed" using"
cutadapt" 1.3" and" fastq!tools" 0.8." Any" read" in"which" either" pair" had" a" length" less"
than" 19" was" removed" from" subsequent" analysis." Read" Mapping" and" Genotype"
Calling" Alignment" was" performed" using" BWA" 0.7.10" mem" GRch38" reference."
Duplicate" reads" were" removed" using" the" Picard" v1.56" MarkDuplicates" program."
Local" realignment" around" indels" was" performed" using" the" GATK" v1.3"
"48"
RealignerTargetCreator" and" IndelRealigner" in" Smith!Waterman" mode" with"
reference"to"dbSNP"v132."The"Picard"v1.56"FixMateInformation"program"was"used"
to" ensure" that" all" mate!pair" information" was" in" sync" between" each" read" and" its"
mate" following" local" realignment." Base" quality" scores" were" recalibrated" using"
GATK"v1.3"CountCovariates"and"TableRecalibration"with"reference"to"dbSNP"v132."
BAM" files" were" sorted" and" then" indexed" using" SAMtools" index." Somatic" Variant"
Analysis"Pileup" files" (created"using"SAMtools"mpileup,"with"parameters" –"d"5000"
and"q!"20)"were"used"as"input"to"VarScan2"v2.3.5."This"was"used"in"somatic"mode,"
with"a"strand"filter,"to"identify"somatic"single"nucleotide"variations"(SNVs)"and"small"
insertions" and" deletions" (indels)." Results" were" then" processed" using"
processSomatic" to" extract" the" somatic" mutations" with" the" specification" that" zero"





High" confidence" somatic" variant" and" indel" calls" were" converted" to" mutation"





Black" constructed" NGS" libraries" with" NEBNext%" reagents" according" to" the"
manufacturer’s" instructions." Data" was" processed" by" Fiona" Platt." BAM" files" were"
generated" as" described" in" the" exome" sequencing" section" (2.5.4)." Following" the"
generation" of" BAM" files," ngCGH" was" used" to" compare" number" of" read" counts"
between"the"cell" line"and"blood"or"parental"samples"using"a"window"size"of"1000."
The" Nexus" Copy" Number" software" package" was" used" to" conduct" GC" correction"
and" copy" number" calling" using" the" FASST2" Segmentation" Algorithm" which" is" a"
Hidden"Markov"Model"(HMM)"based"approach."Segmentation"was"conducted"with"
a" significance" threshold" of" 1.0E!5," with" a" requirement" of" at" least" 3" probes" per"
segment"and"a"maximum"probe"spacing"of"1000"between"adjacent"probes"before"
breaking"a"segment.""











Standard" PCR"was" performed"with" each" reaction" containing" 1x" AmpliTaq"Gold®"
360"buffer,"2.5mM"MgCl2,"0.2μM"of"forward"and"reverse"primers"(see"Table"2.5"for"
primer" sequences)," 1mM"dNTPs," 1U"AmpliTaq"Gold®"360"DNA"Polymerase"and"
20ng"of"DNA"in"a"total"reaction"volume"of"25μl."Reactions"were"performed"in"non!
skirted" 96"well" PCR" plates" (Thermo"Scientific)" in" a" Veriti" thermal" cycler" (Applied"
Biosystems)."Cycling"conditions"were"95°C" for"5"min,"35"cycles"of"95°C" for"30"s,"
60°C" for"30"s"and"72°C" for"30s" followed"by"a" final"extension"step"of"72°C" for"10"
min."Agarose"gel"electrophoresis"was"used"to"check"that"PCR"was"successful."
1μl"ExoProStar"(Illumina)"was"added"to"2.5μl"PCR"products."This"was"mixed"
by" pipetting," incubated" at" 37°C" for" 15" min" then" incubated" at" 80°C" for" 15" min."
Sequencing"was"conducted"with" the"BigDye™"Terminator"v1.1"Cycle"Sequencing"
Kit" (Applied" Biosystems)" according" to" the" manufacturer’s" instructions" (see" Table"




















Standard" PCR" was" performed" following" the" same" methodology" as" for" Sanger"
sequencing."3μl"of"PCR"product"was" run"on"a"2%"agarose"gel" to"check" the"PCR"
was" successful." 3μl" of" shrimp" alkaline" phosphatase" (Sigma!Aldrich)" and" 2μl"
Exonuclease" I" (Affymetrix)"were"added" to" the" remaining"12"μl"PCR"product."This"
was"then"spun"down"for"10"s"at"190"x"g,"incubated"for"60"min"at"37°C"and"15"min"at"
"51"
72°C." Each" SNaPshot" reaction" contained" 1μl" shrimp" alkaline"
phosphatase(SAP)/exonuclease!treated" PCR" product," 2.5μl" SNaPshot" Multiplex"
Ready"Reaction"Mix,"1"x"BigDye"Terminator"sequencing"buffer,"5μM"HRAS"c.DNA"
34"probe,"and"molecular"biology"grade"water"to"a"final"volume"of"9μl"(all"reagents"
Applied" Biosystems)." The" sequence" (5’!>3’)" of" the" HRAS" c.DNA" 34" probe" was"
T(17)CTGGTGGTGGTGGGCGCC." SNaPshot" analysis" was" conducted" with" the"
following"cycling"conditions:"35"cycles"of"95°C"for"10"s,"58.5°C"for"40"s,"hold"at"4°C."

















receptor" tyrosine" kinases." Mohammadi" et! al." reported" that" in" an" in! vitro" kinase"
inhibition" assay" FGFR1" was" inhibited" with" an" IC50" of" 21.5nM." FGFR1"
autophosphorylation" was" inhibited" with" a" half" maximal" inhibitory" concentration"
(IC50)" of" 1!5nM" in" the" fibroblast" cell" line"NIH3T3"which" endogenously" expresses"
FGFR1" (Mohammadi" et! al.," 1998)." Pardo" et! al." demonstrated" that" 100nM" of" PD"
inhibited"autophosphorylation"of"FGFR2"in"NCI!H510A,"a"small"cell"lung"cancer"cell"
line"(Pardo"et!al.,"2009)."In"another"study"PD"inhibited"FGFR3"autophosphorylation"
in"NIH3T3" transfected"with"FGFR3"with"an" IC50"of"approximately"5nM" (Trudel"et!











reported"a"half"maximal"effective" concentration" (EC50)"of" 27nM" in"RT112."FGFR"
TKIs" including" PD" have" been" used" previously" to" study" resistance" in" FGFR!
expressing" cell" lines" including" RT112" and" RT4." The" findings" of" these" previous"
studies" are" summarised" in" section" 1.4.2" of" the" Introduction." This" chapter" will"









RT112"and"RT4" resistant" derivatives"were" derived" by" long!term" culture" in"PD"by"
Helen"McPherson."Characterisation"of"resistant"derivatives"was"not"conducted"prior"
to" this" project." 1µM" was" selected" as" the" initial" concentration" of" PD" to" culture"
parental"RT112"and"RT4"in"to"generate"resistant"derivatives."This"was"because"PD"
exerted"maximal" effect" on" the"growth"of"RT112"and"RT4"at" these" concentrations"
but"some"RT112"and"RT4"cells"could"survive" in" these"PD"concentrations."RT112"
was"cultured"in"PD"for"a"total"of"21"passages"in"order"to"generate"isogenic"resistant"
derivatives" (Fig." 3.1)." Cells" were" passaged" when" 90%" confluent" throughout" the"
generation" of" resistant" derivatives." Parental" RT112"was" cultured" in" 1µM"PD" and"
split" 1" in"2"between"passages"40"and"43."This" took"74"days."At" passage"43" two"
sublines"were"created,"one"which"was"split"1"in"3"and"one"split"1"in"5"for"the"rest"of"
the"resistant"line"derivation."The"subline"split"1"in"3"was"cultured"until"passage"45,"
15" days" later," when" this" subline" was" further" split" to" produce" two" sublines." One"
continued" to" be" cultured" in" 1µM"PD"and" the" other"was" cultured" in" 2µM"PD." The"
subline"cultured"1"in"3"in"1µM"PD"was"cultured"for"a"further"117"days"when"it"was"
frozen"down"at"passage"61"and"termed"R1."The"subline"cultured"1"in"3"in"2µM"PD"
was"cultured" for"a" further"120"days" from"passage"45"when" it"was" frozen"down"at"






cells" when" cultured" without" PD." Treatment" with" PD" induced" RT112" to" have" a"






treatment," as" with" RT112," there" were" many" dead" floating" cells." The" number" of"
floating" cells" had" reduced"by"passage"23."During" the" treatment"with"PD" the"RT4"
cells"became"flatter"and"had"many"peripheral"cytoplasmic"extensions"in"contrast"to"
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the" morphology" of" RT4" when" not" cultured" in" PD" (Fig." 3.3)." Parental" RT4" cells,"
cultured" without" PD," grow" in" tightly" packed" clusters." During" the" derivation" of" the"
RT4"resistant"line,"the"RT4"cells"continued"to"grow"in"clusters"but"did"not"grow"on"
top"of" each"other" (Fig." 3.3)."When" initially" treated"with"PD" the"RT4"cells" stopped"
proliferating"or"proliferated"very"slowly."With"continued"PD"treatment,"the"RT4"cells"
began"proliferating"at"a"faster"rate."However,"the"proliferation"rate"continued"to"be"
slower" than" the" rate" observed" in" parental" RT4."With" both" RT112" and"RT4" there"
were" no" obvious" pre!existing" resistant" cells" or" a" specific" time" when" resistance"
appeared"to"develop."The"development"of"resistance"was"gradual."The"morphology"
and"proliferation"rate"of"the"final"resistant"derivatives"is"examined"in"sections"3.2.2"















is" in" contrast" to" the"mesenchymal" morphology" observed" during" the" derivation" of"
resistant" lines"by" long!term"culture"of"RT112"parental" in"PD" (Fig."3.2)."RT112"R1"
and"R2"cultured"in"PD"exhibited"a"mesenchymal"morphology"whilst"R3"had"a"more"
epithelial" morphology" (Fig." 3.4)." Wang! et! al." reported" that" RT112" cells" cultured"




weeks" (Wang" et! al.," 2014)." In" order" to" determine" if" resistance" to" PD" and" the"
morphological"change"observed"in"R1"and"R2"were"dependent"on"continual"culture"
in"PD,"RT112"resistant"derivatives"were"cultured"without"PD."Following"culture"for"2"
passages" without" PD," approximately" 2" weeks," the" cells" reverted" to" an" epithelial"
morphology"(Fig."3.5)."
RT4" parental" cells," RT4" R1" cells" cultured" in" PD" and" R1" cells" cultured"
without" PD" for" 4" passages" are" pictured" in" Fig." 3.6." RT4" has" an" epithelial"
morphology" and"RT4" grow"as" a" tall" palisade" of" tightly" clustered" cells" rather" than"
spreading" out" across" the" culture" surface." RT4"R1" also" grows" in" clusters" but" the"














To" determine" if" the" cell" density" at" confluence" and" growth" rate" of" the" RT112"
resistant" lines" differed" from" parental" RT112," proliferation" assays"were" conducted"
with" RT112" parental," R1," R2" and" R3" and" growth" curves" constructed" (Fig." 3.7)."
RT112" parental" was" cultured" in" medium" not" supplemented" with" PD." R1" and" R3"
were"cultured"in"1µM"PD"and"R2"was"cultured"in"2µM"PD."Parental"RT112"reached"
a"final"density"of"6.65"x"106"cells/well"whereas"R1"and"R2"reached"a"final"density"of"
8.38" x" 105" cells/well" and" 1.06" x" 106" cells/well" respectively." R3" reached" a" final"
density"of"1.64"x"106"cells/well."It"seemed"likely"that"PD"was"limiting"the"proliferation"
of"RT112"resistant"derivatives,"rather"than"the"resistant"cells"having"an"intrinsically"





and"R3" cultured" in" PD" both" had" doubling" times" of" 38.2" h" and"R1" +"PD" had" the"
longest"doubling" time"of"51.1"h."The"doubling" times"of"R1"and"R2"were" reduced,"
31.3"h"and"34.5"h"respectively,"when"cultured"without"PD"(Table"3.1)."The"doubling"
time"of"parental"+"PD"and"R3"no"PD"was"not"examined."These"results"indicate"that"
PD" treatment" hampered"proliferation"and" cell" density" at" confluence"of" the"RT112"
resistant"lines"despite"these"lines"exhibiting"PD"resistance."The"reduced"rate"of"cell"
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proliferation" in" RT112" R1" and" R2" was" partially" reversed" when" the" cells" were"
cultured"in"the"absence"of"PD"for"4"passages."
Proliferation" assays" were" not" conducted" in" RT4" parental" and" RT4" R1."
However,"from"cell"culture"it"was"apparent"that"RT4"R1"cultured"in"PD"proliferated"
at" a" slower" rate" than" RT4" parental" cultured" without" PD." It" was" also" clear" that,"




































































R3" being"most" resistant" and" showing" no" sensitivity" up" to" 1µM"PD." Viability" was"
approximately" 30%" in" parental" cells" treated" with" between" 0.1" and" 1µM" PD"
indicating"that"some"parental"cells"survived"this"PD"treatment."Parental"RT112"had"












similar" to" parental" RT112" following" culture" without" PD" for" 2" passages"
(approximately" 2"weeks)." To" determine" if" sensitivity" to"PD"was" retained" following"
culture"without" PD" and" a" return" to" an" epithelial"morphology," resistant" derivatives"
were"cultured"without"PD"for"4"passages,"3!5"weeks,"and"viability" in"1µM"PD"was"
examined" (Fig."3.9)."Despite"R1"and"R2" reverting" to"an"epithelial"morphology" the"
cells" remained" resistant" to" PD" compared" to" RT112" parental." However," the"














































retained" its" resistance" following" culture" without" PD," viability" assays" were"
conducted." Sensitivity" to" PD"was" assessed" in"RT4" parental," R1"which" had" been"
cultured" with" PD" and" R1" cultured" without" PD" for" 4" passages" (3!5" weeks)" (Fig."
3.10)."RT4"parental"was"sensitive"to"PD"with"an"IC50"of"19nM."RT4"R1"+"PD"had"
some"resistance"to"PD"and"did"not"reach"IC50."R1"no"PD"was"sensitive"to"PD"with"
an" IC50" of" 17nM." IC50s" were" estimated" from" sigmoidal" dose" response" curve"
plotted"in"GraphPad"Prism&."RT4"parental"had"11%"viability,"R1"cultured"in"PD"had"
55%"viability"and"R1"cultured"out"of"PD"for"4"passages"had"22%"viability"in"1µM"PD"
relative" to" the" vehicle" control." These" results" indicate" that" RT4" R1" had" gained"
resistance" to" PD" but" that" this" resistance" was" not" maintained" following" culture"
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without"PD."The" sensitivity" of"RT4"R1"cultured"without"PD"was" in" contrast" to" the"








































Due" to" the" mesenchymal!like" morphology" observed" in" RT112" R1" and" R2,"
expression"of"mesenchymal" and"epithelial"markers"was"examined" to" determine" if"
these"cells"had"undergone"an"EMT."Cadherins"are"a"class"of"membrane"proteins"
which" form" part" of" the" adherens" junctions." Adherens" junctions" facilitate" the"
attachment" of" neighbouring" cells" to" one" another" (Singh" et! al.," 2017)." FGFR3"
expression" is" of" clear" importance" due" to" the" dependency" of" RT112" and"RT4" on"
FGFR3"signalling"and"the"specificity"of"PD"for"the"FGFR"family."In"addition"to"this,"





























































































































Vimentin," a" mesenchymal" marker," provides" mechanical" strength" to" intermediate"
filaments." Intermediate" filaments" are" a" cytoskeleton" component" and" vimentin"
makes"intermediate"filaments"less"likely"be"damaged"during"cell"migration"(Singh!et!
al.,! 2017)." As" expression" of" N!cadherin" was" increased" in" RT112" R1" and" R2"







































































To"determine" if"EMT!like"changes"were"present" in"RT4"R1"as"observed" in"RT112"
R1" and" R2," expression" of" N!cadherin," vimentin," E!cadherin" and" FGFR3" were"



































































































In" this" study," it" was" found" that" the" viability" of" RT112" in" PD" was" not" entirely"
abolished" with" viability" approximately" 1/3" of" the" vehicle" control" in" parental" cells"
treated" with" between" 0.1" and" 1µM" PD." The" viability" of" RT4" parental" was" not"






al." and" our" viability" assays" could" be" due" to" differences" in"methodology."Herrera!
Abreu! et! al." treated" with" PD" for" 72" h" and" assayed" viability" with" CellTiter!Glo"
whereas"for"our"assay,"PD"treatment"was"for"120"h"and"viability"was"assessed"with"
Cell!Titer"Blue."Herrera!Abreu!et!al."calculated"an"EC50"whereas"we"calculated"an"
IC50." Lamont! et! al." treated"with" PD" for" 120" h," similar" to" our" assay" but" changed"
media"48"h"post"PD"treatment"whereas"in"our"assay"medium"was"replaced"after"72"
h." Lamont! et! al." assessed" viability" with" a" 3!(4,5!dimethylthiazol)!2,5!diphenyl"
tetrazolium" (MTT)" assay." The"RT112" used" by"Herrera!Abreu! et! al." was" obtained"
from" the" same" laboratory" in"which" this"project"was" conducted."The"Lamont! et! al.!
paper"was"produced" in" the"same" laboratory"as" this"project." It" is" therefore"unlikely"
that" the"observed"differences" in" viability" are"due" to"differences" in" the"RT112"and"
RT4"cells"used."There"was"large"variability"between"individual"cell"viability"assays,"
for"example," in" figure"3.8" the"cell"viability"of"parental"RT112" treated"with"1µM"PD"
was" reduced" to"33%"whereas" in" figure"3.9" the"viability"of"RT112"parental" treated"
with" 1µM"PD"was" reduced" to" approximately" 50%." Therefore," it" is" not" possible" to"
draw" conclusions" by" comparing" the" results" of" different" viability" assays." It" would"
have"been"beneficial"to"have"included"the"resistant"lines"cultured"in"PD"as"a"control"
when" the" resistant" lines"cultured"out"of"PD"were"assayed" for" their"PD" resistance."
This" would" have" determined" whether" the" RT112" resistant" lines" maintained" the"
same"level"of"PD"resistance"when"cultured"with"and"without"PD"rather"than"simply"
demonstrating"that"the"resistant"derivatives"cultured"out"of"PD"were"more"resistant"
than"parental"RT112."Additionally," for" each" cell" viability" experiment" it"would"have"
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been"more"reliable"to"have"presented"the"average"of"the"cell"viability"assay"repeats,"
rather" than" presenting" one" representative" example." This" would" have" enabled" a"
statistical" test" to"have"been"conducted"to"determine"whether"observed"differences"
in"viability"were"significant."
RT112"R1,"RT112"R2" and"RT4"R1" cells" had" a" different"morphology" from"
their"parental"lines."These"resistant"lines"returned"to"the"parental"morphology"upon"
culture" without" PD." RT112" R1" and" R2" retained" their" resistance" to" PD" following"
culture"without"PD"whereas"RT4"R1"did" not."RT112"R3"was"distinct" from"RT112"
R1," RT112" R2" and" RT4" R1" in" that" it" retained" the" epithelial" morphology" of" its"
parental" line." Despite" the" mesenchymal!like" morphology" of" RT112" R1" and" R2"
cultured" in" PD" these" cells" did" not" appear" to" have" undergone" a" complete" EMT."
Expression" of" E!cadherin" was" not" decreased" in" these" resistant" derivatives."





an"EMT." In" bladder" cancer" cell" lines," expression" of" FGFR3"has" been" associated"
with" an" epithelial" phenotype," in" contrast" to" FGFR1" expression" which" has" been"
associated"with"a"mesenchymal"phenotype"(Cheng"et!al.,"2013)."Hanze!et!al."found"
that"phenotypically"mesenchymal"bladder"cancer"cell" lines"were"more" resistant" to"
the"FGFR"TKI"dovitinib"than"epithelial"bladder"cancer"cell"lines"(Hanze"et!al.,"2013)."
This"could"be"related"to"the"activation"of"FGFR3"versus"FGFR1"signalling"in"these"
lines," as" there"was" some" overlap" between" the" panel" of" bladder" cancer" cell" lines"
examined" by" Cheng! et! al." and" Hanze! et! al." Therefore," a" shift" from" an" epithelial"
phenotype" to" a" more" mesenchymal" phenotype" as" a" result" of" FGFR" inhibition" is"
logical" in" the" FGFR3!dependent" lines" used" in" this" project." This" switch" to" a"more"
mesenchymal"phenotype"is"of"interest"as"a"mesenchymal"phenotype"is"associated"
with" greater" cell" migration" and" invasion." Therefore," if" FGFR" inhibitors" induce" an"
EMT"in"patients"this"could"lead"to"tumour"metastasis"(Singh"et!al.,"2017).""
Some"studies"examining" the"response"of"RT112" to"FGFR" inhibition,"which"
have"focused"on"the"short!term"mechanisms"of"survival,"have"not"detailed"EMT!like"
changes" occurring" in" RT112" (Harbinski" et! al.," 2012q" Herrera!Abreu" et! al.," 2013q"
Wang"et!al.,"2017b)."This"would"be"expected"as"this"study"found"that"the"EMT!like"








2!4" weeks." In" contrast" to" our" RT112" resistant" derivatives" which"maintained" their"
resistance"following"culture"out"of"PD"for"4"passages,"the"Wang!et!al."resistant"cells"
did" not"maintain" their" FGFR"TKI" resistance" following" culture"without" drug" for" 2!4"
weeks."Wang!et!al."do"not"detail"the"time"taken"to"derive"their"resistant"cells"(Wang"
et! al.," 2014)."Our"RT4" resistant" derivative," RT4"R1," did" re!acquire" PD" sensitivity"
when"cultured"out"of"PD"for"4"passages." If" resistance"to"FGFR"inhibition"could"be"
reversed" in" patients" simply" by" pausing" treatment" with" the" FGFR" TKI," then" this"
would"be"an"ideal"way"to"overcome"the"resistance"as"it"avoids"the"use"of"potentially"
toxic" drug" combinations." Our" results" suggest" that" pausing" treatment" would" not"





rather" than" via" stable" genomic" changes." The" altered" transcription" is" likely" to" be"
mediated"by" epigenetic"modifications."Sharma"et! al.," reported" that" a" treatment" of"
the" NSCLC" cell" line" PC!9" with" the" EGFR" TKIs" gefitinib" or" erlotinib" for" 9" days"
yielded"a"population"of"drug"tolerant"cells"with" increased"protein"expression"of"the"
histone" demethylase" KDM5A." KDM5A" demethylates" lysine" 4" of" histone" 3"
(H3K4me2" and" H3K4me3)" thereby" repressing" transcription" (Santos!Rosa" et! al.,"
2002)." KDM5A" promotes" cell" proliferation" and" inhibits" cell" differentiation," this"
activity"is"modulated"by"the"tumour"suppressor"RB1"(Benevolenskaya"et!al.,"2005q"
Lin"et!al.,"2011)."Knockdown"of"KDM5A"with"RNA"interference"significantly"reduced"
the" number" of" drug" tolerant" PC!9" cells" generated" by" culture" in" an" EGFR" TKI"
(Sharma"et!al.,"2010)."Hypermethylation"of"PDLIM4"which"encodes"PDZ"and"LIM"
domain" protein" 4" has" been" associated" with" shortened" survival" in" CML" patients"
treated"with" imatinib."Gene"hypermethylation"normally" reduces"gene" transcription,"
therefore" this" epigenetic" alteration" may" induce" imatinib" resistance" by" reducing"
PDLIM4" inactivation" of" the" tyrosine" kinase" Src" (Jelinek" et! al.," 2011)." " Roh" et! al."
reported"that,"in"the"urothelial"carcinoma"cell"lines"KU!7"and"5637,"overexpression"
and"knockdown"of"FOXM1"significantly"increased"and"decreased"cell"viability"in"the"
presence" of" the" chemotherapeutic" agent" doxorubicin" respectively." FOXM1" is" a"
global"regulator"of"DNA"methylation."FOXM1"was"shown"to"regulate"expression"of"
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ABCG2"and"drug"efflux."ABCG2" is"a"member"of" the"ATP!binding"cassette" (ABC)"
transporter" family"which" induce" drug" resistance" via" drug" efflux" (Roh"et! al.," 2018q"




The" reduction" in"FGFR3"expression" in" the"RT112"PD" resistant"derivatives"





mediate" short!term" survival" to" exposure" to" PD" in"RT112" (Harbinski"et! al.," 2012)."
Herrera!Abreu"et!al." identified"EGFR"signalling"as"mediating"short!term"survival" to"
PD" in"RT112" (Herrera!Abreu"et!al.,"2013)."Wang"et!al."produced"RT112" resistant"






This" mutation" prevents" the" binding" of" TKIs" to" the" ATP!binding" site" (Chell" et! al.,"
2013)."However,"as"FGFR3"expression"was"downregulated"in"R3,"it"is"unlikely"that"
resistance" has" arisen" in" this" line" via" a" mutation" in" FGFR3." Alternative" genetic"















FGFR3" expression" is" associated" with" an" epithelial" morphology" and" FGFR1"
expression" is" associated" with" a"mesenchymal"morphology" in" bladder" cancer" cell"
lines" (Cheng" et! al.," 2013q" Tomlinson" et! al.," 2012)." It" was" therefore" thought" that"
RT112" R1" and" R2," which" have" a" more" mesenchymal" morphology," could" have"
increased"activation"of"FGFR1,"possibly"by"altered"FGF"expression."FGFR1,"FGF1"
and"FGF2"expression"was"examined"in"this"Chapter"for"this"reason."However,"any"
mechanism"which" induced" FGFR1" activation" in" the" resistant" lines"would" have" to"
overcome"the"inhibition"of"FGFR1"by"PD,"which"inhibits"FGFR1!3"(Mohammadi"et!
al.,"1998q"Pardo"et!al.,"2009q"Trudel"et!al.,"2004).""Activation"of"an"alternative"RTK"
is" a" commonly" reported" mechanism" of" resistance" to" targeted" agents." Such"
activation"of"a"replacement"RTK"would"re!activate"intracellular"signalling"pathways"
inhibited" by" FGFR3" inhibition." Wang" et! al." found" RT112" activated" ERBB2" and"
ERBB3" signalling" as" a"mechanism" of" resistance" to" the" FGFR" TKIs" BGJ398" and"
ponatinib" upon" long!term" culture" in" these" inhibitors" (Wang"et! al.," 2014)."Herrera!
Abreu"et! al." identified" EGFR" activation" as" a"mechanism" of" short!term" survival" in"
RT112"treated"with"PD"(Herrera!Abreu"et!al.,"2013)."Harbinski"et!al."identified"MET"
activation"by"HGF"as"a"mechanism"of" short!term"survival" in" response" to"BGJ398"
(Harbinski"et!al.,"2012)."This"previously"conducted"research"is"examined"in"section"
1.4.2"of" the" Introduction."As" these"RTKs"had"been"previously" implicated" in"FGFR"
TKI"resistance"it"was"imperative"to"examine"total"expression"and"phosphorylation"of"
EGFR" family"members"and"MET."Examination"of"RTK"expression"was"conducted"
predominantly" in" RT112" R1," RT112" R2" and" RT4" R1." This" was" because" it" was"
thought" that"RT112"R3"was" the"most" likely" resistant" derivative" to" have"a" genetic"
mechanism"of"resistance"because,"compared"to"RT112"R1"and"R2,"it"maintained"a"
maximal"cell"density"and"morphology"were"more"similar"to"RT112"parental."Exome"
sequencing" will" be" conducted" in" Chapter" 5" with" the" aim" of" determining" whether"
RT112"R3"has"a"genetic"mechanism"of"resistance."Expression"and"phosphorylation"
of" AKT," a" serine/threonine" kinase" which" is" part" of" the" PI3" kinase" pathway," and"
ERK," a" serine/threonine" kinase" in" the" MAP" kinase" signalling" cascade," will" be"
examined"in"RT112"parental"and"resistant"lines"in"this"Chapter."The"PI3"kinase"and"
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are" reported"albeit" infrequently" (Fischbach"et!al.,"2015)."Cheng"et!al."examined"a"
panel"of"bladder"cancer"cell" lines"and"found"FGFR3"dependence"to"be"associated"
with" an" epithelial" phenotype" and" FGFR1" dependence" to" be" associated" with" a"
mesenchymal"phenotype"(Cheng"et!al.,"2013)."Increased"activation"of"FGFR1"could"
be"a"cause"of"resistance."However,"PD"is"a"pan!FGFR"TKI,"which"inhibits"FGFR1"





parental" line" as" well" as" R1" and" R2," which" had" undergone" phenotypic" changes"
associated" with" a" mesenchymal" phenotype" (Fig." 4.1)." FGFR1" expression" was"
significantly"increased"and"FGFR3"expression"was"significantly"reduced"in"R1"and"
R2." The" reduction" in" FGFR3" mRNA" expression" is" concordant" with" immunoblot"
analysis"conducted"in"Chapter"3"which"found"reduced"expression"of"FGFR3"protein"
in"RT112"R1" and"R2" (Fig." 3.11)." Protein" expression" of" FGFR1"was" examined" in"
RT112"parental,"RT112"R1,"RT112"R2,"RT4"parental"and"RT4"R1"by" immunoblot"
(Fig."4.2)."There"was"no"increase"in"FGFR1"expression"in"the"resistant"derivatives"
compared" to" their" parental" lines." Expression" of" FGFR1" was" low" in" all" RT112"
samples"compared"to"the"JMSU1"positive"control."Therefore,"the"increased"FGFR1"
mRNA"expression" in"RT112"R1"and"R2"did"not" result" in"a"detectable" increase" in"
FGFR1" protein" expression." Phosphorylation" of" FGFR1" was" not" examined."
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However," the" low" expression" of" this" receptor" suggests" that" it" is" not" inducing"
resistance"in"the"resistant"lines"or"inducing"the"EMT!associated"changes"observed"
in"RT112"R1"and"R2."
The" FGFR" family" undergoes" alternative" splicing," mutually" exclusively"
including"exons"8"and"9"to"produce"isoforms"with"different"specificities"for"FGFs."If"
exon"8"is"included"the"IIIb"isoform"is"produced"whereas"if"exon"9"is"included"the"IIIc"
isoform" is"produced."FGF1"activates"FGFR1!3" IIIb"and" IIIc" isoforms."FGF2"has"a"
greater" specificity" for" the" IIIc" isoforms" of" FGFR1!3" which" are" associated" with" a"
mesenchymal"phenotype,"rather"than"the"IIIb"isoforms"associated"with"an"epithelial"
morphology"(Chellaiah"et!al.,"1994q"Ornitz"et!al.,"1996q"Zhang"et!al.,"2006)." It"was"
thought" that" differential" expression" of" these" FGFs" could" be" inducing" greater"






























FGFR1 and FGFR3 expression in R1 and R2
FGFR1
FGFR3
























































As" with" other" FGFRs," expression" of" FGFR2IIIb" is" associated" with" an" epithelial"





and" IIIc." PCR" of" exons" 7!8" produces" a" 278" bp" product" and" detects" FGFR2" IIIb"
expression."PCR"of" exons"7!9"produces"267"bp"product" and"detects"FGFR2" IIIc."
The"FGFR2" IIIb" isoform"but"not" the"FGFR2" IIIc" isoform"was"detected" in"all"of" the"
RT112" samples." Therefore," R1" and" R2" had" not" switched" expression" of" FGFR2"
isoforms"and"this"had"not"induced"the"mesenchymal"change"in"RT112"R1"and"R2."
It" is" possible" that" isoform" switching" has" occurred" in" other" FGFRs," although"








The" EGFR" family" of" RTKs" homodimerize" or" heterodimerize" resulting" in"
phosphorylation" of" the" intracellular" kinase" domain" and" activation" of" the" MAP"
kinase," PI3" kinase" and" PLC"" pathways." (Roskoski," 2014)." EGFR" amplification,"
ERBB2" amplification" and" mutations" and" ERBB3" mutations" are" found" in" MIBC"

















parental" and" RT4" R1" (Fig." 4.6)." Growth" factor" receptor!bound" protein" 2" (Grb2)"
binds"to"the"phosphorylated"Y1068"of"EGFR."Therefore,"autophosphorylation"of"this"
residue" is" required" for" EGFR!mediated" activation" of" the" MAP" kinase" pathway"






































The" other" EGFR" family" members" preferentially" dimerize" with" ERBB2" (Roskoski,"
2014)." The" ERBB3" kinase" domain" is" impaired" in" its" ability" to" undergo"
autophosphorylation" and" so"ERBB3" homodimers" are" unable" to" elicit" activation" of"
intracellular"signalling"pathways"(Shi"et!al.,"2010)."Activation"of"ERBB2"and"ERBB3"
signalling" has" been" reported" as" a"mechanism"of" resistance" in"RT112" to"BGJ398"
and"ponatinib"(Wang"et!al.,"2014)."For"this"reason,"protein"expression"of"phospho!
ERBB2," total"ERBB2"and" phospho!ERBB3"was" examined" in"RT112"parental,"R1"
























































































ERBB3" was" unsuccessful," it" is" not" possible" to" tell" if" the" increase" in" ERBB3"
phosphorylation"is"accompanied"by"an"increase"in"ERBB3."
Expression" of" phospho!ERBB2," total" ERBB2" and" phospho!ERBB3" was"
examined" in"RT4" parental" and"R1" (Fig." 4.9)." Expression" of" phospho!ERBB2"and"
total" ERBB2" was" low" in" RT4" parental" and" R1" compared" to" the" positive" control"
SKBR3."Expression"of"phospho!ERBB3"was"increased"in"R1,"although"it"remained"






























































Expression" of" the" ERBB3" and" ERBB4" ligand" neuregulin" 1" was" reported" to" be"
upregulated"in"BGJ398"resistant"derivatives."Treatment"with"neuregulin"1"was"also"
found" to" rescue" RT112" and" RT4" from" BGJ398!induced" reduction" in" cell" viability"
(Wang" et! al.," 2014)." It" was" thought" that" neuregulin" 1" could" be" inducing"
phosphorylation" of" ERBB3" in" RT112" R1," RT112" R2" and" RT4" R1." Expression" of"
NRG1,"which"encodes"neuregulin"1,"was"examined"in"RT112"parental,"R1"and"R2"
by"qRT!PCR."Expression"of"NRG1"was"increased"by"approximately"3"and"2!fold"in"
RT112"R1"and"R2"compared" to"parental" respectively" (Fig."4.10)."This" increase" in"







































































RT112" treated" with" BGJ398" (Harbinski" et! al.," 2012)." Cheng" et! al.," using"
immunohistochemistry," identified" high" MET" expression" in" 7" out" of" 142" urothelial"
carcinoma" patients" (Cheng" et! al.," 2002)." MET," in" addition" to" other" EGFR" family"
members," is" able" to" heterodimerize" with" ERBB3" to" induce" intracellular" signalling"
(Pérez!Ramírez"et!al.,"2015q"Tanizaki"et!al.,"2011)." "Engelman"et!al." reported"that"
MET" amplification" induced" resistance" to" EGFR" inhibition" in" the" NSCLC" cell" line"
HCC827"cultured" in"gefitinib."MET"activation"mediated"phosphorylation"of"ERBB3"
which" induced" activation" of" the" PI3" kinase" pathway." This" resistance" could" be"
overcome"by" combined"EGFR"and"MET" inhibition."Engelman"et! al." also" reported"
MET" amplification" in"NSCLC"patient" samples"with"acquired" resistance" to"gefitinib"
(Engelman"et!al.,"2007)."
It" was" thought" that" activation" of" MET" could" be" mediating" the" increase" in"
ERBB3" phosphorylation" observed" in" RT112"R1" and"R2." Expression" of" phospho!





increased" phosphorylation" of" EGFR" was" the" likely" mediator" of" PD" resistance" in"
RT4" R1." An" increase" in" phospho!MET" was" observed" in" R3" cultured" with" and"
without"PD"and"a"smaller" increase"was"observed" in"R1"and"R2"cultured"with"PD."
However,"phospho!MET"expression" remained" low" in"R1"and"R2"compared" to" the"

















































































































The"MAP" kinase" and"PI3" kinase" pathways" regulate" cell" proliferation" and" survival"
and" are" activated" downstream" of" FGFR3" (Hart" et! al.," 2001)." Therefore," the"
activation" of" these" pathways" could" be" the" determinant" of" the" differences" in" cell"
proliferation"between"parental"and"resistant"derivatives"observed" in"Chapter"3."To"
determine" whether" the" PI3" kinase" and" MAP" kinase" pathways" were" activated,"
expression"of"phospho!AKT,"total"AKT,"phospho!ERK"and"total"ERK"was"examined"
in" RT112" parental" acutely" treated" with" PD," parental" cultured" without" PD," and"
resistant" derivatives" cultured" with" and" without" PD" (Fig." 4.12)." Expression" of"
phospho!AKT"was" increased" in"R1" and"R2" +"PD" and" reduced" in" parental" +"PD."
Expression"of"phospho!ERK"was"also"decreased" in"parental"+"PD."Expression"of"
total"ERK"remained"fairly"constant"between"parental"and"resistant"derivatives."The"




pathways" may" be" key" to" overcoming" FGFR" inhibition" with" PD." The" increase" in"
phosphorylation" of" AKT" observed" in" R1" and" R2" cultured" with" PD" but" not" R3"
cultured"with"PD"highlights"a"difference"in"the"resistance"mechanism"between"these"

















































































































FGFR1" expression" has" been" associated" with" a" mesenchymal" phenotype" and"
FGFR3" has" been" associated" with" an" epithelial" phenotype" (Cheng" et! al.," 2013)."
FGFR1" activation" is" known" to" induce" EMT" in" urothelial" carcinoma" cell" lines"
(Tomlinson"et!al.,"2012)."It"was"thought"that"the"mesenchymal"phenotypic"changes"
observed" in"RT112"R1"and"R2"could"be"caused"by"a"switch" in"dependency" from"
FGFR3" to" FGFR1." FGFR1" protein" expression" remained" low" in" the" resistant"
derivatives"and" therefore" the"partial"EMT"observed" in"RT112"R1"and"R2"and"PD"
resistance" is" not" induced" by" increased" expression" of" this" RTK." It" was" also"
considered" that" activation" of" the" FGFR" IIIc" rather" than" IIIb" isoform" could" be"
inducing"the"mesenchymal"phenotypic"changes"observed"in"RT112"R1"and"R2."An"
increase" in" FGF2" expression" was" observed" in" RT112" R1" and" R2." This" FGF"
preferentially" activates" FGFR" IIIc" isoforms." However," no" switching" to" the" IIIc"




pan!FGFR" inhibitor," signalling" via" FGFRs" including" IIIc" isoforms" should" not" be"
possible" in" the" presence" of" PD" unless" a" gatekeeper"mutation" has" occurred." The"
V555M" FGFR3" mutation" has" been" identified" as" a" mechanism" of" acquired"
resistance" to" FGFR" inhibition" (Chell" et! al.," 2013)." Unless" an" activating" FGFR"





and"R2." An" increase" in" phospho!MET"was" observed" in" RT112"R3" but" phospho!
ERBB3"was"not"examined"in"this"line."The"phosphorylation"of"these"receptors"could"
be" contributing" to" the" resistant" phenotype" in" these" lines." ERBB3" is" not" able" to"
signal"via"homodimerization"due"to"low"kinase"function."However,"MET,"in"addition"
to" other" EGFR" family"members," is" able" to" heterodimerize"with" ERBB3" to" induce"
intracellular" signalling" (Pérez!Ramírez" et! al.," 2015q" Tanizaki" et! al.," 2011)." It" is"
therefore" possible" that" MET" is" heterodimerising" with" ERBB3" in" the" resistant"
derivatives" and" contributing" to" the" resistance" to" PD." The" activation" of" RTKs" in"
RT112" resistant" lines"was"examined"with"a"phospho!RTK"array" (PathScan®"RTK"
signaling" antibody" array" Kit" #7982)." However," as" the" results" of" this" array" were"
"85"
disappointing"with"a"low"signal"detected"from"RTK"specific"spots,"the"results"of"this"
analysis" were" not" presented" in" this" Chapter." An" alternative" phospho!RTK" array"
from" a" different" supplier" was" identified" but" analysis" was" not" conducted" with" this"
array"due"time"limitations."
Phosphorylation" of" EGFR" was" markedly" increased" in" RT4" R1" and" was"
considered"a" strong"candidate" resistance"mechanism."EGFR" is"able" to" signal" via"
homodimerization" or" heterodimerization" with" other" EGFR" family" members"




in" Chapter" 6"may" uncover" further" signalling" pathways" implicated" in" resistance" to"
PD."RTKs"can"be"targeted"by"TKIs"used"clinically"and"the"dependence"of"resistant"
lines"on"these"RTKs"will"be"tested"in"Chapter"7"of"this"thesis.""
The" increased" phosphorylation" of"AKT" in"RT112"R1" and"R2" compared" to"
RT112" parental" and" R3" highlights" that" there" is" a" difference" in" the" resistance"
mechanism"employed"in"R1"and"R2"compared"to"the"mechanism"employed"in"R3."
However," the" cause" of" this" increased" phosphorylation" is" unknown." The"
maintenance"of"ERK"and"AKT"activation"in"RT112"R3"to"a"similar"level"as"observed"
in" RT112" parental" was" expected" as" R3" has" the" most" similar" phenotype" to" the"
parental"line"of"all"the"resistant"derivatives."Upon"culture"without"PD,"phospho!AKT"
expression"was"reduced"in"RT112"R1"and"R2,"FGFR3"expression"was"increased"in"
all"RT112" resistant"derivatives"and"cell" proliferation"was" increased" in"all" resistant"



















This"Chapter"will" examine"whether" there" is"a"genetic"mechanism"of" resistance" in"
any"of"the"RT112"or"RT4"derivatives."Genetic"mechanisms"of"resistance"to"targeted"
agents" discussed" in" Chapter" 1" included" the" FGFR3" V555M"mutation" which" was"
previously"described"as"a"mechanism"of"acquired"resistance"to"FGFR"inhibition" in"
the" myeloma" cell" line" KMS!11" (Chell" et! al.," 2013)." One" possible" mechanism" by"
which"resistance"could"have"arisen"in"the"RT112"and"RT4"resistant"lines"is"via"the"
acquisition"of"a"mutation"in"an"RTK."It"is"probable"that"any"genetic"change"identified"
as"a"cause"of" resistance"will" induce"activation"of" the"MAP"kinase"and"PI3"kinase"
pathways"as"these"have"been"identified"as"inhibited"in"parental"RT112"upon"acute"
treatment"but"active" in"RT112"resistant"derivatives." In"addition" to"mutations" in" the"
receptor"itself,"mutations"may"be"identified"in"these"pathways,"in"genes"such"as"the"
RAS!genes,"RAF,"PIK3CA,"PTEN"and"AKT"(discussed"in"Chapter"1,"section"1.2.2)."









term" treatment" with" PD" and" focused" on" identifying" non!genetic" changes" in" the"
FGFR" TKI!treated" cells" rather" than" genetic" differences" (Harbinski" et! al.," 2012q"
Herrera!Abreu"et!al.,"2013)."They!identified"MET"and"EGFR"activation"respectively"
as" inducing" short" term" survival." During" the" course" of" this" study," Wang" et! al.,"
conducted" long!term" culture" of" RT112" in" FGFR" TKIs" and" conducted" mRNA"
sequencing" and" reported" activation" of" ERBB2" and" ERBB3" as" a" non!genetic"
mechanism"of"resistance"in"their"resistant"derivatives"(Wang"et!al.,"2014).""
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In"Chapter"4,"a"small" increase" in"ERBB3"phosphorylation"was" identified" in"
RT112" R1" and" R2" (Fig." 4.8)" and" an" increase" in" phosphorylation" of" MET" was"
observed" in" RT112" R1," R2" and" R3" (Fig." 4.11)." An" increase" in" total" and"
phosphorylated" EGFR"was" observed" in"RT4"R1" (Fig." 4.6)." It" is" possible" that" the"
phosphorylation"of" these"RTKs"could"be"mediated"by"an"activating"mutation" in"or"
an"increase"in"the"copy"number"of"these"RTKs."It"was"hypothesised"that"RT112"R3"
was" the" most" likely" RT112" resistant" derivative" to" have" a" genetic" mechanism" of"
resistance"as"it"maintained"a"maximal"cell"density"and"morphology"more"similar"to"
RT112" parental" than" RT112" R1" or" R2." It" was" also" thought" that" RT112" R1" and"
RT112" R2" may" have" the" same" resistance" mechanism" due" to" these" resistant"
derivatives" having" a" similar" phenotype." Therefore," RT112" R2" was" not" examined"
with"whole" exome" sequencing" or" copy" number" analysis." If" a" genetic" alteration" of"
interest"was" identified" in"RT112"R1," analysis"would" be" conducted" to" determine" if"
the" same" mutation" was" present" in" RT112" R2." RT4" parental" and" R1" were" not"
examined"by"whole"exome"sequencing"as"it"was"considered"likely"that"EGFR"was"







pass" whole" genome" sequencing." An" unmatched" blood" sample" was" used" as" a"
reference" sample" in" this" study" because" we" do" not" have" a" matched" reference"
sample" for"RT112"or"RT4."The" sequence"of" centromeres" contains" long"arrays"of"
near" identical" tandem" repeats." The" repetitive" nature" of" these" regions" prevents"
accurate" sequence" alignment" (Hayden," 2012)." This" can" result" in" copy" number"
gains" and" losses" being" falsely" identified" in" centromeric" regions" and" therefore"
apparent" copy" number" alterations" identified" in" these" regions" were" ignored." The"
genome!wide"copy"number"profiles"of"chromosomes"1!22" for"RT112"parental,"R1"
and"R3"normalised"to"a"blood"sample"are"presented"in"Fig."5.1."The"copy"number"
profiles" of" chromosome" 8" and" 9" for" RT112" parental," R1" and" R3" are" shown" in"
Appendix" C," Fig." C.1," to" enable" the" visualization" of" the" smaller" copy" number"




FISH" and" copy" number" changes" have" been" examined" with" array" comparative"
genomic"hybridisation"at"passage"33" (Hurst"et!al.,"2004q"Williams"et!al.,"2005)." In"
this" study" RT112" parental" was" passage" 37" when" DNA" was" harvested" for" copy"
number" analysis." The" copy" number" data" fits" well" with" the" genomic" alterations"
described" by"Williams" et! al." and" Hurst" et! al." (Hurst" et! al.," 2004q"Williams" et! al.,"
2005)." For" example," a" gain" of" chromosome" 20"was" observed" by"Williams"et! al.,"
Hurst"et!al."and"in"this"study."Williams"et!al."observed"a"gain"of"4p"and"Hurst"et!al."




R3" was" observed." No" loss" of" 2q" was" reported" by" Williams" et! al." whilst" loss" of"
2q22.1–q23.1" was" reported" by" Hurst" et! al." and" a" loss" of" 2q21.3!q23.2" was"




5.2." Copy" number" differences" between" RT112" parental" and" R1" and" R3" are"
summarised" in" Table" 5.2" and" Table" 5.3," respectively." As" RT112" parental" is" an"
uncloned" line," copy" number" differences" between"RT112" parental" and" the"RT112"
resistant" derivatives"may" be" due" to" selection" of" a" subclone" rather" than" due" to" a"
genomic" alteration" that" has" occurred" during" the" derivation" of" the" resistant"
derivatives." In" addition" to" the" 2q21.3!q23.2" copy" number" loss" in"RT112" parental,"
R1" and"R3," copy" number" loss" of" 2q37.2!q37.3"was" observed" in"RT112"R1." The"





























of! 4p16.36p11! in!RT112!R3,!however! this!did!not! reach! the! required! threshold!of!!!!!
60.25! to! be! classified! as! a! loss.! FGFR3! is! located! within! the! chromosome! 4!
cytoband! p16.3.! RT112! parental! exhibited! a! gain! of! 4p16.36p11! which! was! not!
observed! in! RT112! R1! or! R3! (Fig.! 5.1).! Therefore,! the! loss! of! 4p16.36q22.1! in!
RT112!R1!appears!to!be!due!to!this!resistant! line! lacking!the!4p!gain!observed!in!
RT112! parental.! Both! RT112! R1! and! R3! exhibited! gain! of! 8p11.236p11.1.! This!
region!contains!FGFR1.!RT112!R1!exhibited! copy!number!gain!of! 5p15.336q11.1!
which!contains!the!genes!LIFR!and!OSMR+which!encode!the!oncostatin!M!(OSM)!
pathway! receptors! leukaemia! inhibitory! factor! receptor! (LIFR)! and! oncostatin! M!
receptor! (OSMR),! respectively.! RT112! R1! also! exhibited! copy! number! gain! of!
















Chromosome:Position!(MbP!hg38)! Cytoband! Copy!Number!Loss/Gain! Potential!Candidate!Genes! Number!of!Genes!in!Region!
2:235,053,661B238,107,785! q37.2!–!q37.3! loss! SH3BP4' 17!
4:90,569,813B190,026,739! q22.1!–!q35.2! gain! FABP2,'SMAD1' 311!
5:0B48,800,000! p15.33!–!q11.1! gain! LIFR,'OSMR,' 136!
5:49,712,701B57,604,516! q11.1!–!q11.2! gain! IL6ST,'MAP3K1' 34!
8:38,057,101B45,200,000! p11.23!–!q11.1! gain! FGFR1' 47!

















Chromosome:Position!(MbP!hg38)! Cytoband! Copy!Number!Loss/Gain! Potential!Candidate!Genes! Number!of!Genes!in!Region!
4:85,661B49,061,875! p16.3!–!p11! loss! FGFRL1,'FGFR3,'
FGFRBP1,'FGFRBP2'
301!
4:51,843,881B190,026,739! q12!–!q35.2! gain! KIT,'SMAD1' 507!




RT4! parental! and! R1.! The! copy! number! profiles! of! RT4! parental! and! RT4! R1!
normalised! to! a! blood! sample! are! presented! in! Figure! 5.3! and! copy! number!
changes!shared!between!RT4!parental!and!R1!are!summarised! in!Table!5.4.!The!
karyotype! of! parental! RT4! has! been! analysed! previously! by! MDFISH! and! copy!
number! changes! have! been! examined! by! with! array! comparative! genomic!
hybridisation! (Hurst! et# al.,! 2004M! Williams! et# al.,! 2005).! The! reported! genomic!
alterations! in! RT4! parental! were! concordant! with! the! copy! number! changes!
observed! in! our! copy! number! data.! For! example,! Williams! et# al.! reported! RT4!
parental,!which!is!tetraploid,!to!have!three!copies!of!chromosome!9!and!five!copies!











the! region! from! 5p15.33Dq11.1,! which! contains! the! LIFR! and!OSMR! genes! was!
also!observed!in!RT112!R1.!These!genes!encode!receptors!in!the!OSM!signalling!
pathway! (Fig.! 6.15).! Transcriptome! analysis! conducted! in! Chapter! 6! identified!
differential! expression! of! OSM! pathway! signalling! genes! in! RT112! resistant!
derivatives!compared!to!parental!RT112!(Fig.!6.9,!6.10,!D.6!and!D.7).!Tables!of!the!
genes!in!5p15.33Dq11.1!which!were!differentially!expressed!between!RT4!parental!
and! RT4! R1! and! between! RT112! parental! and! RT112! R1,! determined! by!
transcriptome! analysis,! are! included! as! supplementary! data.! It! was! possible! that!
the! increase! in!EGFR!expression! in!RT4!R1!could!be!due! to!EGFR!amplification.!
EGFR!is!located!on!chromosome!7,!cytoband!p11.2.!No!change!in!copy!number!in!



























































Chromosome:Position!(MbQ!hg38)! Cytoband! Copy!Number!Loss/Gain! Potential!Candidate!Genes! Number!of!Genes!in!Region!
5:0B48,800,000! p15.33!–!q11.1! gain! LIFR,&OSMR& 136!
5:!50,518,687B181,538,259! q11.1!–!q35.3! loss! IL6ST,&IL31RA,&MAP3K1,&SMAD5,&FGF1,&RASGEFC,&MAPK9& 721!
!100!
5.2.3%Whole%exome%sequencing%of%RT112%R1%




were! visualised! in! Integrative! Genomics! Viewer! (IGV)! and! any! considered! to! be!
artefacts!were!removed!from!variant!lists.!No!insertions!or!deletions!in!RT112!R1!or!
RT112! R3! met! these! criteria.! There! were! fortyJthree! single! nucleotide! variants!
(SNVs)!which!met!the!criteria!in!RT112!R1.!These!are!listed!in!Table!C.1,!Appendix!
C.! TwentyJone!mutations! (49%)!were! nonJsynonymous.! The!mutations! in! RT112!
R1!which!were! thought! to! be!most! likely! to! be! inducing! resistance,! as! they!were!
predicted! to! induce! a! nonsense! mutation,! predicted! to! be! deleterious! by!
Polymorphism! Phenotyping! v2! (PolyPhen)! and! Sorting! Intolerant! from! Tolerant!




Ligase! 2!which! ubiquitinates!Delta,! a!Notch! ligand,! inducing! its! removal! from! the!
cell! membrane! via! endocytosis! (Koo! et% al.,! 2005).! Transfection! of! wildtype!MIB2!
into!melanoma!cell!lines!reduced!MET!protein!expression!and!significantly!reduced!
invasion!in%vitro!and!in%vivo.!(Takeuchi!et%al.,!2006).!Immunoblot!analysis!conducted!










observed! in!RT112!R1!and!was! predicted! to! be! deleterious! by!SIFT! (Table! 5.6).!
HACL1! encodes! 2JhydroxyacylJCoA! lyase! which! is! involved! in! the! !Joxidation!
pathway!which!breaks!down!branched!fatty!acid!and!2Jhydroxylated!fatty!acids!into!
aliphatic! aldehydes! in! the! peroxisome.! The! resulting! aldehyde! is! then! able! to! be!
degraded!with!the!"Joxidation!pathway!(Foulon!et%al.,!2005).!
!101!
! A! nonsense! mutation! (Q144*)! in! SLC35G2! was! observed! in! RT112! R1!
(Table!5.6).%SLC35G2!encodes!solute!Carrier!Family!35!Member!G2.!SLC35!family!
members! are! involved! in! the! transport! of! nucleotide! sugars! or! adenosine! 3′J





and! the! regulation! of! nucleotide! receptors! such! as! the! thyroid! receptor! and! the!
oestrogen!receptors!(Hatakeyama,!2011).!
! A!nonsense!mutation! (E76*)!was!observed! in!SESN3% in!RT112!R1! (Table!









! A! missense! mutation! in! TMPRSS15! resulting! in! a! R583T! amino! acid!
change!was!observed! in!RT112!R1!and!was!predicted! to!be!deleterious!by!SIFT!
and! probably! damaging! by! PolyPhen! (Table! 5.6).! TMPRSS15! encodes!








The!mutations!which!were! thought! to! be!most! likely! to! be! inducing! resistance! in!
RT112!R3,!as!they!were!predicted!to!induce!a!nonsense!mutation,!predicted!to!be!







































MIB2! ENST00000355826! 1:1629393! missense!variant! c.A2693G! p.Q898R! ! tolerated! benign! 33! 0!
ATF2! ENST00000264110! 2:175093201! missense!variant! c.G1045A! p.E349K!
!
deleterious! possibly!damaging! 24! 4!
HACL1! ENST00000321169! 3:15601421! missense!variant! c.T43C! p.S15P!
!
deleterious! benign! 33! 4!
SLC35G2! ENST00000393079! 3:136854890! stop!gained! c.C430T! p.Q144*! ! ]! ]! 32! 3!
TRIM51! ENST00000449290! 11:55886138! stop!gained! c.A427T! p.K143*! ! ]! ]! 27! 4!
SESN3! ENST00000278499! 11:95185375! stop!gained! c.G226T! p.E76*! ! ]! ]! 32! 7!
GRIP1! ENST00000359742! 12:66517916! missense!variant! c.G563A! p.G188E!
!
deleterious! probably!damaging! 26! 6!
TMPRSS15! ENST00000284885! 21:18329201! missense!variant! c.G1748C! p.R583T!
!







! A! missense! mutation! in! CD55$ resulting! in! a! Y245F! amino! acid!
change!was!observed! in!RT112!R3!and!was!predicted! to!be!deleterious!by!SIFT!
and! probably! damaging! by! PolyPhen! (Table! 5.7).! CD55,! also! known! as! decay!
accelerating! factor,! is! an! inhibitor! of! the! complement! system.! CD55! inhibits!
complement!dependent!cytotoxicity!of!cancer!cells!(Reis!et$al.,!2018).!
A!nonsense!mutation! (E2243*)!was!observed! in!XIRP2! in!RT112!R3! (Table!5.7).!
XIRP2! encodes! Xin! Actin! Binding! Repeat! Containing! 2! which! is! expressed! in!
skeletal!and!cardiac!muscle.!XIRP2!stabilises!the!actin!cytoskeleton!via!binding!and!
crosslinking!actin!filaments!(Pacholsky!et$al.,!2004).!!
! A!missense!mutation! in!UGT3A1$ resulting! in!a!V244E!amino!acid! change!
was!observed!in!RT112!R3!and!was!predicted!to!be!deleterious!(low!confidence)!by!
SIFT! and! possibly! damaging! by! PolyPhen! (Table! 5.7).! UGT3A1! transfers! NW
acetylglucosamine! to! the! bile! acid! ursodeoxycholic! acid! from! UDP! NW
acetylglucosamine!(Mackenzie!et$al.,!2008).!!
A!missense!mutation! in! PCSK5! resulting! in! a!W681S! amino! acid! change!
was!observed!in!RT112!R3.!PCSK5!is!a!CalciumWdependent!serine!protease!which!
cleaves!and!activates!ProWrenin,! Integrin!α!subunit!and!MMP14!(KleinWSzanto!and!
Bassi,! 2017).! The! COSMIC! database! v83! catalogues! this! mutation! as! having!






A!missense!mutation! in!ZNF114! resulting! in! a! E362K! amino! acid! change!
was!observed!in!RT112!R3.!This!mutation!was!predicted!to!be!possibly!damaging!
by! Polyphen.! ZNF114! encodes! zinc! finger! protein! 114! which! is! involved! in!
epigenetic! repression! of! proWdifferentiation! genes! to! maintain! a! pluripotent! state!
(Oleksiewicz!et$al.,!2017).!!
It! was! decided! that! the! genetic! alteration! most! likely! to! be! inducing!
resistance!in!RT112!R3!was!the!HRAS!G12S!mutation.!The!HRAS!G12S!mutation!
has!been!previously!reported!and!it! is!known!to!act!as!a!gain!of!function!mutation!










Sanger! sequencing! was! conducted! to! confirm! the! presence! of! the!HRAS! G12S!
mutation! in! RT112! R3! and! absence! in! RT112! parental,! R1! and! R2! (Fig.! 5.6).!
Sanger!sequencing!identified!both!a!guanine!and!adenine!at!position!34!(relative!to!
the! first!base!of! the!ATG!start!codon)! in!exon!1!of! the!HRAS!gene! in!RT112!R3.!
This!confirmed!that!R3!contained!both!wildtype!and!G12S!mutant!HRAS.!
As!whole!exome!sequencing!and!Sanger!sequencing!found!that!the!RT112!
R3!population! contained!both!wildtype!and!G12S!mutant!HRAS,! it!was!unclear! if!
individual! RT112! R3! cells! contained! both! HRAS! alleles! or! if! this! was! a! mixed!





Dr! Julie!Burns,! identified!21!single! cell! clones!with! the!HRAS!G12S!mutation,!14!
with!wildtype!HRAS!and!1!heterozygous/mixed!clone! (data!not!shown).! It! is!most!
likely! that! the!heterozygous/mixed!clone!was!not!of!single!cell!origin.!Therefore,! it!

































CD55$ ENST00000314754$ 1:207331177$ missense$variant$ c.A734T$ p.Y245F$
$
deleterious$ probably$damaging$ 41$ 0$
XIRP2$ ENST00000409195$ 2:167248119$ stop$gained$ c.G6727T$ p.E2243*$ $ $ $ 34$ 0$
UGT3A1$ ENST00000333811$ 5:35962902$ missense$variant$ c.T731A$ p.V244E$
$
deleterious$low$
confidence$ possibly$damaging$ 23$ 0$
PCSK5$ ENST00000376767$ 9:76175271$ missense$variant$ c.G2042C$ p.W681S$ COSM4139532$ $ unknown$ 27$ 0$







deleterious$ tolerated$ 73$ 0$
ZNF114$ ENST00000315849$ 19:48286708$ missense$variant$ c.G1084A$ p.E362K$
$



















76! maintained! in! PD.! Although! SNaPshot! analysis! is! only! semiGquantitative,! the!
proportion!of!mutant!HRAS!could!be!determined!from!these!results!(Fig.!5.7).!The!
proportion!of!mutant!HRAS!in!the!R3!population!increased!with!increased!passage!
number! and! therefore! suggests! that! the! HRAS! G12S! provided! a! selective!
advantage.!!
! In!order! to!examine!whether!mutant!HRAS! could!confer! resistance! to!PD,!
RT112!parental!was!retrovirally!transduced!with!a!construct!encoding!HRAS!G12V!
and! selection! of! transduced! cells! was! conducted.! A!HRAS! G12V! construct! was!
used!because!we!did!not!have!a!HRAS!G12S!available!and!time!was!limited.!It!was!
observed! that! these! cells! had! reduced! sensitivity! to! PD! (Fig.! 5.8).! This! provides!
















EGFR! exons! 18G24! encode! the! tyrosine! kinase! domain! of! this! RTK! (da! Cunha!
Santos! et% al.,! 2011).! The! genomic! regions! examined! by! the! Leeds! Genomics!
Laboratory!include!the!most!common!sites!of!EGFR!(ENST00000275493)!mutation!
in! lung! cancer:! 7:55174013G7:55174015! which! encodes! G719! in! exon! 18! is! a!
common! site! of!missense!mutations,! 7:55174769G55174795!which! encodes! I744G
P753!in!exon!19!is!a!region!in!which!deletions!such!as!the!A746_750del!commonly!
occur,!7:55181312G55181329!encodes!S768GV774!in!exon!20!which! is!a!region! in!
which! insertions! commonly! occur,! 7:55181378! is! the! site! of! the! T790M! exon! 20!
activating! mutation! implicated! in! resistance! to! EGFR! TKIs! and! 7:55191822G!
55191831! encodes! L858GL861! in! exon! 21! which! is! a! site! in! which! missense!
mutations! occur,! notably! the! L858R! mutation! (Tsiambas! et% al.,! 2016).! Exon! 19!
deletions! and! L858!mutations! account! for! greater! than! 90%! of!mutations! in! lung!
adenocarcinoma!(Sholl,!2016).!No!EGFR!mutations!were!detected!in!RT4!R1!in!the!
regions!listed!above!(data!not!shown).!A!mutation!in!EGFR! in!RT4!R1!could!have!






































































































but! not! RT112! parental! or! RT112! R3.! Distal! 2q! deletions! are! associated! with! a!
higher! histological! stage! and! grade! in! urothelial! carcinoma! (Hurst! et% al.,! 2012d!
Lindgren!et% al.,! 2012d! Nishiyama!et% al.,! 2011).! It! is! unclear! whether! this! deletion!
contributed! to! the! resistant! phenotype.! The! following! genes! in! the! 2q37.2Gq37.3!
!111!
region!were! lost! in!RT112!R1:!SH3BP4,!AGAP1,!GBX2,!ASB18,! IQCA1,!ACKR3,!
COPS8,% COL6A3,% MIR6811,!MLPH,! PRLH,!RAB17,% LRRFIP1,!RBM44,!RAMP1,!
UBE2F,! UBE2FASCLY,! SCLY! and! ESPNL.% SH3BP4! modulates! the! amino! acid!





between! the!Rag!GTPase! complex%and!mTORC1.% SH3BP4! deletions! have! been!
reported! in!a!number!of! cancers! including!NSCLC,! renal!and!breast! cancers!and!
SH3BP4!has!been!mooted!as!a!tumour!suppressor!(Kim!and!Kim,!2013).%Its!loss!of!
function! could! allow! mTORC1! activation! in! the! presence! of! FGFR3! inhibition.!
Whether! the! loss!of!SH3BP4! contributed! to!PD! resistance! in!RT112!R1!could!be!
tested! by! inducing! SH3BP4! expression! in! RT112! R1! or! knockdown! of! SH3BP4!
expression! in! RT112! parental! and! examining! if! these! alterations! increased! or!
reduced! sensitivity! to! PD! respectively.! Whole! exome! sequencing! identified! a!
nonsense!mutation! in!SESN3,!which!encodes! the!negative! regulator!of!mTORC1!
sestrin! 3.! This! mutation! could! cooperate! with! the! deletion! of!SH3BP4! to! enable!
greater!activation!of!mTORC1.!However,!as!sestrin!1G3!are! functionally!redundant!
(Chantranupong!et%al.,!2014),! it!was! thought! that! this!mutation!was!unlikely! to!be!
inducing!resistance!to!PD!in!RT112!R1.!
Both! RT112! R1! and! RT112! R3! had! gain! of! 8p11.23Gq11! which! contains!
FGFR1.!However,!increased!copy!number!of!FGFR1!is!unlikely!to!be!the!cause!of!
resistance!to!PD!as!FGFR1!protein!expression!was!low!in!RT112!R1!and!R2!(Fig.!
4.2).! Phosphorylation! of! this! receptor! was! not! examined.! Copy! number! analysis!
showed! that! there! was! a! loss! of! 4p16.3Gq22.1! in! RT112! R1.! A! possible! loss! of!
4p16.3!G!p11!was!also!observed!in!RT112!R3,!however,!the!level!of!this!loss!did!not!
reach! the! threshold! of! G0.25! required! for! this! region! to! be! classified! as! a! loss.!
FGFR3!is!located!in!cytoband!4p16.3.!Immunoblot!analysis!conducted!in!Chapter!3!
showed!that!expression!of!FGFR3!was!reduced!in!RT112!R1,!R2!and!R3!cultured!
in!PD! compared! to!RT112!parental! cultured! out! of!PD! (Fig.! 3.11).!Culture! of! the!
RT112! resistant! derivatives! without! PD! for! 4! passages! induced! an! increase! in!
expression! of! both! wildtype! FGFR3! and! the! FGFR3GTACC3! fusion.! However,!
expression!of!both!wildtype!FGFR3!and!the!FGFR3GTACC3!fusion!remained!lower!
than! in! RT112! parental! cultured! without! PD! (Fig.! 3.11).! As! there! is! differential!
expression! of! wildtype! FGFR3! and! the! FGFR3GTACC3! fusion! in! the! RT112!
resistant!derivatives!depending!on!exposure! to!PD,! this! suggests! that! the!altered!
!112!




thought! that! this! was! the! most! likely! copy! number! alteration! to! be! causing! PD!
resistance.! This! region! contains! the! genes! OSMR! and! LIFR! which! encode! the!
oncostatin!M!receptor!and!leukaemia!inhibitory!family!receptor!respectively.!These!
receptors!are!part! of! the!OSM!signalling!pathway!which! induces!activation!of! the!
STAT! and!MAP! kinase! pathways! (Hermanns,! 2015).! RT112!R1! also! exhibited! a!
gain! of! copy! number! of! 5q11.1Gq11.2! which! contains! the! gene! IL6ST! which!
encodes! glycoprotein! 130,! another! receptor! in! the! OSM! signalling! pathway!
(Hermanns,!2015).! It! is!possible! that! the!signalling!via! the!OSM!pathway! induces!
resistance! via! the! activation! of! these! pathways! in! the! RT112! and! RT4! resistant!
lines.!The!OSM!pathway! is! examined! in! greater! detail! in!Chapter! 6! section!6.2.5!
following!transcriptome!analysis!of!RT112!and!RT4!parental!and!resistant!lines.!
SNVs! in! ATF2,! SLC35G2,% TRIM51,% SESN3,% HACL1,! GRIP1! and!
TMPRSS15!were!identified!in!RT112!R1.!These!SNVs!were!also!present!in!RT112!
R3! at! a! low! variant! allele! frequency.! This! suggests! that! these! mutations! were!
present!in!a!subclone!of!parental!RT112!or!that!the!mutation!arose!prior!to!the!point!
at!which! the!RT112!cells!were!cultured!as!separate! lines!during! the!derivation!of!
the!RT112!resistant!derivatives!(Chapter!3,!Fig.!3.1).!Some!mutations!identified! in!
RT112! R1! and! R3! have! not! yet! been! catalogued! in! the! COSMIC! database.!
However,! this! does! not!mean! these!mutations! are! not! important! as! they!may! be!
novel!mutations!which!contribute!to!FGFR!TKI!resistance.!Out!of!all! the!mutations!
identified! in! RT112! R1! and! R3,! only! the! PCSK5! W681S! and! the! HRAS! G12S!
mutations!in!R3!have!been!curated!in!the!COSMIC!database.!The!PCSK5!W681S!
mutation!(COSM4139532)!has!been!observed!in!head!and!neck!cancer!(Martin!et%
al.,! 2014),! colorectal! cancer! (van! de! Wetering! et% al.,! 2015),! gastric! cancer!
(COSMIC! study! ID!COSU371),! acute!myeloid! leukemia! (COSU544),! lung! cancer!
(COSU583),! prostate! adenocarcinoma! (COSU537)! and! renal! cell! cancer!
(COSU588).! Mutations! in! the! RAS! family! of! GTPases! occur! in! many! cancers!
including!pancreatic,!colorectal!and! lung!adenocarcinomas,!multiple!myeloma!and!
bladder!cancer!(Scott!et%al.,!2016d!Robertson!et%al.,!2017).!
It! was! thought! that! of! the! SNVs! identified! in! RT112! R1! by! whole! exome!
sequencing,! E349K!ATF2! and! Q898R!MIB2! were% the! most! likely! to! be! inducing!
resistance.!ATF2%encodes!activating!transcription!factor!2!which!elicits!its!activity!by!
!113!
forming! homodimers! or! by! heterodimerizing! with! other! activating! protein! 1! (AP1)!
family!members.!ATF2! regulates!genes!which! control! the! cell! cycle,! inflammation!
and!cell!death!(Watson!et%al.,!2017).!The!mutation!observed!in!RT112!R1!induces!
an! amino! acid! substitution,! p.E349K,! in! one! of! the! nuclear! localisation! signals!
(NLS)!in!this!protein.!The!NLS!contains!two!bipartite!NLS!motifs,!both!of!which!are!
capable!of!inducing!nuclear!localisation.!One!NLS!motif!is!encoded!by!amino!acids!





the! introduction!of!basic!amino!acids!near! the!centre!of! the! linker! region! impaired!
the!function!of!an!artificial!NLS!(Kosugi!et%al.,!2008).!Therefore,! it! is! likely!that!the!
ATF2! E349K! mutation! would! impair! the! function! of! the! NLS! motif.! However,! as!
ATF2!possesses!a!second!functional!NLS!this!mutation!is!not!likely!to!impair!ATF2!
function! (Liu! et% al.,! 2006).! Therefore,! it! is! most! likely! that! this! mutation! is! not!
inducing!PD!resistance!in!RT112!R1.!
It! was! thought! that! the! Q898R!mutation! observed! in!MIB2% in! RT112! R1,!
could! be! inducing! resistance! to! PD! (Table! 5.6).! Takechui! et% al.! observed!
hypermethylation!of!the!MIB2!promoter!in!6!out!of!31!invasive!melanoma!samples!
whilst! hypermethylation! was! not! observed! in! 25! benign! nevi! or! five! nonGinvasive!
superficial!spreading!melanomas.!It!was!also!reported!that!transfection!of!wildtype!
MIB2! into!melanoma! cell! lines! reduced!MET! protein! expression! and! significantly!
reduced! invasion! in% vitro! and! in% vivo.! (Takeuchi!et%al.,! 2006).!Total!and!phosphoG
MET! protein! expression! was! examined! in! the! RT112! resistant! derivatives! in!
Chapter! 4! (Fig.! 4.11).! An! increase! in! total!MET! expression! was! not! observed! in!
RT112! R1! compared! to! RT112! parental.! An! increase! in! phosphoGMET! was!
observed! in! R3! cultured! without! PD! and! in! R1,! R2! and! R3! cultured! with! PD!
compared! to! RT112! parental! acutely! treated! with! PD.! However,! as! MET!




due! to! the! copy! number! gain! of! 5p15.33Gq11.1! or! loss! of! 2q37.2Gq37.3! or! could!
arise! due! to! one! of! the! SNVs! identified! in! this! line.! Further! investigation! of! the!
genetic! alterations! observed! in! RT112! R1! was! not! conducted! due! to! time!










was! confirmed! by! Sanger! sequencing.! Retroviral! transduction! of! RT112! parental!
with!HRAS!G12V!indicated!that!a!HRAS!mutation!can!induce!resistance!to!PD.!The!
mutual!exclusivity!of!mutant!RAS!and!FGFR3%in!urothelial!carcinoma!suggests!that!
the!mutations!perform!a!similar! function! (Jebar!et%al.,!2005).! Immunoblot!analysis!
conducted! in! Chapter! 4! found! that! phosphoGERK! and! phosphoGAKT! were!
expressed! in! RT112! parental! cells! cultured! without! PD! and! the! RT112! resistant!
derivatives! in! and! out! of! PD.! PhosphoGERK! and! phosphoGAKT! expression! was!
reduced! in! RT112! parental! cultured! in! PD! for! 24! h! (Fig.! 4.12).! The! reduced!
phosphorylation! in!RT112!parental!acutely! treated!with!PD!showed! that!activation!
of! the!MAP! kinase! and!PI3! kinase! pathways! in! parental! RT112! is! dependent! on!
FGFR3!activation.!As!the!RAS!family!are!also!able!to!activate!the!MAP!kinase!and!
PI3!kinase!pathways,!the!HRAS!G12S!mutation!in!RT112!R3!is!likely!to!be!inducing!
the! phosphorylation! of! ERK! and! AKT! observed! in! RT112! R3! cultured! in! PD!
(Castellano! and! Downward,! 2011).! FGFR3! and! RAS! mutations! occur! more!
frequently! in! bladder! cancers! of! a! lower! stage! (Hurst!et% al.,! 2017d! Kimura!et% al.,!
2001).!In!Chapter!3,!it!was!shown!that!RT112!R3!cultured!in!PD!had!a!reduced!rate!
of!proliferation!and!cell!density!at!confluence!compared!to!RT112!parental!cultured!
without!PD.!This! suggests! that! the!HRAS!mutation,!whilst! providing! resistance! to!
PD,!does!not!confer!exactly!the!same!intracellular!signals!to!induce!cell!proliferation!
as!FGFR3.!!




the! mutation.! The! survival! and! proliferation! of! the! RT112! R3! cells! with! wildtype!












30G40,! and! switch! 2,! encoded! by! residues! 60! to! 76.! Switch! 1! and! 2! undergo! a!
conformational!change!depending!on!the!binding!of!GTP!or!GDP.!When!bound!to!
GTP,!switch!1!and!2!are!able!to!bind!and!activate!a!range!of!effector!molecules!due!
to! their! flexible! structure.! These! effector! molecules! include! RAF,! PI3K,! RALGEF!
and! PLC!.! Whilst! the! sequence! of! the! effector! lobe! is! conserved! between! RAS!
family!members,! the! sequence! of! the! allosteric! and! hypervariable! regions! varies.!
The!allosteric!region!is!involved!in!RAS!dimerization,!which!is!thought!be!important!
in! activation! of! the! MAP! kinase! pathway.! Post! translational! modification! of! the!
hypervariable! region! targets! RAS! to! the! cell! membrane! (SpencerGSmith! and!
O'Bryan,! 2017).! The! majority! of! mutations! in!HRAS,! KRAS! and!NRAS! occur! at!
residues!G12,!G13!and!Q61.!These!residues!are!in!the!RAS!G!domain!which!binds!
to! GTP.! This! domain! is! also! responsible! for! the! hydrolysis! of! GTP! to! GDP.!
Mutations!at!residues!G12,!G13!and!Q61!disrupt!this!GTPase!activity!which!results!
in! constitutively!active!RAS! (Hobbs!et%al.,! 2016).! !Mutations! in! the!RAS! family!of!
GTPases! occur! in! many! cancers! including! pancreatic,! colorectal! and! lung!
adenocarcinomas! and! multiple! myeloma! (Scott! et% al.,! 2016).! Robertson! et% al.!






an!NRAS! Q61R!mutation.! Treatment! of! the! resistant! cells! with! BGJ398! and! the!
MEK!inhibitor!trametinib!reduced!cell!proliferation!to!a!greater!extent!than!treatment!
with! either! BGJ398! as! a! single! agent.! It! was! observed! that! the! combination! of!
BGJ398!and!trametinib!was!well!tolerated,!significantly!slowed!tumour!progression!




treatment! of! RAS! mutant! cancers! has! so! far! been! unsuccessful.! Attempted!
methods! of! inhibition! have! included! inhibiting! the! lipid! modification! of! RAS! to!
prevent!the!translocation!of!RAS!to!the!membrane!and!preventing!the!exchange!of!
RASGbound! GDP! for! GTP! via! inhibition! of! guanine! nucleotide! exchange! factor!
interaction! with! RAS! (Scott! et% al.,! 2016).! Development! of! inhibitors! which! target!
molecules!downstream!of!RAS!has!been!more!successful.!For!example,! the!MEK!




The! likely! mechanism! of! resistance! in! RT4! R1! is! the! activation! of! EGFR!
identified! in! Chapter! 4.! Therefore,! examination! of! RT4! focused! on! identifying! an!
EGFR!mutation!or!amplification!in!this!line.!No!EGFR!mutation!or!amplification!was!
found! and! so! EGFRGupregulated! expression! and! activation! probably! occurs! by! a!
nonGgenetic! mechanism.! HerreraGAbreu! et% al.! reported! that! RT112! increased!
activation! of! EGFR! as! a!mechanism! of! shortGterm! survival! to! treatment! with! PD.!
They! reported! that! PD! treatment! induced! EGFR! accumulation! at! the! plasma!
membrane! and! the! increased! activation! of! EGFR! in! RT112! was! as! a! result! of!
reduced!MAP!kinase!pathway!repression!(HerreraGAbreu!et%al.,!2013).!!
In! conclusion,! of! the! genetic! alterations! identified! in! RT112! and! RT4!
resistant! derivatives! in! this!Chapter,! the!most! likely! to! be! inducing!PD! resistance!
are!the!gain!of!copy!number!of!OSM!family!receptors!in!RT112!R1!and!RT4!R1,!the!
















likely!developed!resistance! to!PD!through!nonGgenetic!mechanisms.! It! is!probable!
that!RT4!R1!developed!resistance!due!to!the!overexpression!and!phosphorylation!
of!EGFR!observed!in!Chapter!4!(Fig.!4.6).!Genetic!analysis!in!Chapter!5!uncovered!
no!amplification!or!mutation!of!EGFR,! indicating!that! this!resistance! is!not!caused!
by! a! genetic! alteration! to!EGFR! in!RT4!R1.!Culture! of!RT4!R1!without! PD! for! 4!
passages!reGsensitized!this!line!to!PD!(Chapter!3,!Fig.!3.10).!Therefore,!RT4!R1!did!
not! maintain! an! epigenetic! state! which! allowed! it! to! respond! to! PD! treatment.!
Culture!of!RT4!R1!for!a!greater!period!of!time!in!PD!may!have!led!to!the!resistant!
line!acquiring!an!epigenetic!state!which!enabled!it!to!maintain!its!PDGresistant!state!!
A! genetic! mechanism! of! resistance! in! RT112! R1! was! not! identified! in!
Chapter!5!through!exome!sequencing!or!copy!number!analysis.!It!was!thought!that!
as!RT112!R1!and!R2!are!phenotypically!similar,! these! lines!may!employ!a!similar!
method! of! resistance! to!PD.! The! resistance! to!PD! in!RT112!R1! and!R2!may! be!
induced!by!the!increased!phosphorylation!of!ERBB3!and!MET!observed!in!Chapter!
4!(Fig.!4.8!and!4.11).!RT112!R1!and!R2!retained!resistance!despite!reverting!to!a!





effect(s)! of! the!HRAS! G12S! mutation! on! gene! expression! in! RT112! R3! and! 3)!
whether!the!resistant!lines!exhibit!gene!expression!features!associated!with!having!
undergone!an!EMT.!
A! wellGreported! mechanism! of! resistance! to! inhibition! of! a! RTK! is! the!
activation! of! an! alternative! RTK.! This! was! discussed! in! section! 1.2.2! of! the!
Introduction.!Increased!expression!of!a!RTK!in!a!resistant! line!cultured!in!PD!may!
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indicate! that! the! receptor! is! a! possible! mediator! of! resistance.! Therefore,!




Expression! analysis! was! conducted! with! DNA! microarrays.! Gene!
expression! changes! could!be! induced!due! to! culture! in!PD,! could!be! ‘passenger’!
gene!expression!changes!which!are!present! in!cells!with!a!selective!advantage!or!
could! be! caused! by! unintended! experimental! differences! such! as! cell! culture!





was! conducted! with! the! following! experimental! conditions! in! triplicate:! RT112!
Parental!+!PD!24!h,!RT112!Parental!no!PD,!RT112!R1!+!PD,!RT112!R1!no!PD,!
RT112! R2! +! PD,! RT112! R2! no! PD,! RT112! R3! +! PD,! RT112! R3! no! PD,! RT4!
Parental!no!PD,!RT4!R1!+!PD!and!RT4!R1!no!PD.!Resistant!line!‘no!PD’!samples!
were!cultured!out!of!drug! for!4G6!passages.!This!was! long!enough! for!RT112!R1,!
RT112!R2!and!RT4!R1!to!regain!a!faster!proliferation!rate!and!morphology!similar!
to! their! parental! line,! enabling! the! identification! of! nonGtransient! gene! expression!
changes! induced! by! PD.! Appendix! D! summarises! the! quality! control! and!
normalisation! of! microarray! data.! Principal! component! analysis! (PCA)! was!
conducted!and! lists!of!genes!which!had!undergone!a!significant!gene!expression!
change! (p<0.05,! oneGway! analysis! of! variance! (ANOVA),! 2Gfold! change)! between!






condition! clustered! close! together! suggesting! that! none! of! the! samples! were!
anomalous.!The!three!parental!+!PD!replicates!clustered!separately!from!the!other!
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+! PD! had! similar! gene! expression! profiles! to! each! other,! distinct! from! the! other!
experimental!conditions.!The!remaining!experimental!conditions!have!similar!gene!
expression.! This! analysis! fits! with! RT112! R1! and! R2! +! PD! exhibiting! a!
mesenchymal! morphology! in! contrast! to! the! epithelial! morphology! of! RT112!
parental!no!PD,!R1!no!PD,!R2!no!PD!R3!+!PD!and!R3!no!PD!(Chapter!3,!Fig.!3.4!
and!Fig.!3.5).! It! is! logical! that!RT112!parental!+!PD! formed!a!separate!cluster!as!






PCA!was!conducted!on! the! full!RT4!microarray!dataset! (Fig.!6.2).!The! repeats!of!
each! experimental! condition! clustered! close! together! suggesting! that! none!of! the!
samples!were!anomalous.!Parental!no!PD,!R1!+!PD!and!R1!no!PD!replicates!each!
separated! into!a!different!cluster.!PCA1!separated!parental!no!PD!and!R1!no!PD!
from! R1! +! PD.! PCA2! separated! R1! no! PD! replicates! from! other! samples.! This!
indicates! that! the! expression! profile! of! each! RT4! experimental! condition! was!
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Table! 6.1! details! the! numbers! of! significantly! differentially! expressed! probes! for!
comparisons! of! RT112! experimental! conditions.! The! threshold! for! significant!
differential!expression!was!a!greater!than!twoGfold!expression!change!and!a!p<0.05!
in!a!oneGway!ANOVA.!Additionally,!a! falseGdiscovery! rate!pGvalue!was!calculated.!









is!most! similar! to!R3! +!PD! and! the! resistant! derivatives! cultured! out! of! PD.! The!
results!are!concordant!with!the!PCA!analysis!which!found!similar!gene!expression!
between!RT112!parental!no!PD,!R1!no!PD,!R2!no!PD,!R3!+!PD!and!R3!no!PD!and!


































R1!No!PD!vs!Parental!No!PD! 289! 624! 913!
R2!No!PD!vs!Parental!No!PD! 726! 772! 1498!
R3!No!PD!vs!Parental!No!PD! 467! 349! 815!
!
Table! 6.2! details! the! numbers! of! significantly! differentially! expressed! probes! for!
comparisons! of! RT4! experimental! conditions.! As!with! the! analysis! of! RT112,! the!
threshold! for! significant! differential! expression! was! a! greater! than! twoGfold!
expression! change! and! a! pGvalue! <0.05! in! oneGway! ANOVA.! The! number! of!
significantly!differentially!expressed!probes!was!greatest!in!the!comparison!of!R1!+!
PD!vs!Parental!no!PD!followed!by!R1!+!PD!vs!R1!no!PD!and!finally!R1!no!PD!vs!
Parental!no!PD.!This! is!concordant!with! the!PCA!analysis!which! found!RT4!R1!+!















R1!+!PD!vs!Parental!No!PD! 849! 1251! 2100!
R1!+!PD!vs!R1!No!PD! 774! 1022! 1796!




Hierarchical! cluster! analysis! enables! the! visualisation! of! expression! data! from!
multiple! probes! and! microarray! samples! and! indicates! which! samples! have! a!
similar! gene! expression! profile.! Hierarchical! cluster! analysis! was! performed! for!
probes! significantly! differentially! expressed! between! RT112! parental! no! PD!
samples!and!the!other!RT112!experimental!conditions!(oneGway!ANOVA!p<0.01,!2G
fold)!(Fig.!6.3).!The!samples!separated!into!two!clusters,!one!containing!parental!+!
















examine! the! effect! of! acute! treatment! on! RT112! parental.! Eight! of! the! ten!most!
significantly! differentially! expressed! pathway! maps! for! the! comparison! of! RT112!
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parental!+!PD!versus!parental!no!PD!relate!to!the!cell!cycle!(Fig.!6.5).!This!reflects!
the! slow! growth! of! parental! RT112! when! acutely! treated! with! PD,! as! observed!
during! the! derivation! of! the! RT112! resistant! lines! (described! in! Chapter! 3).! The!
other! pathways! in! the! top! ten! significantly! differentially! expressed! pathways! are!
‘ATM/ATR! regulation!of!G1/S! checkpoint’! and! ‘Sirtuin! 6! regulation!and! functions’.!
ATM!and!ATR!kinases!are!activated!by!DNA!damage!inducing!the!phosphorylation!
of! targets! involved! in! DNA! repair,! cell! cycle! arrest! and! apoptosis! (Maréchal! and!
Zou,! 2013).! Genes! differentially! expressed! in! the! ‘ATM/ATR! regulation! of! G1/S!
checkpoint’! MetaCore#! pathway! included! ATR! and! genes! involved! in! the!




functions’! MetaCore#! pathway! are! involved! in! the! regulation! of! lipid!metabolism!
such! as! FASN! and! SCD! which! encode! fatty! acid! synthase! and! stearoylGCoA!
desaturaseG1,!respectively.!
MetaCore#!analysis!was!used! to!compare! the!gene!expression!of!RT112!
parental! acutely! treated! with! PD! with! the! expression! of! resistant! derivatives!
cultured! in!PD.!These!differences! in!gene!expression! could!be! critical! to! the!PDG
resistant! phenotype! of! the! derivatives.! Pathway! maps! related! to! cytoskeletal!
remodelling,! EMT! and! TGF! signalling! pathways! were! differentially! expressed! in!
RT112!R1!and!R2!+!PD!compared! to!parental!+!PD! (Fig.!6.6!and!Fig.!6.7).!This!
reflects! the! fact! that! RT112! R1! and! R2! have! a! mesenchymal! morphology! in!
contrast!to!the!epithelial!morphology!of!the!parental!line!(Chapter!3,!Fig.!3.4).!
Eight!of!the!ten!most!significantly!differentially!expressed!pathway!maps!for!
the! comparison! of!RT112!R3! +!PD! versus! parental! +! PD! relate! to! the! cell! cycle!
(Fig.! 6.8).! This! reflects! that!RT112!R3! is! the!most!PDGresistant!RT112!derivative!
whilst!RT112!parental!is!sensitive!to!PD!(Chapter!3,!Fig.!3.8).!The!other!pathways!
in! the! top! ten! significantly! differentially! expressed! pathways! are! ‘ATM/ATR!
regulation!of!G1/S!checkpoint’!and! ‘BRCA1!as!a! transcription! factor’.!Many!of! the!
genes! differentially! expressed! in! the! ‘ATM/ATR! regulation! of! G1/S! checkpoint’!
MetaCore#! pathway! are! involved! in! the! regulation! of! cell! proliferation,! such! as!
members!of! the!cyclin! family!and!MYC.!Expression!of! these!genes!was!higher! in!
R3!+!PD.!Genes!differentially!expressed!in!the!pathway!‘BRCA1!as!a!transcription!
factor’!included!ATM,!ATR,!BRCA1%and%MYC.!Expression!of!BRCA1!and!ATR!was!
higher! in!R3!+!PD,!expression!of!ATM!was!higher! in!parental!+!PD.!BRCA1! is!a!
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used! to! compare! the! gene!expression! of!RT112!parental! not! cultured! in!PD!with!
that!of!the!resistant!derivatives!not!cultured!in!PD.!Pathway!maps!relating!to!OSM!





The!most! significantly! differentially! expressed!MetaCore#! pathway!maps! for! the!
comparisons!RT112!R1!no!PD!and!parental!+!PD,!R2!no!PD!and!parental!+!PD!

















parental! no! PD,! pathways! relating! to! EMT! and! cell! adhesion! were! significantly!
differentially!expressed! for!RT4!R1!+!PD!vs!RT4!parental!no!PD! (Fig.!6.12).!The!
most!significantly!enriched!pathway!map!for!this!comparison!is!‘ENaC!regulation!in!
normal! and! CF! airways’.! Genes! differentially! expressed! in! this! pathway! include!
SCNN1A! and!SCNN1B,! which! encode! subunits! of! the! epithelial! sodium! channel!
ENaC.!Expression!of!these!genes!was!higher!in!parental!no!PD.!The!ENaC!sodium!
channel! permits! the! diffusion! of! sodium! ions! across! the! apical! membrane! of!
epithelial!cells.!ENaC! is!an! important!mediator!of!homeostasis!of!electrolytes!and!
water.! Genes! in! the! ‘immune! response! IFNGalpha/beta! signaling! via! JAK/STAT’!
pathway! map! which! were! differentially! expressed! included! interferon! inducible!
proteins! and!guanylate! binding!proteins! regulated!by!STAT!signalling.! Interferons!
are! antiviral! cytokines! produced! in! response! to! cellular! stress! which! reduce!
proliferation! and! induce! apoptosis! in! cancer! cells! (Snell! et% al.,! 2017).! Differential!
expression!of!other!pathways!in!the!list!of!the!top!10!most!differentially!expressed!









RT4!R1!no!PD!did! not! retain! resistance! to!PD! following! culture!without!PD! for! 4!
passages.! Therefore,! the! gene! expression! in! this! experimental! condition! did! not!
reflect! a! resistant! state! although! persistent! gene! expression! changes! caused! by!
FGFR!inhibition!may!be!present!in!this!line.!Increased!expression!of!ILG1!alpha!and!
beta!in!R1!no!PD!features!in!a!number!of!pathways!for!the!comparison!of!RT4!R1!
no!PD!vs!parental!no!PD! (Fig.!6.13).!The! ILG1! family!of! cytokines!are!pleiotropic,!
















5.2,! Table! 5.2).! Therefore,! it!was! considered! that! signalling! via! the!Oncostatin!M!
(OSM)!pathway!could!be! inducing! resistance! to!PD! in!RT112!R1!and!RT112!R2.!
Signalling!downstream!of!OSM!is!summarised!in!Fig.!6.15.!OSM!binds!the!receptor!
glycoprotein! 130! (gp130),! and! then! either! the! Oncostatin! M! receptor! (OSMR)! or!
Leukaemia!inhibitory!factor!receptor!(LIFR)!are!recruited!to!the!complex.!The!OSM!
pathway!primarily!signals!via!the!Janus!kinase!(JAK)!family!of!nonGreceptor!tyrosine!
kinases! which! phosphorylate! and! activate! the! signal! transducer! and! activator! of!
transcription!(STAT)!family!of!transcription!factors.!This!is!known!as!the!JAK/STAT!
pathway.! OSM! signalling! also! activates! the! MAPK! pathway,! JNK,! the! AKT/PI3K!
















Blue! denotes! the! gp130! and!OSMR%/LIFR%! heterodimer! and! yellow! denotes!OSM.! ! ‘P’s!
represent! the! intracellular! phosphorylation! of! gp130! and! OSMR%/LIFR%.! Image! adapted!
from!Hermanns%et%al,%2015.!
!
IL6ST,!OSMR! and!LIFR,%which!encode! receptors! in! the!OSM!signalling!pathway,!








increased! in! R1! +! PD,! R1! no! PD,! R2! +! PD! and! R2! no! PD! and! significantly!
decreased! in! parental! +! PD! compared! to! parental! no! PD! (Fig.! 6.17).! qRTGPCR!




+! PD! and! also! showed! that! expression! was! significantly! increased! in! R1! no! PD!
(Fig.!6.18).!The!observed!increase!in!expression!of! IL6ST,!OSMR!and!LIFR!could!
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be! mediating! an! increase! in! activation! of! the! OSM! signalling! pathway! in! RT112!


































































































































































































Microarray! analysis! showed! that! the! OSM! signalling! pathway! ligands!OSM! and!
IL31!were!not!significantly!differentially!expressed!between!RT112!parental!no!PD!
and!the!other!RT112!experimental!conditions!(Appendix!D,!Fig.!D.10).!Therefore,!if!
activation!of! the!OSM!signalling!pathway!is! increased!in!RT112!it! is!unlikely!to!be!
due!to!increased!presence!of!ligand.!!
! In! RT4,! MetaCore"! pathway! analysis! did! not! suggest! that! the! OSM!
signalling!pathway!was!differentially!expressed! in!RT4!parental!and!RT4!R1! (Fig.!
6.13,! 6.14!and!D.9).!However,! as! this! pathway!had!been! identified! as!a!possible!




differentially! expressed! in! RT4! R1! +! PD! compared! to! RT4! parental! no! PD!
(Appendix! D,! Fig.! D.11).! OSM! and! IL31! were! not! significantly! differentially!
expressed! between! RT4! experimental! conditions! (Appendix! D,! Fig.! D.12).!
Therefore,! differential! expression! of! these! receptors! or! ligands! is! unlikely! to! be!
contributing! to! resistance! in! RT4! R1! and! the! copy! number! alterations! on!



























































































(Hermanns,! 2015).! For! this! reason,! phosphorylation! of! STAT1! and! STAT3! was!
examined!in!RT112!parental!and!resistant!lines!(Fig.!6.20!and!6.21).!A431!treated!
with! EGF! was! selected! as! a! positive! control! for! STAT1! and! STAT3! as! previous!
research! has! shown! that! A431! treated! with! EGF! expresses! total! and!
phosphorylated!STAT1!and!STAT3!(Grudinkin!et%al.,!2007).!Phosphorylated!STAT1!
and! STAT3! could! not! be! detected! by! immunoblot! in! any! RT112! samples.!
Therefore,! STAT1! and! STAT3! are! not! mediating! resistance! in! RT112! resistant!
lines.! As! the! STAT! family! of! transcription! factors! are! commonly! activated! when!
OSM!and!OSMR!signalling! is!active,! it! is!unlikely!that!the! increased!expression!of!
OSMR,! LIFR! and! IL6ST! is! inducing! resistance! in! RT112! R1! and! RT112! R2! via!
STAT!activation.!However,!it!is!possible!that!OSMR,!LIFR!and!IL6ST!are!mediating!
resistance! via! activation! of! the!MAP! kinase! pathway!without! activating! the!STAT!
family! of! transcription! factors.! Phosphorylation! of! STAT1! or! STAT3! was! not!
examined! in! RT4! as! the! microarray! data! indicated! that! there! was! no! significant!
increase!in!OSM,%IL31,%IL6ST,%OSMR,%LIFR,%STAT1,%STAT3,%STAT5A%or%STAT5B%
expression!in!RT4!R1!compared!to!parental.!
As! previously! stated,! OSM! signalling! can! activate! the!MAPK! pathway! (Fig.!





other!APG1!family!members! to! form!the!APG1!transcription! factor.!Jun! is!a!positive!
regulator! of! cell! proliferation! (Shaulian,! 2010).! A! key! difference! between! RT112!
parental!acutely!treated!with!PD!and!the!RT112!resistant!lines!is!the!maintenance!
of!ERK!phosphorylation!in!the!resistant!lines!(Chapter!4,!Fig.!4.12).!OSM!pathway!
signalling! could! be! activating!APG1! via! the!MAPK!pathway! in!RT112!R1! and!R2.!
JUN! expression! was! also! significantly! increased! in! RT4! R1! +! PD! and! nonG
significantly! increased! in!R1!no!PD!compared! to!parental!no!PD! (Fig.!6.22).!This!









































































































































































































































































al.! reported! that! FGFR3! knockdown! in! RT112! reduced! expression! of! genes!
involved!in!fatty!acid!and!sterol!biosynthesis!and!metabolism!(Du!et%al.,!2012).!The!
transcription! factors!SREBP1! and!SREBP2,! encoded! by! the! genes!SREBF1! and!
SREBF2,! preferentially! regulate! synthesis! of! unsaturated! fatty! acids! and!
cholesterol,! respectively! (Hagen! et% al.,! 2010).! In! RT112,! microarray! analysis!
showed!that!expression!of!SREBF1!was!significantly!differentially!downregulated!in!
parental! +! PD,!R1! +! PD,!R2! +! PD! and!R2! no!PD! compared! to! parental! no! PD.!
Additionally,!SREBF1!was!nonGsignificantly!reduced!in!R1!no!PD,!R3!+!PD!and!R3!
















































































































experimental! conditions! compared! to! parental! no! PD! (Fig.! 6.23).! qRTGPCR!
validation!found!significantly!reduced!expression!of!SREBF1!in!parental!+!PD,!R1!+!
PD,!R1!no!PD,!R2!+!PD!and!R2!no!PD!compared!to!parental!no!PD!(Fig.!6.24).!In!
contrast! to! the! microarray! analysis,! qRTGPCR! analysis! indicated! that! SREBF1!
expression! in! R3! no! PD! was! significantly! increased! (Fig.! 6.24).! Therefore,! the!











FullGlength! SREBP1! and! SREBP2! are! endoplasmic! reticulumGbound! precursor!
proteins! which! are! cleaved! to! produce! their! mature! form! (Hagen! et% al.,! 2010).!
Immunoblot! analysis! showed! that! expression! of!mature!SREBP1!was! reduced! in!
RT112! parental! +! PD,! R1! +! PD,! R2! +! PD,! R3! +! PD! and!R3! no! PD! (Fig.! 6.25).!
StearoylGCoA!desaturaseG1!(SCD1)!is!the!rateGlimiting!enzyme!in!the!production!of!
monoGunsaturated! fatty!acids! from!saturated! fatty!acids!and! increases! lipogenesis!
(Igal,! 2016).! Immunoblot! analysis! showed! that! SCD1! protein! expression! was!
highest! in!RT112!parental!no!PD!and!R2!no!PD,! lower! in!RT112!R1!no!PD,!R3!+!
PD!and!R3!no!PD!and!lowest!in!RT112!parental!+!PD,!R1!+!PD!and!R2!+!PD!(Fig.!
6.25).! These! results! suggest! there! is! a! reduction! in! monoGunsaturated! fatty! acid!








































































































































































































































































































































transcriptional! upregulation! induced! by! SREBP1.! Blue! lines! indicate! a! chemical! reaction.!
Modified!from!Hagen!et%al.,!2010.!
!
Du!et%al.! reported!a!set!of!33!genes! involved! in! fatty!acid!and!sterol!biosynthesis!
and!metabolism!that!were!downregulated!upon!knockdown!of!FGFR3!in!RT112!(Du!
et% al.,! 2012).!Unsupervised! hierarchical! cluster! analysis!was! performed! in!RT112!
microarray! samples! for! this! set! of! genes! (Fig.! 6.27).! Expression! of! this! cohort! of!




predominantly! high! expression! of! this! cohort! of! genes.! Overall,! the! differential!
expression!of! this!cohort!of!genes! indicated! that! fatty!acid!and!sterol!biosynthesis!
and!metabolism!was!likely!to!be!reduced!in!RT112!parental!+!PD,!RT112!R1!+!PD!
and! RT112! R2! +! PD! compared! to! the! other! RT112! experimental! conditions.!
Therefore,! the! mechanism! of! resistance! to! PD! in! RT112! R1! and! R2! did! not! reG
establish! the! expression! of! fatty! acid! and! sterol! biosynthesis! genes! whereas! the!
mechanism!of! resistance! in!RT112!R3,! the!HRAS!G12S!mutation,! did.!However,!
the!mutant!HRAS! in! RT112!R3! did! not! activate! fatty! acid! synthesis! to! the! same!
extent!as!the!signalling!via!FGFR3ATACC3!and!wildtype!FGFR3!in!parental!no!PD.!
Du! et% al.! observed! that! treatment! with! a! MEK! inhibitor! reduced! FGF1Ginduced!



















3.11)! found! reduction! in! FGFR3! expression! in! the! RT112! resistant! lines.!
Examination! of! phosphoGFGFR3! expression! via! immunoprecipitation! was!
unsuccessful.!A!reduction!in!FGFR3!expression!in!RT112!R1!+!PD,!R1!no!PD,!R2!
+! PD,! R2! no! PD,! R3! +! PD! and! R3! no! PD! compared! to! parental! no! PD! was!
observed!with!microarray!analysis!and!qRTGPCR!analysis!(Fig.!6.28).!In!contrast!to!
the!immunoblot!and!microarray!analysis,!qRTGPCR!showed!a!significant!increase!in!
FGFR3!expression! in!parental!+!PD! (Fig.!6.28).!The! low!expression!of!FGFR3! in!
R3!+!PD! indicates! that!R3!maintains!expression!of! the!Du!et%al.! cohort! of! genes!
when!cultured!in!PD!by!a!mechanism!other!than!signalling!via!FGFR3.!
As!was!observed!for!RT112!experimental!conditions,!genes!involved!in!lipid!
homeostasis! were! differentially! expressed! between! RT4! experimental! conditions!
(Supplementary! data,! 2Gfold! change! lists).! Microarray! analysis! showed! that!
expression! of! SREBF1! and! SREBF2! was! nonGsignificantly! reduced! in! RT4! R1!
compared! to! parental! no!PD.! qRTGPCR!analysis! found! that!SREBF1!mRNA!was!
significantly!downregulated!in!RT4!R1!+!PD!and!R1!no!PD!(Fig.!6.29).!
Hierarchical!cluster!analysis!was!performed! in!RT4!microarray!samples!for!
the!Du!et% al.! cohort! of! fatty! acid! and! lipid! synthesis! genes! (Fig.! 6.30).!One!RT4!





of! this! gene! cohort! relative! to! the! other! RT4! experimental! conditions.! R1! +! PD!
samples! formed! a! cluster! of! samples! with! predominantly! low! expression! of! this!
gene!cohort.!Expression!of!some!genes!was!maintained!or!upregulated!in!RT4!R1!





















































































































































































































qRTGPCR! analysis! showed! that! FGFR3! expression! was! significantly! increased!












































































































the! mean.! Signal! intensity! is! given! relative! to! parental! no! PD.' Asterisks! indicate! the!
experimental!conditions!in!which!FGFR3!is!differentially!expressed!compared!to!parental!no!
PD.! microarray! statistical! test:! ANOVA! p<0.05,! 2Gfold! expression! change.! qRTGPCR!










Immunoblot! analysis! found! that! expression! of! the! epithelial! marker! EG
cadherin!was!constant!between!RT112!parental!no!PD,!R1!+!PD!and!R2!+!PD!and!
that! NGcadherin! expression! was! increased! in! RT112! R1! and! R2! +! PD,! and! to! a!
lesser!extent!RT112!R3!+!PD!compared!to!RT112!parental!no!PD!(Chapter!3,!Fig.!
3.12).!Microarray!analysis!of!expression!of!CDH1,!which!encodes!EGcadherin,!was!
concordant! with! this! and! showed! that! CDH1! was! not! significantly! differentially!
expressed!in!any!experimental!condition!compared!to!RT112!parental!no!PD!(Fig.!
6.32).! Microarray! analysis! showed! that! expression! of! the! CDH2% gene,! which!
encodes! NGcadherin,! was! increased! in! RT112! R1,! R2! and! R3! +! PD,! and! by! a!
smaller!magnitude!in!RT112!R1!and!R2!no!PD!compared!to!parental!no!PD.!This!
increase!was!only! significant! for!RT112!R2!+!PD! (Fig.! 6.32).!A! small! increase! in!
protein! expression! of! another! mesenchymal! marker,! vimentin,! was! observed! in!
RT112!R1!and!R2!compared!to!the!parental!line!(Chapter!3,!Fig.!3.12).!Concordant!































































encodes! vimentin,! VIM,! was! seen! in! RT112! parental,! R1,! R2! and! R3! +! PD!
compared!to!RT112!parental!no!PD!(Fig.!6.32).!!
Microarray! analysis! showed! expression! of! FN1,! which! encodes! the!
mesenchymal!marker!fibronectin,!was!significantly!increased!in!RT112!R1+!PD,!R1!
no! PD! and! R2! +! PD! approximately! 27Gfold,! 3Gfold! and! 19Gfold,! respectively,!









6.32).! The! expression! changes! observed! in! FN1,% SNAI2% and% ELF5% were! not!
validated! by! qRTGPCR! or! immunoblot! due! to! time! limitations.! The! microarray!
analysis,!in!conjunction!with!the!morphological!and!immunoblot!analysis!in!Chapter!




RT4!R1!+!PD!(Fig.!6.12).! Immunoblot!analysis!conducted! in!Chapter!3! found!that!
expression!of!NGcadherin!and!vimentin!was!low!in!RT4!parental!and!R1.!EGcadherin!
expression! was! found! to! be! increased! in! RT4! R1! compared! to! the! parental! line!
(Chapter! 3,! Fig.! 3.13).! Consistent! with! this,! CDH1,! CDH2! and! VIM! were! not!
significantly!differentially!expressed!between!parental!no!PD,!R1!+!PD!and!R1!no!
PD! (Fig.! 6.33).! However,! FN1! expression! was! significantly! increased! by!
approximately!6! in!R1!+!PD!and!nonGsignificantly! increased!by!approximately!11G
fold! in! R1! no! PD! (Fig.! 6.33).! A! nonGsignificant! increase! in!SNAI2! expression! of!
approximately!2!and!1.5Gfold!was!observed! in!RT4!R1!+!PD!and!RT4!R1!no!PD,!
respectively! (Fig.!6.33).!Expression!of!ELF5!was!nonGsignificantly! reduced! in!RT4!
R1!no!PD! to!approximately!half! the!expression!observed! in!RT4!parental!no!PD.!























2014ad! Dadhania! et% al.,! 2016d!Warrick! et% al.,! 2016),! as! discussed! in! Chapter! 1,!
section! 1.1.2.! It! was! observed! that! basal! and! luminal! markers! were! differentially!
!153!
expressed!between!RT112!parental!no!PD!and!RT112!R1!+!PD,!R2!+!PD!and!R3!+!
PD! (Supplementary! datad! 2Gfold! gene! lists).! Basal! tumours! are! more! aggressive!
than! luminal! tumours,! although! they! are! typically! sensitive! to! chemotherapy!
(Dadhania! et% al.,! 2016).! Choi! et% al.! reported! that! p53Glike! subtype! tumours! were!
typically!resistant!to!chemotherapy!(Choi!et%al.,!2014a).!Both!RT112!and!RT4!have!
been! previously! classified! as! luminal! (Warrick!et% al.,! 2016).! ! If! the! resistant! cells!
have!undergone!a!switch!from!a!luminal!to!a!basal!or!p53Glike!subtype!during!their!
derivation,! the! resistant! line! could! be! more! aggressive! or! could! have! reduced!
sensitivity! to! treatment.! If! FGFR! inhibitors! induce! a! similar! switch! subtype! in!
patients,!this!could!result!in!worse!patient!survival.!




R2! +! PD! had! increased! expression! of! ERBB2,! ERBB3! and! KRT7! and! reduced!
expression! of! FGFR3,! FOXA1,! GPX2% and% CYP2J2.! Expression! of! the! luminal!
markers!ERBB2,%ERBB3%and%KRT7%was!generally!low!in!RT112!R1!no!PD,!R2!no!
PD,! R3! no! PD,! and! R3! +! PD! (Fig.! 6.34).! This! analysis! suggests! that! acute!
treatment! with! PD! induced! a! more! luminal! phenotype! in! parental! RT112.! The!
expression! of! luminal!markers! in!R1! and!R2! culture! in! PD! is!more! complex!with!









Expression! of! the! transcription! factor! PPARG,! which! promotes! a! luminal!
phenotype!in!MIBC,!was!nonGsignificantly!reduced!in!all!RT112!microarray!samples!
compared! to!parental!no!PD! (Choi!et%al.,!2014a).!This! reduction!was! found! to!be!
significant! in!R1! +! PD! and!R1! no! PD! by! qRTGPCR! (Fig.! 6.36).! The! transcription!
factors!GATA3!and!FOXA1!work!with!PPARG! to!promote!a! luminal!phenotype! in!
bladder!cancer!cell!lines!(Warrick!et%al.,!2016).!Microarray!analysis!showed!GATA3!
expression!was! significantly! increased! in! R1! +! PD! compared! to! parental! no! PD.!
!154!
The! increase! in! R1! +! PD! GATA3! expression! was! confirmed! by! qRTGPCR! and!
GATA3! expression! in!R1! no!PD!was! also! found! to! be! significantly! reduced! (Fig.!























FGFR3! is! a! luminal! marker! (Choi! et% al.,! 2014).! As! discussed! in! section!
6.2.6,!microarray!and!qRTGPCR!analysis!showed!that!compared!to!RT112!parental!




parental!no!PD.!qRTGPCR!showed!ERBB3! to!be!significantly! increased! in!RT112!
parental!+!PD,!R1!+!PD,!R1!no!PD,!R1!+!PD!and!R2!+!PD!compared! to!RT112!
parental!no!PD! (Fig.!6.37).!ERBB3! is!a!possible!mediator!of! resistance! in!RT112!
R1! and! R2! as! an! increase! in! phosphoGERBB3! expression! was! seen! in! these!
resistant!lines!(Chapter!4,!Fig.!4.8).!!
Uroplakins,! encoded! by!UPK1A,!UPK2,!UPK3A! and!UPK3B,! are! luminal!
markers! expressed! at! the! apical! surface! of! the! urothelium! (Hu! et% al.,! 2000).!
Microarray!analysis!showed! that!UPK1A!expression!was!significantly! increased! in!
RT112!parental!+!PD,!R1!+!PD!and!R2!+!PD!and!significantly!reduced!in!R1!no!PD,!
R2!no!PD!and!R3!no!PD!(Fig.!6.38).!UPK2!expression!was!significantly!increased!
in!RT112! parental! +! PD! and!R1! +!PD! and! significantly! decreased! in!R2! no!PD.!











































































































































































































































































































































































































































































































































between! R3! +! PD! and! parental! no! PD.! The! expression! of! a! number! of! luminal!
markers!is!significantly!reduced!in!R1!no!PD,!R2!no!PD!and!R3!no!PD,!supporting!
the! hypothesis! that! expression! of! luminal!markers! is! reduced! upon! culture! of! the!
resistant!lines!without!PD.!!
The!Choi!et%al.!p53Glike!subtype!of!MIBCs!had!an!activated!wildtype!TP53!
gene! expression! signature! (Choi! et% al.,! 2014).! Unsupervised! hierarchical! cluster!
analysis! was! performed! with! RT112! microarray! expression! data! for! the! p53Glike!
subtype! markers! reported! by! Choi! et% al.! These! markers! were! not! differentially!
expressed! between! RT112! experimental! conditions! (Appendix! D,! Fig.! D.13).!




Unsupervised! hierarchical! cluster! analysis! performed! with! the! basal! subtype!
markers! reported! by! Choi! et% al.! showed! that! basal! markers! were! differentially!
expressed!in!RT112!microarray!samples!(Fig.!6.39).!!
In! order! to! validate! the! changes! in! basal! marker! expression! observed! in! the!
microarray! data,! qRTGPCR! was! performed! using! assays! specific! for! a! selected!
panel! of! these! markers.! Microarray! analysis! found! expression! of! KRT6C! to! be!
significantly! reduced,! by! approximately! 70%,! in! RT112! parental! +! PD! and!
significantly!increased!approximately!13Gfold!in!R1!no!PD!compared!to!parental!no!
PD!(Fig.!6.40).!qRTGPCR!analysis!showed!significantly!higher!KRT6C!expression!in!
R1! +! PD! and! R1! no! PD! (Fig.! 6.40).! Microarray! analysis! showed! expression! of!
KRT5!was!increased!in!RT112!R1!no!PD!compared!to!RT112!parental!no!PD!(Fig.!
6.40).! The! expression! data! generated! from! one! microarray! probe! indicated! that!
there!was!an!approximate!6Gfold!significant! increase!whilst! the!second!microarray!
probe! indicated! that! there! was! an! approximate! 1.4Gfold! nonGsignificant! increase!
(Fig.! 6.40).!KRT5! expression! was! significantly! reduced! for! at! least! one! probe! in!
RT112! parental! +! PD,! R1! +! PD,! R3! +! PD! and! R3! no! PD! compared! to! RT112!
parental!no!PD.!qRTGPCR!analysis!showed!that!KRT5!was!significantly!reduced!in!
RT112! R1! +! PD! and! significantly! increased! in! R1! no! PD! (Fig.! 6.40).! Microarray!
analysis!showed! that!expression!of! the!basal!marker!KRT14,!which! is!associated!
!160!




















































































































































































KRT5 microarray probe expression
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expression! of! cytokeratin! 5/6! was! RT112! parental! no! PD! (Fig.! 6.41).! Therefore,!
treatment! with! PD,! or! subsequent! removal! of! PD,! did! not! induce! an! increase! in!
cytokeratin!5/6!protein!expression.!The!discrepancy!between!the!KRT5!and!KRT6C!










Microarray! analysis! showed! that! expression! of! the! basal! marker! CD44! was!
significantly!decreased!in!RT112!parental!+!PD!and!R2!+!PD!compared!to!parental!
no! PD! (Fig.! 6.42).! However,! no! CD44! protein! expression! was! detected! in! any!
RT112! samples! with! immunoblot! (Fig.! 6.43).! This! indicates! that! despite! the!
observed!differential!expression!of!basal!marker!mRNA!in!the!RT112!experimental!
conditions,! this! may! be! insufficient! to! induce! detectable! changes! in! protein!
expression.!As!the!immunoblot!analysis!conducted!to!examine!cytokeratin!5/6!and!
CD44!did!not!show!that!protein!expression!of!these!basal!markers!was!increased!in!









































































basal! subtype! in! MIBC! (Kiselyov! et% al.,! 2016).! Unsupervised! hierarchical! cluster!

















no! PD! (Fig.! 6.45).! GATA3! and! PPARG! were! not! significantly! differentially!
expressed! across! RT4! experimental! conditions! (Fig.! 6.45).! Compared! to! RT4!
parental! no! PD! expression! of! the! luminal! marker! CYP2J2! was! significantly!
!165!
increased!approximately!4Gfold!and!nonGsignificantly!increased!approximately!2Gfold!
in! R1! +! PD! and! R1! no! PD! respectively! (Fig.! 6.45).! qRTGPCR! analysis! found!
expression! of!FGFR3! to! be! significantly! increased! in!RT4!R1!+!PD! compared! to!
RT4! parental! no! PD! (Fig.! 6.31).! However,! immunoblot! analysis! of! FGFR3! in!
Chapter!3!found!FGFR3!to!be!expressed!at!similar!levels!in!RT4!parental!and!R1!+!
PD!(Chapter!3,!Fig.!3.13).!Microarray!analysis!found!a!nonGsignificant!decrease!in!





Microarray! analysis! showed! that! expression! of! UPK1A! and! UPK2! was!
significantly! increased! and! expression! of! UPK3A,! UPK3B! and! ELF3! was! nonG









Unsupervised! hierarchical! cluster! analysis! was! performed! on! RT4! microarray!
samples!with!Choi!et%al.!basal!markers!(Fig.!6.48).!This!suggested!that!expression!
of! CD44,! KRT14! and! CDH3! could! be! differentially! expressed! between! RT4!
experimental! conditions.! Further! examination! of! the!microarray! data! showed! that!
KRT14! and! CDH3% were% not! significantly! differentially! expressed! (Fig.! 6.49).!
Expression!of!CD44!was!significantly!lower!in!R1!+!PD!than!in!parental!and!R1!no!
PD!(Fig.!6.49).!As!the!microarray!analysis!showed!that!expression!of!basal!markers!













































































































































































































in! resistance! to! FGFR! inhibition! in! RT112! was! conducted! in! Chapter! 4.! This!
showed!that!resistance!to!PD!is!not! likely!to!have!arisen!in!RT112!R1!and!R2!via!
an! increase! in! the! activation! of! EGFR! and! ERBB2! (Chapter! 4,! Fig.! 4.5! and! Fig.!









not! increased! in! the!RT112!resistant!derivatives! therefore!resistance! is!unlikely! to!
be!mediated!in!these!lines!by!an!increase!in!KIT!expression.!Expression!of!ERBB2,!

























































































































































































































































































































































































































significant! increase! in! IGF1R! expression! in! R2! +! PD! (Fig.! 6.51).! Immunoblot!
analysis!was!not!conducted! to!examine! IGF1R!expression!due! to! time! limitations.!
The!microarray!analysis!showed!that!MET!expression!was!significantly!increased!in!
RT112!R1!+!PD!and! iR3!+!PD,! and!nonGsignificantly! increased! in!R2!+!PD! (Fig.!
6.51).! Resistance! to! PD! in! RT112! R1! and! R2! could! be! mediated! via! increased!
signalling! of! IGF1R! or! MET! and! whether! this! is! the! case! requires! further!
investigation.!!
Increased!expression!of!a!RTK! ligand!could! induce! increased!activation!of!
an! RTK! and! downstream! signalling! pathways,! and! therefore! cause! resistance! to!
PD.! As! IGF1R,! MET! and! ERBB3! had! been! identified! as! possible! mediators! of!
resistance!to!PD!in!RT112!R1!and!R2,!the!expression!of!the!ligands!with!specificity!
to! these! receptors!was!examined.!Microarray!analysis! showed! that! expression!of!
IGF1,! which! encodes! the! IGF1R! ligand! insulinGlike! growth! factor! 1,! HGF,! which!
encodes! the! MET! ligand! hepatocyte! growth! factor,! EREG! and! NRG2,! which!
encode! the! ERBB3! ligands! epiregulin! and! neuregulin! 2! respectively,! were! not!
significantly!differentially!expressed!in!the!RT112!resistant!derivatives!compared!to!
the!parental! line! (Appendix!D,!Fig.!D.16).!Expression!of! IGF2!which!encodes! the!
IGF1R!ligand!insulinGlike!growth!factor!2!was!significantly!reduced!in!R1!+!PD!and!




(Fig.! 6.52).! Therefore,! it! is!most! probable! that! R1! and!R2! did! not! gain! their! PDG
resistant! phenotype! due! to! an! increase! in! expression! of! any! of! the! ligands!
examined.!
Microarray! analysis! showed! that! expression! of! FGFR2% and% FGFR3,% was!
increased! in! RT4! R1! +! PD! (Fig.! 6.53),! however! these! RTKs! are! unlikely! to! be!
inducing!resistance!as!these!receptors!are!inhibited!by!PD.!Expression!of!EPHA3,%
which!encodes!ephrin!receptor!A3,!was!significantly!increased!approximately!2Gfold!
in! RT4! +! PD! compared! to! the! parental! line! (Fig.! 6.53! and! Fig.! 6.54).The! Ephrin!
family! of! RTKS! are! implicated! in! angiogenesis! (Pitulescu! and! Adams,! 2014).!






4.9).!Microarray! analysis! showed! that! expression!of!ERBB4!was!nonGsignificantly!































microarray! analysis! was! used! to! examine! expression! of! EGFR! family! ligands! in!
RT4! experimental! conditions.! Expression! of! EREG,! HBEGF,! EGF! and! EPGN,%




































































































































































































































by! culturing! parental! PC9! in! gefitinib! for! 9! days.! These! cells! mediated! their!
resistance! by! activation! of! IGF1R.! An! increase! in! expression! of! histone!
demethylase!KDM5A!was!observed!in!the!resistant!cells!and!the!drug!tolerant!state!
of! these! cells! was! dependent! upon! KDM5A! expression! (Sharma! et% al.,! 2010).! It!
was!observed! that,! upon!culture!without!an!EGFR!TKI,! resistant! cells!maintained!
their! resistant!phenotype! for!approximately!30!passages!before! regaining!gefitinib!
sensitivity! (Sharma! et% al.,! 2010).! It! was! considered! that! increased! expression! of!

































































































RT112!has!a!heterozygous!P1139fs!mutation! in!KDM6A.! It!was!noted! that!
expression! of! the! histone! demethylase% KDM6A! was! significantly! increased! in! the!
RT112!resistant!derivatives!cultured!in!PD!compared!to!parental!no!PD!(Fig.!6.56).!
KDM6A! expression!was! also! nonGsignificantly! increased! in! parental! +!PD,!R1! no!





























































































An! online! cancer! microarray! database! such! as! Oncomine! (Rhodes! et% al.,! 2007)!
could! have! been! used! to! identify! genes! differentially! expressed! in! urothelial!
carcinoma!compared!to!normal!urothelium.!It!would!then!have!been!possible!to!use!
the! list!of!genes!differentially!expressed! in!urothelial!carcinoma!to!filter!our! lists!of!
significantly!differentially!expressed!genes.!This!would!have!removed!genes!whose!
differential! expression!has!not! previously!been! implicated! in!urothelial! carcinoma,!





































































































































































R1! no!PD!may! be! due! an! increase! in! the! copy! number! of! these! genes! as! copy!
number! analysis! showed! that! RT112! R1! has! a! gain! of! 5p15.33! G! q11.1! which!
contains! LIFR! and!OSMR! and! a! gain! of! 5q11.1! G! q11.2! which! contains! IL6ST,!
compared! to! RT112! parental! (Chapter! 5,! Fig.! 5.2,! Table! 5.2).! However,! the! 5p!





Microarray! analysis! showed! that! the! ligands! which! activate! the! OSMR!
pathway,! OSM! and! IL31,! were! not! differentially! expressed! between! RT112!
experimental! conditions.! The! protein! expression! levels! of! OSMR%,! LIFR%! and!
gp130!was!not!examined.!STAT!phosphorylation!is!commonly!used!as!a!readout!of!
activation! of! the! OSM! pathway! (Moidunny! et% al.,! 2016d! Zhang! et% al.,! 2017).!
However,! immunoblot! analysis! found! that! phosphorylation! of! STAT1! and! STAT3!
remained! low! in! RT112! resistant! derivatives.! Therefore,! the! OSM! signalling!
pathway! is! not! activating! STAT1! and! STAT3! in! the! RT112! resistant! derivatives.!
However,! immunoblot! analysis! conducted! in! Chapter! 4! showed! that! ERK! was!
phosphorylated! in! RT112! resistant! derivatives! but! not! RT112! parental! acutely!
treated! with! PD! (Fig.! 4.12).! It! is! possible! that! the! OSM! signalling! pathway! is!
inducing! resistance! in! RT112! resistant! lines! via! activation! of! the! MAP! kinase!
pathway.! No! significant! increase! in! OSM! pathway! ligands! or! receptors! was!
observed!in!the!microarray!analysis!of!RT4!R1.!!
Microarray! analysis! showed! that! genes! which! regulate! the! synthesis! of!
cholesterol! and! fatty! acids! were! differentially! expressed! in! RT112! and! RT4!
experimental! conditions.! It!was! thought! that! the! resistance!mechanism! in! the!PD!
resistant! lines! might! maintain! the! expression! of! fatty! acid! synthesis! genes.!
Alternatively,! the! resistant! lines! could! be! proliferating! despite! reduced! fatty! acid!
synthesis.!It!was!previously!reported!that!expression!of!a!cohort!of!genes!regulating!
fatty!acid!and!sterol!biosynthesis!was!reduced! in!RT112!upon!FGFR3!knockdown!
for! 48! h! (Du! et% al.,! 2012).! Our! microarray! analysis! found! that! expression! of! the!
majority!of!genes!in!this!cohort!was!reduced!in!RT112!acutely!treated!in!PD!for!24!
!179!
h! compared! to! RT112! parental! no! PD.! SCD1! is! the! rateGlimiting! enzyme! in! the!
production!of!monoGunsaturated!fatty!acids!from!saturated!fatty!acids!and!increases!
lipogenesis! (Igal,! 2016).! As! expression! of! this! protein! was! reduced! in! RT112!
resistant! derivatives! this! suggests! that! the! resistance! mechanism! employed! in!
these! lines! does! not! restore! fatty! acid! synthesis! to! the! level! observed! in! RT112!
parental.!!









sterol! biosynthesis! to!a!greater! extent! than! it!was!maintained! in!RT112!R1!+!PD!
and!R2!+!PD.!The! resistance!mechanism! in!R3!may!enable! fatty! acid!and!sterol!
biosynthesis!and,!therefore,!could!be!the!reason!that!R3!exhibits!greater!resistance!




experimental! conditions! but! expression! of! the! Du! et% al.! gene! cohort! was!
predominantly!reduced!in!RT4!+!PD!compared!to!RT4!parental.!This!suggests!that!
there!was!reduced!fatty!acid!and!sterol!biosynthesis!in!RT4!+!PD.!The!effect!of!the!
reduced!expression!of!genes! regulating! fatty!acid!and!sterol! biosynthesis!on! lipid!
metabolism!in!resistant! lines!could!be!investigated!by!measuring!the!incorporation!
of!14C!labelled!acetate!into!fatty!acids!as!conducted!by!Du!et%al.!!(Du!et%al.,!2012).%




BJG398! and! ponatinib,! to! produce! TKIGresistant! derivatives,! exhibited! a!
mesenchymal!morphology.!It!was!found!that!removal!of!the!FGFR!TKIs!resulted!in!
the! derivatives! regaining! an!epithelial!morphology!within! 2G4!weeks! (Wang!et% al.,!
2014).! In!Chapter!3! it!was!observed! that!RT112!R1!and!R2!cultured! in!PD!had!a!
!180!
mesenchymal! morphology! and! had! increased! expression! of! the! mesenchymal!
marker! NGcadherin! (Chapter! 3,! Fig.! 3.4! and! Fig.! 3.11).! These! cells! had! low! NG
cadherin! expression! and! regained! an! epithelial! morphology! following! culture!
without!PD!for!4!passages!(Chapter!3,!Fig.!3.5!and!Fig.!3.11).!The!mesenchymal!
phenotype! is! associated! with! greater! cell! migration! and! invasion.! Therefore,! if!
FGFR!TKIs!induce!an!EMT!in!patients!this!could!lead!to!tumour!metastasis!(Singh!
et%al.,!2017).!EMT!has!been!observed!in!NSCLC!patients!with!acquired!resistance!
to! EGFR! TKIs! (Sequist! et% al.,! 2011).! The! microarray! analysis! showed! that!
expression! of! some! epithelial! and! mesenchymal! markers,! such! as! the! epithelial!
marker!CDH1,! remained! similar! in! all!RT112!experimental! conditions!whilst! other!
markers!were!differentially!expressed,!such!as!the!mesenchymal!marker!FN1.!This!
supports!the!previouslyGheld!hypothesis!that!RT112!R1!and!R2!underwent!a!partial!
EMT! during! their! production.! MetaCore"! pathway! analysis! also! showed! that! R3!
had! undergone! some! EMTGlike! expression! changes! compared! to! parental.! The!
evidence!for!an!EMT!in!RT4!R1!is! limited!compared!to!the!evidence!in!RT112!R1!
and!R2.!However,!MetaCore"!pathway!analysis!did!find!enrichment!of!the!pathway!
‘regulation!of!epithelial! to!mesenchymal! transition! (EMT)’! for! the!comparison!RT4!
R1!+!PD!and!RT4!parental!no!PD!(Fig.!6.12).!EMTGlike!gene!expression!changes!
could! pose! a! problem! for! patients! treated! with! FGFR! inhibitors! if! this! facilitates!
tumour!metastasis.!
Basal! bladder! cancers! tend! to! be! more! aggressive! than! luminal! bladder!
cancers! (Choi! et% al.,! 2014ad! Kiselyov! et% al.,! 2016).! Microarray! and! qRTGPCR!
analysis! indicated! that! expression! of! some! basal! markers! was! increased! and!
expression! of! some! luminal!markers!was! reduced! in!RT112! resistant! derivatives.!
Expression!of!GATA3!and!UPK1A!was! increased!in!R1!+!PD!and!R2!+!PD!whilst!
expression!of!FOXA1!was!reduced!in!R1!+!PD!and!R2!+!PD.!Immunoblot!analysis!
would! have! confirmed! whether! the! differences! in! mRNA! expression! resulted! in!





Therefore,! it! is! unlikely! that! RT112! resistant! derivatives! underwent! a! luminal! to!
basal!subtype!switch.!!
As!microarray! analysis! showed! that! expression! of! basal!markers!was! not!
significantly! increased! in! RT4! R1! +! PD! or! R1! no! PD,! and! expression! of! some!
luminal! markers! was! increased! in! RT4! R1! +! PD,! it! is! unlikely! that! RT4! R1!
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underwent! a! luminal! to! basal! switch! during! the! derivation! of! this! resistant! line! or!
upon! culture! without! PD.! Luminal/basal! expression! changes! were! not! examined!
with!qRTGPCR!or!immunoblot!in!RT4!due!to!time!limitations.!Expression!of!p53Glike!
markers! was! not! significantly! different! between! RT4! or! RT112! experimental!
conditions,! therefore! the! RT4! and!RT112! resistant! derivatives! did! not! undergo! a!
luminal!to!p53Glike!subtype!switch.!!
Sharma!et.%al.%produced!PC9!cells!resistant!to!EGFRGTKIs,!which!mediated!
their! resistance! via! activation! of! IGF1R,! via! culture! in! gefitinib! for! 9! days.! It! was!
observed! that! the! resistant! cells! had! increased! expression! of! KDM5A! and! that!
KDM5A! knockdown! did! not! reduce! the! proliferation! of! parental! PC9! cells! but! did!
reduce!the!production!of!resistant!cells!upon!treatment!with!gefitinib!(Sharma!et%al.,!
2010).! Gale! et% al.! developed! the! KDM5A! inhibitor! YUKA1! and! observed! that!
treatment! with! this! inhibitor! reduced! the! formation! of! gefitinibGresistant! colonies!
following!the!culture!of!PC9!in!gefitinib!for!35!days.!Culture!with!YUKA1!as!a!single!
agent!did!not!reduce!the!growth!of!PC9!!(Gale!et%al.,!2016).!Sharma!et%al.!observed!
that,! upon! culture!without! an!EGFR!TKI,! resistant! cells!maintained! their! resistant!
phenotype! for! approximately! 30! passages! before! regaining! gefitinib! sensitivity!







in! fibroblasts! is! an! increase! in! expression! of! retinoblastoma! binding! proteins!
required!for!the!function!of!RB1!as!a!tumour!suppressor!(Wang!et%al.,!2010).!Its!role!
in!epithelial!cells,!including!the!urothelium,!is!unknown.!Microarray!analysis!showed!
that! expression! of! KDM6A! was! increased! in! the! RT112! and! RT4! resistant!
derivatives!when!cultured! in!PD.!Whether! the! resistant!derivatives!are!dependent!




the! IGF1R! ligand! IGF1! induced!gefitinib! resistance! in!glioblastoma!cell! lines.!The!
combination! of! gefitinib! and! the! small! molecule! inhibitor! linsitinib,! which! has!
specificity! for! IGF1R! and! insulin! receptor! (InsR),! reduced! the! cell! viability! of! the!
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glioblastoma! cell! lines! GBM39! and! GBM76! more! effectively! than! treatment! with!




to! gemcitabine! in! the! bladder! cancer! cell! line! 5637.! Additionally,! a!metaGanalysis!
showed!that!bladder!cancer!patients!with!high!expression!of!IGF1R!mRNA!have!a!
lower! overall! survival! time! and! lower! time! to! disease! recurrence! (Wang! et% al.,!
2017a).! IGF1R!activates! the!MAP!kinase!and!PI3!kinase!pathways!(Hartog!et%al.,!
2007).!Immunoblot!analysis!in!Chapter!4!showed!that!signalling!via!these!pathways!
was! reduced! in!RT112!parental!acutely! treated!with!PD!whereas! these!pathways!
were!activated!in!RT112!resistant!lines!cultured!in!PD!(Fig.!4.12).!Therefore,!IGF1R!
could! be! mediating! resistance! via! activation! of! the! MAP! kinase! and! PI3! kinase!
pathways!in!RT112!R1!and!R2.!Whether!IGF1R!protein!expression!is!increased!in!
the! RT112! resistant! lines! and! whether! signalling! via! IGF1R! is! active! in! parental!
RT112!and!the!resistant! lines!could!be!confirmed!with!immunoblot!analysis.!A!cell!
viability! assay!with! the! IGF1R! inhibitor! linsitinib!will! be! described! in!Chapter! 7! to!
examine!the!sensitivity!of!parental!RT112!and!the!RT112!resistant! lines!to! IGF1R!
inhibition.!
Microarray!analysis! identified!an! increase! in!MET!expression! in!the!RT112!
resistant!derivatives.!This!is!discrepant!with!the!immunoblot!analysis!in!Chapter!4,!
in!which!total!MET!protein!expression!was!reduced!in!R1+!PD!and!R2!+!PD!(Fig.!
4.11).!As! the! immunoblot!analysis! identified!an! increase! in! the!phosphorylation!of!
MET,! this! RTK! may! be! mediating! resistance! to! PD.! MET! signalling! has! been!
reported! as! a! mechanism! of! short! term! survival! in! response! to! FGFR! inhibition!
(Harbinski!et%al.,!2012).!!
qRTGPCR! analysis! identified! an! increase! in! ERBB3! expression! in! RT112!
parental!acutely!treated!with!PD,!R1!+!PD!and!R2!+!PD.!An!increase!in!phosphoG
ERBB3!expression!was!observed! in!Chapter! 4! (Fig.! 4.8)! but! examination!of! total!
ERBB3!protein!expression!was!unsuccessful.!Signalling!via!ERBB3,! together!with!
its! dimerization! partner! ERBB2,! has! been! previously! reported! as! a! resistance!
mechanism! to! FGFR! inhibition! in! RT112! (Wang! et% al.,! 2014).! ERBB3! remains! a!
possible!mediator!of! resistance! in! the!RT112!resistant!derivatives.!MET!has!been!
reported!to!heterodimerize!with!ERBB3!(PérezGRamírez!et%al.,!2015d!Tanizaki!et%al.,!
2011),! therefore! it! is! possible! that! these! two! RTKs! act! together! to! induce! PD!
resistance.!
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EPHA3! mRNA! expression! was! significantly! increased! in! RT4! +! PD!
compared! to! RT4! R1! no! PD.! Conflicting! evidence! has! found! the! EPH! family! of!
RTKs! to! be! both! oncogenic! and! tumourGsuppressive.! Agonistic! and! antagonistic!
targeted!agents!specific!for!EPH!family!members,!such!as!ifabotuzumab!which!is!a!
EphA3! agonist,! have! entered! early! stage! clinical! trials! (Lodola! et% al.,! 2017).!
Expression!of!ERBB4!was!nonGsignificantly!increased!in!RT4!R1!+!PD.!Canfield!et%
al.!showed!that!knockdown!of!ERBB4!induced!apoptosis!in!ERBB2Gpositive!breast!




The! increased! expression! of! EGFR! in! RT4! R1! +! PD! observed! in! the!
microarray!analysis! is!concordant!with! the!previously!observed! increase! in!EGFR!
protein!expression!and!phosphorylation.!This!increased!activation!of!EGFR!remains!
the!most!likely!mediator!of!resistance!in!RT4!R1.!HerreraGAbreu!et%al.!showed!that!
EGFR!mediated!shortGterm!survival! in!RT112! treated!with!PD!by! reGactivating! the!
MAP! kinase! pathway! (HerreraGAbreu! et% al.,! 2013).! Harbinski! et% al.! screened! a!
secreted! protein! cDNA! library! and! identified! that! TGFG',! which! activates! EGFR!
signalling,! was! able! to! induce! resistance! to! the! FGFR! TKI! BGJ398! in! RT112!
(Harbinski! et% al.,! 2012d! Singh! and! Coffey,! 2014).! EGFR! is! reported! to! induce!
intrinsic!resistance!to!BRAF!inhibition!via!reGactivation!of!the!MAP!kinase!pathway!
in! cell! line! models! of! colorectal! cancer! (Corcoran! et% al.,! 2012d! Prahallad! et% al.,!
2012).!Approximately!6%!of!MIBC!tumours!exhibit!gain!of!copy!number!of!7p11.2!
which! contains! EGFR! (Robertson! et% al.,! 2017).! Approximately! 60%! of! bladder!
cancer!tumours!express!membranous!EGFR!(Ibrahim!et%al.,!2009).!These!tumours!
could!be!intrinsically!resistant!to!FGFR!inhibition.!
















several! RTKs! was! identified! by! immunoblot! and! transcriptome! analysis.!
Experiments! described! in! this! Chapter! were! performed! in! order! to! test! whether!
these!RTKs!could!be!acting!as!mediators!of!resistance!to!PD.!
Immunoblot! analysis! in! Chapter! 4! examined! the! phosphorylation! of! RTKs!
previously! implicated! in! resistance! to! FGFR! inhibition.! An! increase! in! phosphoG
ERBB3!was! identified! in!RT112!R1!and!R2.!However,!phosphorylation!of!ERBB2!
and! EGFR! remained! low! in! these! lines.! An! increase! in! phosphoGMET! was! also!
observed! in! the!RT112! resistant! lines.! Total! and! phosphoGEGFR!expression!was!
increased! in! RT4! R1! but! expression! of! phosphoGERBB2! and! phosphoGERBB3!
remained!low.!
In! Chapter! 6,! qRTGPCR! showed! ERBB3! expression! to! be! increased! in!
RT112!parental!acutely!treated!with!PD,!R1!and!R2.!Microarray!analysis!identified!
a! significant! increase! in! IGF1R!mRNA! in!RT112!R1!and!R2.!Microarray! analysis!
also!showed!EGFR!mRNA!expression!to!be!increased!in!RT4!R1,!concordant!with!
the!increase!in!total!EGFR!observed!by!immunoblot!in!Chapter!4.!
The! EGFR! family,! MET! and! IGF1R! can! be! targeted! with! smallGmolecule!
inhibitors!which! have! specificity! to! a! small! number! of!RTKs.! In! this!Chapter,! cell!
viability!assays!conducted!with! smallGmolecule! inhibitors!will! be!presented.!These!
were! carried! out! to! test! the! dependency! of! resistant! lines! on!RTKs! for! which! an!
increase!in!expression!or!phosphorylation!has!been!identified.!This!was!carried!out!
with! the! aim! of! determining! which! RTKs! may! be! mediating! resistance! and! to!
suggest! which! drug! combinations! could! be! used! in! the! clinic! to! overcome!
resistance! to! FGFR! inhibition.! Cell! viability! assays! were! conducted! with! these!




Exome! sequencing,! in! Chapter! 5,! identified! a! HRAS! G12S! mutation! in!












immunoblot! analysis! (Fig.! 4.11).! MET! activation! has! been! reported! to! overcome!






HGF,!with! IC50s!of!1.2!and!12.4!nM! respectively.!Capmatinib!was! inactive! in! the!
gastric!cancer!cell!line!SNUG1!and!in!the!kidney!cell!line!HEK293!which!express!no!
and!a!low!level!of!MET!respectively!(Liu!et%al.,!2011).!Capmatinib!is!currently!being!
assessed! in! clinical! trials! for! the! treatment!of!EGFR!TKIGresistant!NSCLC! (Wu!et%
al.,! 2017).! As! sensitivity! to! capmatinib! had! been! previously! reported! at!
concentrations!between!2!and!13nM!in!METGdependent!cell!lines!(Liu!et%al.,!2011),!
it! was! thought! that! 1μM! capmatinib! was! a! sufficiently! high! concentration! to!
determine!if!the!RT112!cells!were!sensitive!to!MET!inhibition.!Therefore,!sensitivity!
to!1μM!capmatinib!was!examined!by!cell!viability!assay!(Fig.!7.1).!1μM!capmatinib!
did! not! reduce! cell! viability! in! RT112! parental,! R1,! R2! or! R3.! The! sensitivity! of!
RT112! parental! and! resistant! lines! to! a! range! of! capmatinib! concentrations! in!
combination!with!1μM!PD!was!also!tested!(Fig.!7.2).!Treatment!with!capmatinib!+!
PD! did! not! reduce! cell! viability! any! more! than! was! observed! with! PD! alone!
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(Chapter! 3,! Fig.! 3.8).! Therefore,! RT112! parental! and! resistant! lines! are! not!
dependent!upon!signalling!via!MET.!
Expression!of!MET!has!previously!been!reported!in!the!urothelial!carcinoma!
cell! line!5637!and!activation!of!MET!signalling!by!hepatocyte!growth! factor! (HGF)!
has!been!reported!to!increase!invasiveness!in!5637!(Shintani!et%al.,%2017d!Wang!et%
al.,% 2007).! Immunoblot! analysis! showed! that! 5637! expressed! phosphoGMET! and!
MET! (Chapter!4,!Fig!4.11).!Therefore,!5637!was!selected!as!a!positive!control! to!
determine! if! capmatinib! was! successfully! inhibiting! MET.! However,! 5637! was!
insensitive! to! treatment! with! capmatinib! (Fig.! 7.3).! This! could! indicate! that!
capmatinib!was! not! inhibiting!MET!at! the! concentrations! used! in! this! assay.!One!
alternative! explanation! is! that,! whilst! 5637! expresses! phosphoGMET! and! the!
activation! of! MET! signalling! increases! the! invasiveness! of! 5637,! MET! inhibition!
does!not!reduce!5637!cell!proliferation!or!survival.!It!is!also!possible!that!MET!could!
be! promoting! cell! proliferation! and! survival! in! 5637! via! crosstalk! with! another!
receptor,!and!when!MET! is! inhibited!activation!of! the!other! receptor!compensates!
for! the! reduced!MET! activity.! There! was! insufficient! time! to! conduct! immunoblot!
analysis! to! examine! whether! capmatinib! inhibited! MET! phosphorylation! in! the!
RT112!resistant!derivatives!or!5637.!This!experiment!would!have!clarified!whether!

















































































































































































































































To! determine! if! ERBB3! activation,! or! activation! of! an! alternative! EGFR! family!
member,! was! contributing! to! the! resistant! phenotype! of! the! RT112! resistant!
derivatives,! cell! viability! was! tested! in! RT112! parental! and! resistant! derivatives!





the! buccal! carcinoma! cell! line! KB! (Hickinson! et% al.,! 2010).! Sapitinib! inhibited!
ERBB2!and!ERBB3!phosphorylation! in!the!breast!adenocarcinoma!cell! line!MCF7!
with! IC50s!of!3!and!4nM!respectively! (Hickinson!et%al.,!2010).!Sapitinib!has!been!
assessed! in! phase! I! and! II! clinical! trials! with! breast! cancer! patients! with! limited!
success!(Johnston!et%al.,!2016d!Kurata!et%al.,!2014).!
Single!agent!treatment!with!sapitinib!did!not!appreciably!reduce!cell!viability!
in! RT112! parental! or! the! resistant! derivatives! (Fig.! 7.4).! The! combination! of!
sapitinib!and!PD!reduced!the!cell!viability!of!the!RT112!resistant!derivatives!to!50G
60%! of! the! vehicle! control! and! viability! in! parental! RT112! was! reduced! to!
approximately! 20%! (Fig.! 7.5).! It! was! observed! in! Chapter! 3! that! single! agent!
treatment!with!PD!reduced!the!viability!of!RT112!parental!to!33%,!R1!to!53%,!R2!to!









7.6).! The! cell! viability! of! DSH1! cultured! in! 1μM! sapitinib!was! 34%!of! the! vehicle!
control.!As!DSH1!was!sensitive!to!sapitinib!we!can!conclude!that!the!sapitinib!was!


















































































































































































































































R1! and!R2! (Chapter! 6,! Fig.! 6.51).! Linsitinib! is! a! smallGmolecule! ATPGcompetitive!
kinase! inhibitor! developed! to! inhibit! IGF1R.! A! cellGfree! assay! found! that! linsitinib!
inhibited! IGF1R,! the! insulin! receptor! (IR)! and! insulin! receptorGrelated! protein!
(INSRR)! with! IC50s! of! 0.035,! 0.075! and! 0.075μM! respectively! but! that!
concentrations!greater! than!10μM!were!required! to! inhibit!other!RTKs!(Mulvihill!et%
al.,! 2009).! Linsitinib! has! been! assessed! in! clinical! trials:! for! example,! a! phase! III!
clinical! trial! was! conducted! with! patients! with! locally! advanced! or! metastatic!
adrenocortical!carcinoma!but!was!not!found!to!increase!patient!survival!(Fassnacht!
et%al.,!2015).!
To! examine! whether! signalling! via! upregulated! IGF1R! might! be! inducing!
resistance!to!PD,!sensitivity!to!linsitinib!was!assayed!in!RT112!parental!and!RT112!
resistant! derivatives! (Fig.! 7.7).! The! IC50s! of! linsitinib! in! RT112! parental,! R1,! R2!
and!R3!were!0.8,!0.4,!0.9!and!3.3μM!respectively.!This!indicated!that!all!lines!were!
sensitive!to!linsitinib.!The!sensitivity!of!RT112!parental!to!linsitinib!was!unexpected!
as!this!cell! line! is!able!to!signal!via!FGFR3!to!promote!cell!growth!and!survival.! It!
was!also!surprising!that!RT112!R3!was!sensitive!to!linsitinib!as!it!was!hypothesised!
that! the! HRAS% mutation% in! this! line% would! enable! constitutive! activation! of! cell!
proliferation!and!cell! survival.!However,! the! IC50!values! indicated! that!RT112!R3!
was!less!sensitive!to!linsitinib!than!RT112!parental,!R1!or!R2.!!
RT112! parental! and! RT112! R1! were! then! assayed! for! their! sensitivity! to!
linsitinib!in!combination!with!1μM!PD!(Fig.!7.8).!RT112!parental!and!R1!treated!with!
a! range! of! linsitinib! concentrations! in! combination! with! 1μM! PD,! had! IC50s! of!
0.11μM!and!0.34μM!respectively.!Therefore,!in!RT112!parental!inhibition!of!IGF1R!
with! linsitinib! was! more! efficacious! in! combination! with! FGFR! inhibition! than!






























































































Transcriptome! analysis! identified! that! expression! of!EGFR! RNA!was! significantly!
increased! in! RT4! R1! cultured! with! and! without! PD! compared! to! RT4! parental!
(Chapter! 6,! Fig.! 6.52).! Immunoblot! analysis! confirmed! that! both! phosphoGEGFR!
and! total!EGFR!expression!were! increased! in!RT4!R1!compared! to!parental!RT4!
(Chapter! 4,! Fig.! 4.5).! Erlotinib! is! an! ATPGcompetitive! inhibitor! with! selectivity! for!
EGFR! (Moyer! et% al.,! 1997).! Moyer! et% al.! examined! the! selectivity! of! erlotinib! on!
purified! RTKs! and! found! that! erlotinib! inhibited! EGFR! with! an! IC50! of! 2nM! and!
exhibited! over! 1000Gfold! greater! selectivity! for! EGFR! than! for! the! other! kinases!
examined:! SRC! and! ABL.! Immunoblot! analysis! and! densitometry! showed! that!
erlotinib!inhibited!the!phosphorylation!of!EGFR!following!treatment!with!EGF!in!the!
head! and! neck! squamous! cell! carcinoma! cell! line! HN5! with! an! IC50! of! 20nM!
(Moyer!et%al.,!1997).!Erlotinib!inhibited!the!proliferation!of!the!colorectal!carcinoma!
cell! line!DiFi!with!an! IC50!of!100nM! in!an!8!day!proliferation!assay! (Moyer!et%al.,!
1997).! Erlotinib! is! approved! for! treatment! of! NSCLC! and! pancreatic! cancer!
(Mosquera! et% al.,! 2016d! Singh! and! Jadhav,! 2017).! To! determine! if! activation! of!
EGFR!was!mediating!resistance!to!PD!in!RT4!R1,!RT4!parental!and!RT4!R1!were!
assayed! for! their! sensitivity! to! erlotinib! (Fig.! 7.9).! RT4! parental! had! an! IC50! of!
6.1μM!and!RT4!R1!had!an!IC50!of!10μM.!Erlotinib!reduced!viability!in!RT4!parental!
and!RT4!R1!to!approximately!15%!and!20%!of!the!vehicle!control!respectively.!RT4!
parental! and! RT4! R1! were! then! assayed! for! their! sensitivity! to! erlotinib! in!
combination!with! 1μM!PD! (Fig.! 7.10).! In! combination!with! 1μM!PD!RT4! parental!
had! an! IC50! of! 0.07μM! and! RT4! R1! had! an! IC50! of! 0.37μM! and! viability! was!
reduced!in!RT4!parental!and!RT4!R1!to!approximately!15%!and!6%!of!the!vehicle!






















































































resistant! derivatives.!However,! the! resistant! lines!were! not! sensitive! to! treatment!
with! the! MET! inhibitor! capmatinib.! It! was! hoped! that! treatment! of! 5637,! which!
expresses!phosphoGMET,!with! capmatinib!would!demonstrate! that! the! capmatinib!
used! in! the! cell! viability! assays! was! successfully! inhibiting! MET! and! was! not!
defective.!Cell! viability!was! not! reduced! in! 5637! upon! treatment!with! capmatinib.!
There! was! insufficient! time! to! conduct! immunoblot! analysis! to! determine! if!
capmatinib!was! inhibiting!phosphorylation!of!MET! in!5637!or! the!RT112! resistant!
derivatives.! As! we! did! not! demonstrate! that! capmatinib! was! capable! of! reducing!
cell! viability! in! a! METGdependent! cell! line! or! reducing! MET! phosphorylation! it! is!
possible!that!our!batch!of!capmatinib!was!defective.!!
There! are! a! number! of! other! explanations! which! could! explain! the!
insensitivity!of!5637!to!capmatinib.! It! is!possible! that!5637! is!not!sensitive!to!MET!
inhibition!under! the!conditions!used! in! the!viability!assay.!Previous! research!such!






induced! invasion! in! 5637! but! cell! proliferation! was! not! examined! (Wang! et% al.,!
2007).!Therefore,!it!is!possible!that!signalling!via!MET!in!5637!may!induce!invasion!
but! not! affect! cell! proliferation.! An! alternative! explanation! for! the! insensitivity! of!
5637!to!capmatinib! is!that!5637!may!express!an!ATPGbinding!cassette!transporter!
such!as!PGglycoprotein!which!can! induce!drug!resistance!by!transporting!TKIs!out!
of! cancer! cells! (He! and!Wei,! 2012).! It!was! considered! that! 5637!may! possess! a!
gatekeeper! mutation! in! MET! which! renders! the! line! resistant! to! capmatinib.!
However,!the!exome!of!5637!was!previously!sequenced!by!Nickerson!et%al.!and!a!
mutation! in!MET! was! not! detected! (Nickerson!et% al.,! 2017).! Finally,! it! is! possible!
that!MET! could! be! promoting! cell! proliferation! and! survival! in! 5637! via! crosstalk!
with! another! receptor,! and!when!MET! is! inhibited!activation!of! the!other! receptor!
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compensates! for! the! reduced! MET! activity.! Therefore,! whether! capmatinib! was!
defective! or! RT112! parental! and! the! resistant! derivatives! were! resistant! to! MET!
inhibition! not! was! not! confirmed.! Immunoblot! analysis! to! examine! whether!
capmatinib! inhibited! MET! phosphorylation! in! the! RT112! resistant! derivatives! or!
5637!would!have!clarified!this.!!
Cell! viability! was! examined! in! RT112! parental! and! R1! for! the! combined!
treatment! of! the! IGF1R! inhibitor! linsitinib! and! PD! and! for! each! drug! as! a! single!
agent.! RT112! parental! was! sensitive! to! linsitinib! single! agent! treatment.! This!
suggests! that! IGF1R!signalling! is!active! in!RT112!parental!cells! rather! than!being!
activated!as!a!mechanism!of!acquired! resistance! in! the! resistant!derivatives.!The!
RT112!resistant!derivatives!also!displayed!sensitivity!to!the!IGF1R!TKI!linsitinib.!In!
RT112!parental!a!greater! sensitivity!was!displayed! to! the!combination!of! linsitinib!
and!PD!than!to!either!drug!as!a!single!agent.!This!suggests!that!if!either!FGFR3!or!
IGF1R! is! inhibited! in! parental! RT112,! signalling! via! the! other! receptor! maintains!
some!cell!viability.!!!
IGF1R!has!been! implicated! in! resistance! to! inhibition!of!EGFR! in!NSCLC,!





et%al.,!2016).!A!phase! II/III! clinical! trial! tested!addition!of! the!monoclonal!antibody!




that! the! addition! of! this! monoclonal! antibody! to! treatment! with! chemotherapy! or!
erlotinib! did! not! increase! patient! survival! (Langer! et% al.,! 2014d! Scagliotti! et% al.,!
2015).! The! results! in! this! Chapter! suggest! that! single! agent! treatment! with! an!









The! reduced! cell! viability! in! RT112! R3! was! unexpected! as! exome!
sequencing! and! single! cell! cloning! in! Chapter! 5! revealed! that! a! HRAS! G12S!
mutation!was!present!in!73%!of!RT112!R3!cells.!As!HRAS!is!downstream!of!RTKs,!
it!was!thought!that!this!mutation!would!constitutively!promote!cell!proliferation!and!
survival! in! RT112! R3! despite! FGFR3! and! EGFR! family! inhibition.! It! is! unclear!
whether!EGFR!family!signalling!contributes!to!the!cell!proliferation!or!survival!of!all!
or!only!a!subset!of!the!RT112!parental!and!RT112!resistant!derivative!cells.!It!may!
be! that! the! combinatorial! treatment! of! sapitinib! and!PD!primarily! reduces! the! cell!
viability!of!RT112!R3!due!to!efficacy!in!the!subpopulation!of!RT112!R3!cells!which!
do!not!possess!the!HRAS!G12S!mutation.!!
It! was! considered! that! only! a! small! reduction! in! cell! viability! observed! in!
RT112! parental! and! resistant! derivatives! could! be! due! to! the! batch! of! sapitinib!
being! less! active.! For! this! reason! the! efficacy! of! the! sapitinib! was! assessed! in!
DSH1,! which! has! been! previously! reported! to! be! sensitive! to! the! TKI! lapatinib!
which!exhibits!specificity!for!EGFR!and!ERBB2!(de!Martino!et%al.,!2014).!DSH1!was!
found! to!be!sensitive! to!single!agent! treatment!with!sapitinib.!Therefore,! it!can!be!
concluded! that! inhibition! of! the! EGFR! family! of! RTKs! did! not! overcome! PD!
resistance!in!the!RT112!resistant!lines.!!
Wang! et% al.! generated! RT112! derivatives! resistant! to! FGFR! inhibition! via!
long! term! culture! with! the! FGFR! TKIs! BGJ398! and! ponatinib.! These! resistant!
derivatives!had!become!resistant!via!activation!of!ERBB2!and!ERBB3!(Wang!et%al.,!
2014).! Single! agent! treatment! with! sapitinib! reduced! the! viability! of! the! BGJ398!
resistant!derivatives! to!approximately!70%!of! the!untreated!control.!They!reported!
that!treatment!with!sapitinib!in!combination!with!the!FGFR!TKI!BGJ398!reduced!cell!
viability! to!20G30%!of! the!untreated!control! in! these!resistant!derivatives!(Wang!et%
al.,!2014).!It!can!be!concluded!that!the!RT112!PD!resistant!derivatives!in!this!study!
have! become! resistant! to! FGFR! inhibition! by! a! different! mechanism! than! the!
mechanism!observed!by!Wang!et%al.!in!their!RT112!resistant!derivatives.!!
IGF1R! has! been! reported! to! heterodimerise! with! EGFR! family! members!
inducing! resistance! to! EGFR! family! targeted! agents.! Morgillo! et% al.! produced! an!
EGFR!TKI!resistant!derivative!of!the!NSCLC!cell!line!H460!via!long!term!culture!in!
erlotinib.! Immunoblot! analysis! showed! that! this! resistant! line! had! increased!
expression! of! phosphoGIGF1R! compared! to! parental! line.! Coimmunoprecipitation!
showed! that! there! was! an! increased! binding! of! EGFR! to! IGF1R! in! the! H460!
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erlotinibGresistant! derivative,! and! in! parental! H460! acutely! treated! with! erlotinib!
compared!to!the!parental!line!cultured!without!erlotinib.!Treatment!with!erlotinib!and!
the! IGF1R! inhibitor!AG1024! reduced! colony! formation! in! both!parental!H460!and!
the!H460!erlotinibGresistant!derivative!to!a!greater!extent!than!treatment!with!either!
drug!as!a! single!agent! (Morgillo!et%al.,! 2006).!Nahta!et%al.! produced! trastuzumab!
resistant!cells! from! the!breast!cancer!cell! line!SKBR3!via! longGterm!culture!of! the!
parental! line! in! trastuzumab.! These! resistant! cells! had! increased! expression! of!
phosphoGIGF1R!and!coimmunoprecipitation!of!ERBB2!and!IGF1R!was!observed!in!
the!resistant!cells!but!not!the!parental!line.!Stimulation!of!the!resistant!cells!with!the!
IGF1R! ligand! IGF1! induced!ERBB2! phosphorylation! in! the! resistant! cells! but! not!
parental!SKBR3!(Nahta!et%al.,!2005).!IGF1R!has!also!been!reported!to!interact!with!







in!RT4!R1!compared! to! the!parental! line.!Both! these! lines!exhibited! sensitivity! to!
erlotinib!which! confirms! that! both!RT4! parental! and!R1! are! dependent! on!EGFR!
signalling.!The!inhibition!of!EGFR!by!erlotinib!in!parental!RT4!and!RT4!R1!could!be!
confirmed!by!immunoblot!analysis.!The!efficacy!of!erlotinib!was!potentiated!by!the!
addition! of! PD.! This! suggests! that! targeting! the! FGFR! family! and! EGFR! in!
combination!could!be!an!effective!treatment!for!urothelial!carcinoma.!Signalling!via!
EGFR! has! previously! been! implicated! in! resistance! to! FGFRGtargeted! agents! in!
bladder! cancer! cell! lines.!An! siRNA!screen!which! identified!EGFR!as! limiting! the!
sensitivity!to!PD!in!three!bladder!cancer!cell!lines!with!mutant!FGFR3,!RT4,!RT112!
and!MGHGU3!(HerreraGAbreu!et%al.,!2013).!RT112!and!639V,!a!bladder!cancer!cell!
line! with! an! FGFR3! point! mutation,! showed! increased! phosphorylation! of! EGFR!
upon! acute! treatment! with! PD.! A! RT112! xenograft! mouse! model! showed! that!
treatment! with! PD! and! gefitinib! reduced! tumour! volume! to! a! greater! extent! than!
either!of!the!drugs!given!separately!(HerreraGAbreu!et%al.,!2013).!!
EGFRGtargeted!agents!are!already! in!use!as! treatments! for! treat! lung!and!
pancreatic!and!colorectal!cancer!(Lubner!et%al.,!2017d!Mosquera!et%al.,!2016d!Singh!
and! Jadhav,! 2017).! EGFRGtargeted! agents! may! be! efficacious! in! a! subset! of!
urothelial! carcinoma! patients! who! have! relapsed! on! FGFRGtargeted! therapy.!
Approximately! 60%! of! bladder! cancer! tumours! express! membranous! EGFR! and!
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expression! does! not! correlate!with! the! stage! or! grade! of! tumours! (Ibrahim!et% al.,!
2009).!Approximately!6%!of!MIBC!tumours!exhibit!gain!of!copy!number!of!7p11.2!
which! contains! EGFR! (Robertson! et% al.,! 2017).! TKIs! targeting! the! EGFR! family!
have! entered! clinical! trials! in! urothelial! carcinomas! with! EGFR! or! ERBB2!
overexpression!and!have!generally!been! found!not! to!significantly!benefit!patients!
(Choudhury! et% al.,! 2016d! Miller! et% al.,! 2016d! Petrylak! et% al.,! 2010d! Powles! et% al.,!
2017).! It!may!be! that!combinatorial! treatment!with!an!EGFR!and!an!FGFR! family!
inhibitor!would!be!beneficial!in!those!patients!who!have!FGFR3!alterations.!
The! results! of! this! Chapter! have! some! limitations.! There! was! large!
variability! between! individual! cell! viability! assays,! therefore,! it! would! have! been!
beneficial!to!have!assayed!the!resistant! lines!for!their!sensitivity!to!PD!as!a!single!
agent,!as!a!control,!at! the!same! time!as!examining! the!sensitivity!of! the! resistant!





















R2! and!RT4!R1! had! a! different!morphology! to! their! parental! lines! but! that! these!
changes! in!morphology! were! reversed! upon! culture! without! PD.! RT112! resistant!
derivatives! maintained! resistance! to! PD! following! culture! without! PD! and!
phenotypic!reversion,!whereas!RT4!R1!did!not.!Reduced!expression!of!FGFR3!was!
observed!in!the!RT112!resistant!derivatives! indicating!that!FGFR3!overexpression!
or!mutation!or!drug!efflux! is!not! the!cause!of! resistance! in! these!cells.! Increased!
expression! of! NGcadherin! was! observed! in! RT112! R1! and! R2! cultured! in! PD,!
suggesting! these! cells! may! have! undergone! an! EMT.! Following! the! initial!
characterisation!of!the!parental!and!resistant!cells,!expression!and!phosphorylation!
of! a! number! of! RTKs! was! examined! with! immunoblot! analysis.! This! identified!
increased!expression!of!phosphoGMET!in!the!RT112!resistant!derivatives,!phosphoG
ERBB3! in!RT112!R1!and!R2!and!phosphoGEGFR! in!RT4!R1.!Exome!sequencing!
identified! a!HRAS! G12S!mutation! in! RT112! R3.! Retroviral! transfection! of!HRAS!
G12V! into! parental! RT112! demonstrated! that! gain! of! constitutively! active!HRAS!
induces! resistance! to! PD.! Copy! number! analysis! showed! that! EGFR! was! not!
amplified!in!RT4!R1!and!a!NGS!assay!which!screens!for!common!EGFR!mutations!
did! not! identify! an! EGFR! mutation! in! this! line.! Transcriptome! analysis! identified!
EMTGassociated! gene! expression! changes! in! the! RT112! resistant! derivatives!
compared! to! parental! RT112! and! identified! a! reduction! in! expression! of! genes!
which! regulate! fatty! acid! synthesis! in! RT112! and! RT4! resistant! derivatives.!
Immunoblot! analysis! confirmed! reduced! expression! of! mature! SREBP1,! a!
transcription! factor! which! regulates! the! synthesis! of! unsaturated! fatty! acids,! and!
SCD1,!the!rate!limiting!enzyme!in!the!production!of!monounsaturated!fatty!acids,!in!
RT112! resistant! derivatives.! Additionally,! transcriptome! analysis! identified! an!
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increase!in!expression!of!IGF1R!in!RT112!R1!and!R2!and!increase!in!expression!of!
KDM6A! in! RT112! and! RT4! resistant! derivatives.! Finally,! a! range! of! TKIs! were!
tested! for! their! efficacy! at! reducing! the! viability! of! resistant! cells.! The! IGF1R!TKI!
linsitinib!and!the!EGFR!TKI!erlotinib!proved!effective!at!reducing!viability!in!RT112!
and!RT4!resistant!lines!respectively.!
A! key! finding! of! this! project! was! the! identification! of! the! HRAS! G12S!
mutation! in!RT112!R3!and! the!confirmation! that! the! introduction!of!mutant!HRAS!
into! RT112! parental! induces! resistance! to! PD.! This! suggests! that! mutation! of!
HRAS! may! occur! in! urothelial! carcinoma! patients! as! a! mechanism! of! acquired!
resistance! to! FGFRGtargeted! agents.! RAS! and! FGFR3! mutations! are! mutually!
exclusive! in! urothelial! carcinoma! (Jebar! et% al.,! 2005).! This! suggests! that! these!
mutations!have!a!similar!function!and!therefore!there!is!no!selective!pressure!for!a!
urothelial! carcinoma! to! gain! activating!mutations! in! both! these! genes.! It! appears!
that! the! inhibition! of! FGFR3! induces! a! selective! pressure! to! gain! a! mutation! of!
similar! functionality.!RAS!activates!the!MAP!kinase!and!PI3!kinase!pathways:! two!
pathways! also! activated! by! FGFR3! (Klint! et% al.,! 1999d! RodriguezGViciana! et% al.,!
1994d! van!Weering!et% al.,! 1998d! Zhang!et% al.,! 1993).! As! activation! of! both! these!
pathways!was!reduced!in!RT112!parental!acutely!treated!with!PD!but!not!in!RT112!
resistant! derivatives,! the! reactivation! of! these! pathways! may! be! key! to! inducing!
resistance!to!PD.!!
Despite! decades!of! research,! development! of! direct! inhibitors! of!RAS!has!
proved! difficult! due! to! RAS! lacking! deep! hydrophobic! binding! pockets! to! which!
small!molecule!inhibitors!could!bind!and!the!low!affinity!of!RAS!for!GTP!(SpencerG
Smith! and!O'Bryan,! 2017).!Attempts! to! inhibit!RAS!with! small!molecule! inhibitors!
have! included! inducing! GTP! hydrolysis! with! a! GTP! analogue! which! is! more!
effectively! hydrolysed! by! the! mutant! RAS! than! GTP! (Ahmadian! et% al.,! 1999).!
Another!possible!way!to!directly!inhibit!RAS!may!be!by!inhibiting!the!interaction!of!
RAS! with! guanine! exchange! factors.! For! example,! Patgiri! et% al.! developed! a!
mimetic!of!the!guanine!exchange!factor!SOS!which!reduced!the!interaction!of!GDPG
bound! mutant! RAS! with! SOS,! thereby! preventing! the! mutant! RAS! from! binding!
GTP! and! reducing! the! activation! of! downstream! signalling! (Patgiri! et% al.,! 2011).!
Monoclonal! antibodies! have! been! developed!which! directly! inhibit! RAS,! although!
full! size! antibodies! cannot! cross! the! plasma! membrane! to! target! intracellular!
molecules!(Furth!et%al.,!1982).!A!monoclonal!antibody,!RT11,!has!been!developed!
which!was!able! to!enter! the!cytosol!via!clathrinGmediated!endocytosis!and!bind! to!
the! proteinGprotein! interface! of! the! active!GTPGbound! form!of!RAS.%This% inhibited!
downstream! signalling.! Upon! further! engineering! of! RT11! so! that! it! could! bind!
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tumourGassociated! integrins,! this! antibody! was! able! to! inhibit! the! growth! of! RAS!
mutant! xenografts! in! mice! (Choi! et! al.,! 2014ad! Shin! et! al.,! 2017).! An! alternative!
approach!taken!to!reduce!the!activity!of!mutant!RAS!is!by!reducing!the!presence!of!
RAS! at! the! cell! membrane.! This! can! be! achieved! with! farnesyltransferase! and!
PDEδ! inhibitors.! Farnesyltransferase! inhibitors! disrupt! the! postGtranslational!
modifications! of! RAS! which! results! in! reduced! RAS! localisation! at! the! cell!
membrane! (Choy! et% al.,! 1999d! Reiss! et% al.,! 1990).! PDEδ! inhibitors! inhibit! the!
binding!of!PDEδ! to!KRAS,! reducing! the! trafficking!of!KRAS! to! the!cell!membrane!
(Zimmermann!et%al.,!2013).!




for! the! treatment! of! BRAF! V600! mutant! melanoma! (Cheng! and! Tian,! 2017).!
Inhibition!of!MEK!has!so!far!been!unsuccessful!as!a!mechanism!of!treating!KRAS!
mutant!colorectal!cancer!(Bahrami!et%al.,!2018).!A!number!of!ongoing!phase!I!and!II!
trials! are! examining! the! efficacy! of! MEK! inhibitors! in! combination! with!
chemotherapy! or! other! targeted! agents,! including! PI3! kinase! inhibitors,! in! KRAS!
mutant!NSCLC!(Tomasini!et%al.,!2016).!Bockorny!et%al.!reported!that!the!longGterm!
culture!of! the!FGFR1Gamplified!NSCLC!cell! line,!NCIGH2077,!produced!a!resistant!
derivative!with!an!NRAS!Q61R!mutation.!Treatment!of! the! resistant!cells!with! the!
panGFGFR!TKI!BGJ398!and!the!MEK!inhibitor! trametinib!reduced!cell!proliferation!
to!a!greater!extent!than!treatment!with!BGJ398!as!a!single!agent.!It!was!observed!
that! the! combination! of! BGJ398! and! trametinib! was! well! tolerated,! significantly!
slowed! tumour! progression! and! increased! progressionGfree! survival! in! a! mouse!
NCIGH2077!xenograft!model!(Bockorny!et%al.,!2018).!Treatment!with!a!MEK!inhibitor!
such!as!trametinib!may!overcome!the!resistance!to!PD!observed!in!RT112!R3!and!
could!overcome!resistance! to!FGFR! inhibitors! in!urothelial!carcinomas! if! they!had!
gained! mutations! in! the! MAP! kinase! pathway.! Examination! of! whether! MEK!
inhibition!would!overcome!PD! resistance! in!RT112!R3!was!not! conducted!due! to!
time!limitations.!
Inhibition! of! EGFR! with! erlotinib! overcame! resistance! to! PD! in! RT4! R1.!
However,!erlotinib!was!more!effective!in!parental!RT4!than!RT4!R1!suggesting!that!
EGFR! inhibition! may! be! more! effective! as! a! first! line! rather! than! second! line!
treatment.!Treatment!of!RT4!R1!with! the!combination!of!erlotinib!and!PD!reduced!




activation!of!EGFR!was!a!mechanism!of!short! term!survival! in! response! to!PD! in!
RT112! that! could! be! overcome! by! combined! treatment! with! PD! and! the! small!
molecule! inhibitor!of!EGFR,!gefitinib.! Immunoblot!analysis! revealed! that! treatment!
with!the!MEK!inhibitor!CIG1040!induced!an!increase!in!EGFR!phosphorylation!and!
that! PD! treatment! induced! EGFR! accumulation! at! the! cell! membrane! and! giant!
early! endosomes.! The! mechanism! by! which! expression! of! EGFR! and! phosphoG
EGFR! was! increased! in! RT4! R1! is! unknown.! Small! molecule! inhibitors! and!




EGFR! family!members! (Roskoski,!2014),! therefore! it! is!possible! that!other!EGFR!
family! members! are! implicated! in! the! resistance! to! PD! in! RT4! R1.! Wang! et% al.!
found! RT112! activated! ERBB2! and! ERBB3! signalling! as! a! mechanism! of!
resistance!to!the!FGFR!TKIs!BGJ398!and!ponatinib!upon!longGterm!culture!in!these!
inhibitors! (Wang! et% al.,! 2014).! Canfield! et% al.! showed! that! knockdown! of!ERBB4!
induced! apoptosis! in! ERBB2Gpositive! breast! cancer! cell! lines! with! acquired!
resistance!to!the!EGFR,!ERBB2!and!ERBB3!TKI!lapatinib!and!the!ERBB2Gspecific!
monoclonal! antibody! trastuzumab! (Canfield! et% al.,! 2015).! Immunoblot! analysis!
showed! that! expression! of! phosphoGERBB2! remained! low! in! RT4! R1,! whereas,!
phosphoGERBB3!expression!was!increased!in!RT4!R1.!Immunoblot!analysis!of!total!
ERBB4!and!phosphoGERBB4!expression!was!not!conducted!with!RT4!parental!or!
R1!due! to! time! limitations.!Microarray!analysis!showed! that!expression!of!ERBB4!
was!nonGsignificantly!increased!in!RT4!R1!+!PD!compared!to!parental!no!PD.!It! is!




Microarray! analysis! showed! that! expression! of! AREG! and! BTC,! which!
encode! the! EGFR! ligands! amphiregulin! and! betacellulin! respectively,! was!
significantly!increased!in!RT4!R1!+!PD!compared!to!parental!no!PD.!Therefore,!the!
increased! activation! of! EGFR! in! RT4! R1! may! be! mediated! by! the! increased!
expression! of! these! ligands.! Whether! protein! expression! of! amphiregulin! and!
betacellulin!was!increased!in!RT4!R1!could!have!been!examined!with!immunoblot!
analysis.! Whether! these! ligands! mediate! PD! resistance! could! be! determined! by!
examining!whether!knockdown!of!AREG!or!BTC!expression!reGsensitised!RT4!R1!
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to! PD.! Additionally,! whether! treatment! with! amphiregulin! or! betacellulin! induced!
resistance!to!PD!in!parental!RT4!could!be!examined.!These!experiments!were!not!
conducted!due!to!time!limitations.!
Urothelial! carcinomas! with! expression! or! mutation! of! EGFR,! ERBB2! or!
ERBB3! could! be! intrinsically! resistant! to! FGFRGtargeted! agents! as! they! may! be!
able! to! signal! via! these! EGFR! family! members.! The! sensitivity! of! urothelial!
carcinomas! to! EGFRGtargeted! agents! has! been! assessed! in! clinical! trials! but!
unfortunately! these! have! mainly! been! disappointing.! A! phase! II! clinical! trial!
conducted! by! Pruthi! et% al.! examined! erlotinib! as! a! neoadjuvant! prior! to! radical!
cystectomy.!Erlotinib!was!well!tolerated!and!the!results!indicated!that!erlotinib!may!
be! efficacious! as! a! single! agent! (Pruthi!et% al.,! 2010).!A! phase! II! clinical! trial!with!
gefitinib! in! metastatic! urothelial! carcinoma! patients! who! had! failed! previous!
chemotherapy! concluded! that! further! study! with! this! TKI! in! this! setting! was! not!
justified! (Petrylak! et% al.,! 2010).! Another! phase! II! clinical! trial! showed! that! the!
addition! of! gefitinib! to! treatment! with! chemotherapy! did! not! significantly! increase!
time! to!progression,! the!primary!endpoint,! in!patients!with!advanced!or!metastatic!
urothelial! carcinoma! (Miller! et% al.,! 2016).! Choudhury! et% al.! conducted! a! phase! II!
study!in!platinumGrefractory!metastatic!urothelial!carcinoma!patients!with!the!EGFR!




with! the!EGFR!and!ERBB2!TKI! lapatinib! following!on! from!chemotherapy!did!not!
significantly! improve! outcomes! in! urothelial! carcinoma! patients! with! EGFR! or!
ERBB2!overexpression! (Powles!et%al.,! 2017).!The! findings! in! this! project! and! the!
research! conducted! by! HerreraGAbreu! et% al.! indicate! that! EGFRGtargeted! agents!
may!benefit!urothelial!carcinoma!patients!with!resistance!to!FGFRGtargeted!agents.!
To!my! knowledge,! clinical! trials! have!not! been! conducted! in! urothelial! carcinoma!
patients! whose! tumours! are! FGFR3! mutant! or! overexpress! FGFR3! with! the!
combination!of!EGFRG!and!FGFRGtargeted!agents.!Similarly,!the!efficacy!of!EGFRG
targeted!agents!has!not!been!assessed!in!urothelial!carcinoma!patients!who!have!








as! ifabotuzumab!which! is!a!EphA3!agonist,!have!entered!early!stage!clinical! trials!
(Lodola! et% al.,! 2017).! Immunoblot! analysis! could! have! been! used! to! confirm! if!
expression!of!EphA3!and!phosphoGEphA3!was! increased! in!RT4!R1.!Whether! the!
increase!in!expression!of!EPHA3!contributes!to!the!resistant!phenotype!in!RT4!R1!
could! be! tested! by! examining! whether! knockdown! of! EPHA3! expression! reG
sensitised!RT4!R1!to!PD.!This!was!not!conducted!due!to!time!limitations.!
Inhibition!of!IGF1R!with!linsitinib!was!efficacious!in!RT112!parental,!R1,!R2!
and!R3.!As! linsitinib! reduced!cell!viability! in!parental!RT112,!signalling!via! IGF1R!
did! not! arise! in! the! RT112! resistant! lines! as! a! mechanism! of! resistance! to! PD,!
rather!the!dependency!on!IGF1R!signalling!was!preGexisting.!It!was!surprising!that!
RT112! R3! exhibited! sensitivity! to! IGF1R,! as! this! line! had! a! HRAS! mutation,!
resulting! in! a! constitutively! active! protein,! and! it! was! thought! that! this! mutation!
would!diminish!the!dependency!on!RTK!activation!in!RT112.!Isobologram!analysis!
could! have! been! conducted! to! determine! if! treatment! with! linsitinib! and! PD! was!
additive! in! RT112! parental! and! resistant! derivatives,! but! was! not! due! to! time!
limitations.! Immunoblot! analysis! to! determine! the! expression! of! IGF1R! and!
phosphoGIGF1R!in!RT112!parental!and!the!resistant!lines!was!not!conducted!during!
this! project! due! to! time! limitations.! This! would! have! determined! whether! the!
resistant! lines! cultured! in! PD! or! parental! RT112! acutely! treated! with! PD! had!
increased!activation!of! IGF1R,!suggesting! that! IGF1R!activation!compensated! for!
the!loss!of!FGFR!signalling.!Alternatively,!IGF1R!may!be!activated!at!a!similar!level!
in!RT112!parental!and!the!RT112!resistant!derivatives.!Higher!expression!of!IGF1R!
RNA! correlates! with! a! lower! overall! survival! time! in!MIBC! patients! (Wang! et% al.,!
2017).!Sun!et%al.!reported!that!treatment!of! the!urothelial!carcinoma!cell! line,!T24,!
with! IGF1! significantly! reduced! mitomycinGinduced! apoptosis.! Furthermore,!
depletion! of! IGF1R! by! treatment! with! an! antisense! oligodeoxynucleotide,! in!
combination! with!mitomycin,! induced! apoptosis! and! cell! proliferation! to! a! greater!
extent!than!single!agent!treatment!with!either!therapy!(Sun!et%al.,!2001).!
!Unfortunately,! the! results! of! clinical! trials! with! targeted! agents! with!
specificity! for! IGF1R! have! been! disappointing! (Janssen! and! Varewijck,! 2014).! A!
phase! III! clinical! trial! was! conducted! with! linsitinib! in! patients! with! advanced! or!
metastatic!adrenocortical! carcinoma,!but! linsitinib!did!not! increase!overall! survival!
(Fassnacht!et% al.,! 2015).! EGFR! is! reported! to! transactivate! IGF1R!and! signalling!
via! IGF1R!has!been! implicated! in!resistance!to!EGFRGtargeted!therapy! in!NSCLC!
(Burgaud!and!Baserga,!1996d!Li!et%al.,!2017d!Morgillo!et%al.,!2007).!For!this!reason,!
phase! II! trials! in! NSCLC! patients! have! compared! treatment! with! erlotinib! to!
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treatment! with! linsitinib! in! combination! with! erlotinib.! ! Unfortunately,! these! trials!
have! found! that! linsitinib!did!not! improve!patient!outcomes! (Ciuleanu!et%al.,!2017d!
Leighl! et% al.,! 2017).! Phase! II/III! clinical! trials! in! colorectal! cancer! patients! have!
examined! the! addition! of! the! monoclonal! antibody! dalotuzumab,! which! has!
specificity! for! IGF1R,! to! treatment! with! the! EGFRGspecific! monoclonal! antibody!
cetuximab!and!chemotherapy.!These! trials!have! indicated! that! this! targeted!agent!
is! ineffective!at! treating!colorectal! cancers.!However,!expression! levels!of! IGF1R,!




clinical! trial!stage,!and! the! results!of!clinical! trials!have!so! far!been!disappointing,!
the! use! of! biomarkers! to! stratify! who! receives! IGF1RGtargeted! agents! may! yield!
more!promising!results.!
The! activation! of! RTKs! in! RT112! resistant! lines! was! examined! with! a!
phosphoGRTK! array! (PathScan®! RTK! signaling! antibody! array! Kit! #7982).!
However,!as!the!results!of!this!array!were!disappointing!with!a!low!signal!detected!
from! RTK! specific! spots,! the! results! of! this! analysis! were! not! presented! in! this!
thesis.!An! alternative! phosphoGRTK!array! from!a! different! supplier!was! identified.!
However,! analysis! was! not! conducted! with! this! array! due! time! limitations.! This!
analysis!may!have!identified!other!RTKs!which!were!activated!in!RT112!R1!and!R2!!
The! initial!examination!of!RT112!R1!and!R2! revealed! that! these!cells!had!
lost!the!parental!RT112!epithelial!morphology,!gained!a!mesenchymal!morphology!
and! increased! protein! expression! of! NGcadherin.! A! complete! EMT! was! not!
observed! in! these! lines! as! EGcadherin! expression! remained! constant! between!
RT112!parental,!R1!and!R2.!NGcadherin!expression!was!not! increased! in!parental!
RT112!acutely!treated!with!PD!and!microarray!analysis!showed!that!EMT!markers!
were! not! significantly! differentially! expressed! between! parental! RT112! cultured!
without! PD! and! parental! RT112! acutely! treated!with! PD.!MetaCore#! analysis! of!
microarray!data!found!that!pathways!relating!to!EMT!maps!were!upregulated!in!R1,!
R2!and!R3!compared!to!RT112!parental!and!in!RT4!R1!compared!to!RT4!parental.!
This! is! similar! to! what! was! reported! by! Wang! et% al.! whose! FGFR! TKIGresistant!
RT112! derivatives,! produced! by! long! term! culture! in! either! ponatinib! or! BGJ398,!
reverted! to! a! mesenchymal! morphology! and! had! increased! expression! of!CDH2!
and! FN1! (Wang! et% al.,! 2014).! EMTGlike! changes! have! been! reported! in! in% vitro!
models!of!adaptive! resistance! to!other! targeted! therapies!such!as!EGFR,!ERBB2!
and! ALK! TKIs! (Brown! et% al.,! 2016d! Gower! et% al.,! 2016d! Lee! et% al.,! 2017).! A!
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mesenchymal!phenotype! is!associated!with!greater! cell!migration!and! invasion.! It!
would!be!undesirable!for!treatment!with!a!FGFR!TKI!to!induce!these!characteristics!
in!a!patient!as!this!could!result! in!a!greater!risk!of!metastasis!(Singh!et%al.,!2017).!
This! project! has! not! determined! whether! the! EMTGlike! changes! observed! in! the!
resistant! lines!were!fundamental!to,!or!a!byGproduct!of,!the!resistant!phenotype.!Li!
et%al.!reported!that!activation!of!signalling!via!IGF1R!in!gefitinib!resistant!derivatives!
of! the! EGFRGmutant! NSCLC! cell! lines! PC9! and! HCC827! induced! an! EMT.!
Treatment! of! the! PC9! gefitinib! resistant! derivatives! with! the! IGF1R! inhibitor!
picropodophyllin! increased! sensitivity! to! gefitinib! and! reduced! expression! of!
mesenchymal!markers!(Li!et%al.,!2017).!Signalling!via!FGFR3!is!associated!with!an!
epithelial! morphology! in! urothelial! carcinoma! cell! lines! (Cheng! et% al.,! 2013).! It! is!
possible!that,!upon!culture!with!PD,!the!resistant!cells!lose!the!signals!from!FGFR3!
that! induce! an! epithelial! phenotype! and! gain! a! more! mesenchymal! phenotype.!
Signalling! via! EGFR! has! also! been! associated! with! EMT! (Chang! et% al.,! 2012d!
Serrano!et%al.,! 2014).!However,!EGFR!did!not! induce!an!EMT! in!RT4!R1!as! this!
resistant! derivative! did! not! exhibit! a! mesenchymal! morphology,! exhibited! low!
expression! of!NGcadherin! and! vimentin! and!maintained! expression! of!EGcadherin.!
Cell! migration! and! invasion! was! not! examined! in! the! parental! lines! and! their!
resistant!derivatives!so! the!extent! to!which! long! term!culture! in!PD! induces! these!
characteristics!has!not!been!established.!
Bladder! cancers! can! be! classified! as! ‘luminal’! if! their! gene! expression! is!
more!similar! to! the!superficial!or! intermediate! layers!of! the!urothelium!or! ‘basal’! if!
their! gene! expression! is!more! similar! to! the! basal! layer! of! the! urothelium.! Basal!
tumours! exhibit! upregulation! of! p63! target! genes! and! are! more! likely! to! have!
mutations! in!TP53% (Choi!et% al.,! 2014bd! Robertson!et% al.,! 2017).! Luminal! tumours!
exhibit!upregulation!of!PPAR(!target!genes!and!are!more!likely!to!have!mutations!in!
FGFR3,!ELF3,!CDKN1A,!and!TSC1.!Basal!MIBC!are!more!aggressive!and!patients!
with!basal! tumours!have!shorter!survival! times! than!patients!with! luminal! tumours!
(Dadhania! et% al.,! 2016).! Therefore,! if! urothelial! tumours! switch! towards! a! more!
basal!phenotype!upon!being!treated!with!FGFRGtargeted!agents!this!could!result!in!
a! worse! prognosis! for! patients.! Both! RT112! and! RT4! have! been! previously!
classified! as! luminal! (Warrick! et% al.,! 2016).! Microarray! and! qRTGPCR! analysis!
suggested! that! the! expression! of! some! basal! markers! was! increased! and!
expression!of!some!luminal!markers!was!decreased!in!RT112!resistant!derivatives!
compared! to! the! parental! line.! However,! immunoblot! analysis! showed! that!
expression! of! the! basal! markers! cytokeratin! 5/6! and! CD44! was! low! in! RT112!
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parental! and! the! RT112! resistant! derivatives.! Therefore,! it! is! unlikely! that! the!
RT112!resistant!derivatives!have!gained!a!basal!phenotype.!!
Previous!research!has!shown!that!fatty!acid!synthesis!is!reduced!in!RT112!
upon! FGFR3! knockdown! due! to! FGFR3! regulation! of! the! transcription! factor!
SREBP1! (Du! et% al.,! 2012).! The! weak! base! chloroquine! induces! lysosomal! cell!
death! by! diffusing! into! lysosomes! and! raising! the! lysosomal! pH.! This! induces!
lysosomal! swelling,! cathepsin! leakage! and! cathepsinGmediated! activation! of!
caspases.! King! et% al.! reported! that! inhibition! of! FGFRs,! PI3K',! AKT! or! mTOR!
potentiated! the! lysosomal! cell! death! induced! by! chloroquine! in! RT112.! This! was!
due!to!a!reduction!in!the!biosynthesis!of!cholesterol!which!can!promote!the!integrity!
of! lysosomal!membranes! (King! et% al.,! 2016).! Here,!microarray! analysis! indicated!
that!there!was!differential!expression!of!genes!regulating!lipid!metabolism!between!
RT112! experimental! conditions! and! between! RT4! experimental! conditions.!
Immunoblot!analysis!indicated!that!expression!of!mature!SREBP1,!the!transcription!
factor! which! regulates! expression! of! fatty! acid! synthesis! genes,! was! reduced! in!
RT112!parental!acutely!treated!with!and!RT112!R1!cultured!in!PD.!Mature!SREBP1!
expression!was!reduced! to!a! lesser!extent! in!R2!and!R3!cultured! in!PD.!SCD1! is!
the! rateGlimiting! enzyme! in! the! production! of! monoGunsaturated! fatty! acids! from!
saturated! fatty!acids!(Igal,!2016).! Immunoblot!of!SCD1!showed!that!expression!of!
this!protein!was!reduced!in!RT112!parental!acutely!treated!with!PD!and!R1!and!R2!
cultured! in! PD.! Expression!was! also! reduced! but! to! a! lesser! extent! in!R3! +!PD.!
These! results! confirmed! that! fatty!acid! synthesis!was! reduced! in!RT112! resistant!
derivatives.! Protein! expression! of! SCD1! and!SREBP1!was! not! examined! in!RT4!
parental! and! R1.! However,! microarray! analysis! indicated! that! genes! involved! in!
fatty!acid!synthesis!were!downregulated!in!RT4!R1!compared!to!RT4!parental.!This!
indicates! that! the!reduced!sensitivity! to!PD!exhibited!by!RT112!and!RT4!resistant!
derivatives!is!not!mediated!by!the!restoration!of!fatty!acid!synthesis!during!FGFR3!
inhibition.!Even!the!HRAS!mutation! in!RT112!R3!did!not! induce!the!return!of! fatty!
acid! synthesis!markers! to! the! expression! level! observed! in!RT112! parental.! This!
highlights!that,!although!the!two!mutations!are!mutually!exclusive,!they!do!not!have!
an! identical! function! in! the! context! of! driving! urothelial! carcinoma.! Further!
examination! of! fatty! acid! synthesis! could! have!been! conducted!by! examining! the!
incorporation! of! 14CGlabelled! acetate! into! fatty! acids! as! conducted! by! Du! et% al.%
Alternatively,! cellular! lipid! composition! of! parental! and! resistant! lines! could! be!
examined!with!mass!spectrometry!as!conducted!by!Griffiths!et%al.! ! (Griffiths!et%al.,!
2013).! ! This! could! have! confirmed! whether! the! observed! changes! in! gene!
expression!resulted!in!an!overall!reduction!in!fatty!acid!synthesis.!
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As!RT4!R1,! RT112!R1! and!RT112!R2! exhibited!morphological! and! gene!
expression!changes!which!were!reversible!upon!culture!without!PD,!it!was!thought!
that! these! lines! were! in! a! resistant! state! mediated! via! epigenetic! or! gene!
expression! changes! rather! than! via! a! genetic! mechanism.! RT112! R1! and! R2!
maintained! their! resistance! following! culture! without! PD! for! 4! passages,! despite!









R2! was! mediated! via! epigenetic! or! gene! expression! changes! rather! than! via! a!
genetic!mechanism,!the!inhibition!of!epigenetic!modifiers!could!be!a!useful!strategy!
to! overcome! resistance! FGFR! TKIs.! Examination! of! whether! knockdown! of!
epigenetic!modifiers!or!treatment!with!inhibitors!of!epigenetic!modifies!reGsensitizes!
the! resistant! lines! to! PD! could! identify! epigenetic! alterations! which! facilitate! PD!
resistance! and! therefore! highlight! an! alternative! therapeutic! approach! to!
overcoming!PD!resistance.!!
Epigenetic!modifiers!have!been!targeted!to!overcome!resistance!to!targeted!
therapy.!Gastrointestinal! stromal! tumours! (GISTs)!often!have!activating!mutations!
in!RTKs!KIT!and!PDGFRA%(Heinrich!et%al.,!2003d!Hirota!et%al.,!1998).!Mühlenberg!et%
al.! reported! that! treatment! with! the! nonGselective! histone! deacetylase! inhibitor!
vorinostat! and! imatinib! were! additive! in! KITGpositive! GIST! cell! lines.! Vorinostat!
reduced! KIT! mRNA! expression! and! increased! acetylation! of! HSP90,! a! KIT!
chaperone,! inducing! KIT! degradation! (Muhlenberg! et% al.,! 2009).! Bauer! et% al.!
conducted! a! phase! I! clinical! trial! which! assessed! the! efficacy! of! imatinib! in!
combination! with! the! nonGselective! histone! deacetylase! inhibitor! panobinostat! in!
overcoming!resistance!in!patients!with!gastrointestinal!stromal!tumours!refractory!to!
the!combination!of! imatinib!and! the!multitargeted!TKI!sunitinib.!One!out!of! the!11!
patients! showed! a! partial! response,! 7! had! stable! disease! and! 3! patients! had!
progressive!disease!(Bauer!et%al.,!2014).!!
Sharma!et.%al.%produced!PC9!cells!resistant!to!EGFRGTKIs,!which!mediated!
their! resistance! via! activation! of! IGF1R,! via! culture! in! gefitinib! for! 9! days.! It! was!
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observed! that! the! resistant! cells! had! increased! expression! of! KDM5A! and! that!
KDM5A! knockdown! did! not! reduce! the! proliferation! of! parental! PC9! cells! but! did!
reduce!the!production!of!resistant!cells!upon!treatment!with!gefitinib.!Upon!culture!
without! an! EGFR! TKI,! resistant! cells! maintained! their! resistant! phenotype! for!
approximately! 30! passages! before! regaining! gefitinib! sensitivity! (Sharma! et% al.,!
2010).! Treament! with! the! KDM5A! inhibitor! YUKA1! reduced! the! formation! of!
gefitinibGresistant! colonies! following! the! culture! of! PC9! in! gefitinib! for! 35! days.!
Culture!with!YUKA1!as!a!single!agent!did!not!reduce!the!growth!of!PC9!(Gale!et%al.,!
2016).!How!long!RT112!R1!and!R2!would!have!to!be!cultured!without!PD!to!regain!
PD! sensitivity! is! unknown.! Hou! et% al.! observed! that! expression! of! KDM5A! was!
increased!in!the!breast!cancer!lines!SUM149!and!SUM102!following!6!and!9!days!
culture! in! erlotinib.! Stable! knockdown! of! KDM5A! in! the! breast! cancer! cell! lines!
SUM149! and! HCC1937! reduced! the! number! of! drugGtolerant! SUM149! and!
HCC1937!cells! following!30Gday! culture! in!erlotinib! (Hou!et%al.,! 2012).!Gale!et%al.!
cultured! the!breast! cancer! cell! line!BT474!with!a! low!dose!of! trastuzumab! for! 35!
days!with!and!without!YUKA1!and!observed!that!YUKA1!reduced!the!formation!of!
trastuzumabGresistant! colonies.! Culture! with! YUKA1! as! a! single! agent! did! not!
reduce!the!growth!of!BT474!(Gale!et%al.,!2016).!Whether!knockdown!of!KDM5A!or!
treatment! with! a! KDM5A! inhibitor! could! reGsensitise! RT112! R1! and! R2! was! not!
examined! in! this! project! due! to! time! limitations.! ! However,! microarray! analysis!
showed! that! KDM5A! mRNA! expression! was! not! significantly! differentially!
expressed!between!RT112!parental! and! the!RT112! resistant! lines.!Expression!of!
the!histone!demethylase%KDM6A!was!significantly!increased!in!the!RT112!and!RT4!
resistant! cells! cultured! in! PD! compared! to! their! parental! lines.! Whether! KDM6A!
contributes! to! the! resistant! phenotype! could! be! tested! by! examining! whether!
knockdown!of!KDM6A!reGsensitizes!these!cells!to!PD.!
Inhibition!of! the!bromodomain!and!extraterminal! (BET)! family!of! chromatin!
readers!has!been!previously!examined!in!RT112!as!a!mechanism!of!increasing!the!
efficacy! of! FGFRGtargeted! therapy.! Binding! of! the! BET! bromodomainGcontaining!
protein! BRD4! to! MYC! enhancers! induces! transcription! of! the! oncogene! MYC!
(Lovén! et% al.,! 2013).! Mahe! et% al.! observed! that! siRNA! knockdown! of! the!
transcription! factor!MYC! decreased!FGFR3!expression! in! the!bladder! cancer! cell!
lines! MGHGU3,! which! has! a! Y375! FGFR3! activating! mutation,! and! RT112.!
Treatment!with!PD!reduced!MYC!expression!in!MGHGU3!and!RT112!suggesting!a!
MYC/FGFR3! positive! feedback! loop.! In! MGHGU3! and! RT112,! treatment! with! the!
PI3! kinase! inhibitor! LY294002! decreased! phosphorylation! of! glycogen! synthase!
kinase!3!%!which!induces!the!proteosomal!degradation!of!MYC.!Additionally,!siRNA!
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knockdown! of!MAPK14,! which! encodes! the! MAP! kinase! protein! p38',! reduced!
MYC! mRNA! expression.! This! demonstrated! that! both! the! MAP! kinase! and! PI3!
kinase!pathway!act!downstream!of!FGFR3!to!increase!MYC!expression.!Treatment!
with! the! BET! bromodomain! inhibitor! JQ1,! in! combination! with! PD,! reduced! cell!
viability! in! MGHU3! and! RT112! in! an! additive! fashion! (Mahe! et% al.,! 2018).! It! is!
possible! that! treatment! with! a! BET! bromodomain! inhibitor! such! as! JQ1,! in!





RT4!was!available! at! the! start! of! this! project,!whilst! a! single! cell! clone!of!RT112!




term! culture! in! PD.! Additionally! a! number! of! copy! number! differences! were!
observed!between!parental!RT112!and!the!RT112!R1!and!between!parental!RT112!
and! the!RT112!R3.!These! copy!number!differences!may!have!been!present! in! a!




A! limitation! of! the! transcriptome! analysis! was! that,! as! this! involved! examining!
expression!of!a! large!number!of!genes,!a!number!of!genes!will!have!been! falsely!
classified!as!differentially!expressed!between!experimental!conditions.!Raising!the!
threshold! for! classifying! genes! as! differentially! expressed!may! have! reduced! the!
number!of! false!positives.!However,! this!would!have!reduced!the!detection!of! true!
gene! expression! differences.! The! use! of! a! greater! number! of! repeats! per!
experimental!condition!would!have! increased! the!reliability!of! the!microarray!data.!






not! been! used! to! authenticate! the! identity! of! the! RT112! and! RT4! resistant!
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resistant! lines.! Additionally,! immunoblot! analysis! could! have! been! used! to! show!
that! treatment! with! capmatinib! reduced! MET! phosphorylation! in! RT112! resistant!
lines,! demonstrating! the! efficacy! of! this! TKI.! Microarray! analysis! identified! an!
increase! in! expression!of!KDM6A!mRNA!expression! in!RT112!and!RT4! resistant!
derivatives! when! cultured! in! PD.! Additionally,! microarray! analysis! identified! an!
increase! in!ERBB4! and!EPHA3!mRNA!expression! in!RT4!R1! +!PD.! Immunoblot!
analysis! could! have! determined! whether! these! changes! in! mRNA! expression!
induced! a! change! in! protein! expression! of! KDM6A,! ERBB4! and! EphA3! and! to!
examine! whether! ERBB4! and! EphA3! were! phosphorylated! in! RT4! R1.! Whether!
KDM6A,!ERBB4!or!EPHA3!contributed!to!PD!resistance!could!have!been!tested!by!
examining!whether!knockdown!of!these%genes,!or!treatment!with!a!specific!inhibitor,!
reGsensitised! the! resistant! lines! to! PD.! A! cell! viability! assay! could! have! been!







to! FGFR! inhibition.! Currently! RAS! mutations! cannot! be! directly! targeted! with!
therapeutic!agents.!As!RAS!mutations!are!frequent!in!cancer!there!is!a!requirement!
for!effective! treatments! for!RAS!mutant! tumours!and! research! is!ongoing! to!meet!
this!need.!As! the!RT112! resistant!derivatives!exhibited!sensitivity! to! linsitinib,! this!
suggests!that!it!may!be!possible!to!target!IGF1R!to!overcome!resistance!to!FGFR!
inhibition.! EGFR! was! identified! as! a! mediator! of! acquired! resistance! to! FGFR!
inhibition! in! RT4! R1.! EGFR! activation! has! been! previously! identified! as! a!
mechanism!of! shortGterm!survival! following! treatment!with!PD! in!RT112! (HerreraG
Abreu!et%al.,!2013).!A!number!of!different!RTKs!have!been!reported! in! this!study,!
and! elsewhere,! to! induce! resistance! to! FGFRGtargeted! agents! in! urothelial!
carcinoma!cell!lines.!Therefore,!the!examination!of!the!RTK!expression!profile!of!an!
FGFRGTKI! resistant! urothelial! carcinoma,! by! a! method! such! as!
















































































































































































































































































MIB2! ENST00000355826! 1:1629393! missense!variant! c.A2693G! p.Q898R!
!
tolerated! benign!




ATF2! ENST00000264110! 2:175093201! missense!variant! c.G1045A! p.E349K!
!
deleterious! possibly!damaging!
HACL1! ENST00000321169! 3:15601421! missense!variant! c.T43C! p.S15P!
!
deleterious! benign!
BTD! ENST00000417015! 3:15601421! missense!variant! c.A17G! p.D6G!
!
_! unknown!
SLC35G2! ENST00000393079! 3:136854890! stop!gained! c.C430T! p.Q144*!
!
_! _!
NDUFS4! ENST00000296684! 5:53646367! synonymous!variant! c.A312G! p.R104=!
!
_! _!
MIER3! ENST00000336942! 5:56946947! synonymous!variant! c.A78G! p.S26=!
!
_! _!
MDN1! ENST00000369393! 6:89698985! missense!variant! c.G9048A! p.M3016I!
!
tolerated! benign!
ZP3! ENST00000336517! 7:76440270! synonymous!variant! c.G699A! p.L233=!
!
_! _!
GIMAP8! ENST00000307271! 7:150466710! synonymous!variant! c.G12A! p.Q4=!
!
_! _!
SHB! ENST00000377707! 9:38068185! missense!variant! c.C461T! p.S154L!
!
tolerated! benign!




PRRG4! ENST00000257836! 11:32853436! missense!variant! c.G590A! p.R197K!
!
tolerated! benign!
TRIM51! ENST00000449290! 11:55886138! stop!gained! c.A427T! p.K143*!
!
_! _!
SESN3! ENST00000278499! 11:95185375! stop!gained! c.G226T! p.E76*!
!
_! _!






GRIP1! ENST00000359742! 12:66517916! missense!variant! c.G563A! p.G188E!
!
deleterious! probably!damaging!




2574D22.6! ENST00000562285! 16:29819568! synonymous!variant! c.G69A! p.R23=! !
_! _!
IGHV3OR16_9! ENST00000354689! 16:32066301! synonymous!variant! c.G237A! p.L79=!
!
_! _!
USP43! ENST00000285199! 17:9680360! missense!variant! c.C1099T! p.L367F!
!
tolerated! benign!
WDR18! ENST00000251289! 19:991968! synonymous!variant! c.T936C! p.N312=!
!
_! _!
MUM1! ENST00000415183! 19:1370676! synonymous!variant! c.C1587G! p.V529=!
!
_! _!




DIRAS1! ENST00000323469! 19:2717258! synonymous!variant! c.G549C! p.G183=!
!
_! _!
ZNF554! ENST00000317243! 19:2820107! synonymous!variant! c.G36A! p.R12=!
!
_! _!
TBXA2R! ENST00000375190! 19:3600458! synonymous!variant! c.G177A! p.T59=! COSM5510987!COSM5510988! _! _!
TMIGD2! ENST00000301272! 19:4294626! missense!variant! c.G503T! p.W168L!
!
tolerated! benign!
CTB_50L17.10! ENST00000589486! 19:4493711! synonymous!variant! c.A312G! p.P104=!
!
_! _!
ARHGEF18! ENST00000359920! 19:7440096! synonymous!variant! c.C156T! p.G52=!
!
_! _!
CYP4F8! ENST00000325723! 19:15615676! synonymous!variant! c.G60T! p.L20=!
!
_! _!
CYP4F3! ENST00000620621! 19:15615676! synonymous!variant! c.G60T! p.L20=!
!
_! _!








INSL3! ENST00000317306! 19:17821381! synonymous!variant! c.A126G! p.L42=!
!
_! _!
LRRC25! ENST00000339007! 19:18392025! missense!variant! c.C880T! p.P294S!
!
tolerated! benign!
GDF1! ENST00000247005! 19:18869363! missense!variant! c.C353T! p.A118V!
!
tolerated! benign!




CERS1! ENST00000429504! 19:18895839! synonymous!variant! c.T234C! p.T78=!
!
_! _!
SUGP1! ENST00000247001! 19:19279376! synonymous!variant! c.C1365T! p.Y455=!
!
_! _!
CILP2! ENST00000291495! 19:19540331! synonymous!variant! c.A291G! p.E97=!
!
_! _!



























COL8A2! ENST00000481785! 1:36098553! synonymous!variant! c.G933A! p.G311=!
! ! !
YY1AP1! ENST00000295566! 1:155672698! missense!variant! c.G643A! p.A215T!
!
tolerated! benign!
CD55! ENST00000314754! 1:207331177! missense!variant! c.A734T! p.Y245F!
!
deleterious! probably!damaging!
XIRP2! ENST00000409195! 2:167248119! stop!gained! c.G6727T! p.E2243*!
! ! !
SPATA3! ENST00000424440! 2:230996329! synonymous!variant! c.C96T! p.S32=!
! ! !
PRR21! ENST00000408934! 2:240042962! synonymous!variant! c.A21G! p.T7=! COSM3695376!COSM3695377! ! !
YIPF7! ENST00000332990! 4:44624624! synonymous!variant! c.T657C! p.G219=!
! ! !
TENM3! ENST00000511685! 4:182753541! synonymous!variant! c.G3954T! p.L1318=!
! ! !




DENND2A! ENST00000275884! 7:140601525! synonymous!variant! c.A873G! p.K291=!
! ! !
IFNA21! ENST00000380225! 9:21166592! synonymous!variant! c.A21G! p.L7=!
! ! !
PHF2! ENST00000359246! 9:93676725! synonymous!variant! c.G2964T! p.P988=! COSM3750192!
! !
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PHF2! ENST00000359246! 9:93676737! synonymous!variant! c.C2976A! p.T992=! _!
! !








MUC5AC! ENST00000621226! 11:1190532! synonymous!variant! c.A12387G! p.T4129=! _!
! !
CRACR2A! ENST00000535292! 12:3640718! missense!variant! c.G301A! p.D101N!
! !
unknown!




GOLGA6L6! ENST00000619213! 15:20534627! synonymous!variant! c.C1807A! p.R603=!
! ! !
GOLGA6L6! ENST00000619213! 15:20534645! missense!variant! c.G1789A! p.E597K!
!
tolerated! unknown!
GOLGA6L6! ENST00000619213! 15:20534648! missense!variant! c.C1786T! p.R596W!
!
tolerated! unknown!




MESP2! ENST00000341735! 15:89776918! synonymous!variant! c.G561A! p.G187=!
! ! !
KRTAP4_16! ENST00000440582! 17:41101693! missense!variant! c.G517C! p.V173L! COSM5177690!
!
unknown!
CCDC130! ENST00000588809! 19:13759339! missense!variant! c.C557A! p.P186H!
! !
unknown!








This! appendix! contains! the! first! stages! of! transcriptome! analysis.! Affymetrix!
GeneChip! HTA! 2.0! raw! data! files! (.CEL! files),! were! imported! into! Expression!
Console!and!the!quality!of!the!data!was!assessed!using!quality!controls!included!on!





all!microarray!samples!(Fig.!D.1)!was!greater! than!or!equal! to!0.98! for!microarray!













and! cre! should! be! present! in! every! array! sample! and! bioB! should! present! in! a!






























was! conducted! using! the! raw!data! from! the!CEL! files! generating!CHP! files.!SST!
removes! significant! foldVchange!compression!and!RMA!minimises!probe! variance!
(Irizarry! et- al.,! 2003).! After! normalisation,! CHP! file! summarized! probe! set! signal!
values! have! a! reduced! variability! compared! to! the! probe! cell! intensity! values! of!
microarray!samples!measured!from!CEL!files!(Fig.!D.5).!This!indicates!that!the!data!
normalisation!was!successful!and!array!samples!can!now!be!compared.!
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!
Figure(D.5(Log(expression(signal(of(CHP(files(generated(from(the(CEL(files(through(
SSTLRMA(normalisation.(This!box!plot!shows!the!signal!intensity!of!each!array!following!
the!SSTVRMA!normalisation!and!therefore!differences!in!signal!intensities!between!arrays!
should!not!be!present.!This!analysis!was!conducted!in!Affymetrix!Expression!Console™.!
(
D.3(Supplementary(expression(analysis(
!
Figure(D.6(The(10(most(significantly(differentially(expressed(pathway(maps(between(
RT112(R1(no(PD(and(parental(+(PD(according(to(MetaCore!.(!
!
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!
Figure(D.7(The(10(most(significantly(differentially(expressed(pathway(maps(between(
RT112(R2(no(PD(and(parental(+(PD(according(to(MetaCore!.(!
!
!
Figure(D.8(The(10(most(significantly(differentially(expressed(pathway(maps(between(
RT112(R3(no(PD(and(parental(+(PD(according(to(MetaCore!.(
(
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(
Figure(D.9(The(10(most(significantly(differentially(expressed(pathway(maps(between(
RT4(R1(+(PD(vs(R1(no(PD(according(to(MetaCore!.(
(
!
Figure(D.10(Expression(of(OSM(and(IL31(in(RT112(determined(by(microarray(analysis.(
A)!OSM!B)!IL31.!Error!bars!indicate!standard!error!of!the!mean.!Signal!intensity!is!given!
relative!to!parental!no!PD.!OSM!and!IL31!were!not!differentially!expressed!in!any!
experimental!conditions!compared!to!parental!no!PD!(ANOVA!p<0.05,!2Vfold!expression!
change).!!
!
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(
Figure(D.11(Expression(of(IL6ST,(OSMR(and(LIFR(in(RT4(determined(by(microarray(
analysis.(A)!IL6ST.!B)!OSMR.!C)!LIFR.!Error!bars!indicate!standard!error!of!the!mean.!
Signal!intensity!is!given!relative!to!RT112!no!PD.!Asterisks!indicate!the!experimental!
conditions!in!which!IL6ST,!OSMR!or!LIFR!were!differentially!expressed!compared!to!
parental!no!PD!(ANOVA!p<0.05,!2Vfold!expression!change).!!
!
!
Figure(D.12!Expression(of(OSM(and(IL31(in(RT4(determined(by(microarray(analysis.(
Error!bars!indicate!standard!error!of!the!mean.!A)!OSM.!B)!IL31.!Signal!intensity!is!given!
relative!to!parental!no!PD.!OSM!and!IL31!were!not!differentially!expressed!in!any!
experimental!conditions!compared!to!parental!no!PD!(ANOVA!p<0.05,!2Vfold!expression!
change).!
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Figure(D.13!Unsupervised(hierarchical(cluster(analysis(of(Choi(et.al.(cohort(of(p53L
like(markers(in(RT112(microarray(samples.((The!Log2!gene!expression!was!normalised!
by!dividing!each!expression!value!by!the!probe’s!mean!Log2!gene!expression.!Following!
Log2!gene!expression!normalisation,!the!expression!profiles!of!samples!and!genes!were!
clustered!in!Partek"!Genomics!Suite"!6.6!using!Euclidean!distance!and!complete!linkage.!
Scale!bar!indicates!the!normalised!Log2!gene!expression!with!colour!depicting!the!level!of!
gene!expression!as!high!(red),!intermediate!(black)!and!low!(green).!
(
!
0.72!!!!!!!!!!!!!!!!!!!!!!!!1.28!
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(
Figure(D.14!Unsupervised(hierarchical(cluster(analysis(of(Choi(et.al.(cohort(of(p53L
like(markers(in(RT4(microarray(samples.(The!Log2!gene!expression!was!normalised!by!
dividing!each!expression!value!by!the!probe’s!mean!Log2!gene!expression.!Following!Log2!
gene!expression!normalisation,!the!expression!profiles!of!samples!and!genes!were!
clustered!in!Partek"!Genomics!Suite"!6.6!using!Euclidean!distance!and!complete!linkage.!
Scale!bar!indicates!the!normalised!Log2!gene!expression!with!colour!depicting!the!level!of!
gene!expression!as!high!(red),!intermediate!(black)!and!low!(green).!
!
!
!
!
0.8
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!0.88!!!!!!!!!!!!!!!!!!!!!!!!1.12!
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!
Figure(D.15(Expression(of(PGM5(and(ACTG2(in(RT4(determined(by(microarray(
analysis.(A)(PGM5.(B)(ACTG2.(Error!bars!indicate!standard!error!of!the!mean.!Signal!
intensity!is!given!relative!to!parental!no!PD.!Asterisks!indicate!the!experimental!conditions!in!
which!PGM5!and!ACTG2!were!differentially!expressed!compared!to!parental!no!PD!
(ANOVA!p<0.05,!2Vfold!expression!change).!(
!
Figure(D.16(Expression(of(IGF1,(HGF,(EREG(and(NRG2(in(RT112(determined(by(
microarray(analysis.(A)!IGF1.!B)!HGF.!C)!EREG.!D)!NRG2.!Error!bars!indicate!standard!
error!of!the!mean.!Signal!intensity!is!given!relative!to!RT112!no!PD.!Asterisks!indicate!the!
experimental!conditions!in!which!genes!were!significantly!differentially!expressed!compared!
to!parental!no!PD!(ANOVA!p<0.05,!2Vfold!expression!change).!For!genes!with!specificity!to!
more!than!one!probe,!the!data!generated!from!each!probe!is!shown!separately!with!a!
legend!indicating!the!probe’s!Affymetrix!IDs.!
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(
Figure(D.17!Expression(of(EREG,(HBEGF,(EGF,.NRG2(and(EPGN(in(RT4(determined(
by(microarray(analysis.(A)!EREG.!B)!HBEGF.!C)!EGF.!D)!NRG2.!E)!EPGN.!Error!bars!
indicate!standard!error!of!the!mean.!Error!bars!are!absent!where!the!standard!error!of!the!
mean!was!too!small!to!plot.!Signal!intensity!is!given!relative!to!RT4!no!PD.!Asterisks!
indicate!the!experimental!conditions!in!which!genes!were!significantly!differentially!
expressed!compared!to!parental!no!PD!(ANOVA!p<0.05,!2Vfold!expression!change).!(
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(
Figure(D.18(Expression(of(NRG1(and(NRG2(in(RT4(determined(by(microarray(
analysis.(A)!NRG1.!B)!NRG2.!Error!bars!indicate!standard!error!of!the!mean.!Error!bars!are!
absent!where!the!standard!error!of!the!mean!was!too!small!to!plot.!Signal!intensity!is!given!
relative!to!RT4!no!PD.!Asterisks!indicate!the!experimental!conditions!in!which!genes!were!
significantly!differentially!expressed!compared!to!parental!no!PD!(ANOVA!p<0.05,!2Vfold!
expression!change).!For!genes!with!specificity!to!more!than!one!probe,!the!data!generated!
from!each!probe!is!shown!separately!with!a!legend!indicating!the!probe’s!affymetrix!IDs.!
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